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ABSTRACT OF THE DISSERTATION 
The Mechanism of the Gastric Epithelial Stem Cell Response to Metaplastic Injury 
by 
Shradha Sachin Khurana 
Doctor of Philosophy in Developmental, Regenerative and Stem Cell Biology 
Washington University in St. Louis, 2013 
Professor Jason C. Mills, Chair 
 
Almost nothing is known about the identity of the epithelial stem cell of the gastric corpus, either 
during normal turnover or in response to injury. Our lab has shown that injection of the selective 
estrogen receptor modulator tamoxifen leads to near complete atrophy of parietal cells by 3 days 
and induces expansion of an undifferentiated cell population within the normal stem cell niche in 
the isthmus of the gastric unit. Here we show that CD44 labels the membranes of such 
undifferentiated isthmal cells, both in the normal gastric epithelium and when those cells expand 
fourfold upon injury with tamoxifen. Loss of CD44, either in knockout mice or by blocking its 
interaction with its ligand, leads to reduced proliferation. We found CD44 regulates proliferation 
by binding to active STAT3 and occupying the CyclinD1 promoter; accordingly, blocking 
STAT3 activity completely abrogates atrophy induced proliferation.  We screened for signaling 
kinases potentially responsible for increased CD44 and/or proliferation and found only ERK 
MAPK was activated during early stages following injury (as few as 6 hours following 
tamoxifen injection). This burst of ERK activation is localized to non-differentiated cells of the 
xvi 
 
isthmus, and blocking ERK activation with the inhibitor U0126 blocked the expansion of CD44-
positive cells.  
To determine which cytokines induced ERK in progenitor cells, we assayed sera of mice treated 
with tamoxifen for 6h. Compared to control injected mice, tamoxifen treated mice have a 
significant increase in the STAT3-inducing cytokine IL-6 levels, correlating with increased 
F4/80+ macrophages in the gastric mesenchyme. Isolated peritoneal macrophages treated ex vivo 
with tamoxifen showed significantly increased IL-6 expression, and depletion of bone-marrow 
derived macrophages in vivo blocks tamoxifen induced metaplasia and increased progenitor cell 
proliferation. Depletion of macrophages also blocks activation of ERK and expression of the 
stress signal, iNOS, in parietal cells. Inhibition of iNOS and scavenging of nitric oxide blocks 
parietal cell atrophy and stem cell expansion.  Taken together, our data suggest that CD44 marks 
a population of undifferentiated epithelial cells within the stem-cell niche of the gastric unit, 
which greatly expands on injury and is regulated by ERK-MAPK signaling. ERK, in turn, is 
potentially regulated by cytokines like IL-6 secreted by peritoneal and resident macrophages. 
Once induced, CD44 associates with pSTAT3 to increase Cyclin D1 expression and consequent 
stem/progenitor cell proliferation. In conclusion, this thesis identifies a marker and pathway for 
the presumptive stem cell of the gastric epithelium during response to atrophy and during normal 
homeostasis. 
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CHAPTER 1: Introduction 
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I. The Stomach 
a. Development 
The source of nutrients for an embryo is obviously different from that of a neonate. Until birth, 
the developing embryo procures its nourishment from the placenta and from substances in the 
swallowed amniotic fluid, which might also contain factors that aid in development. As the 
newborn develops, maturation and gland formation in the gastrointestinal tract continue, with the 
rate of growth peaking at around three weeks in rodents. The stomach grows at a more rapid rate 
just after birth as compared to the rest of the body. At birth, gastric acid secretion capacity is 
low, but it rapidly increases by about threefold during the first 3 days post-partum. The gastric 
epithelium undergoes continuous renewal throughout the life of the animal.  
b. Structure and organization 
The mouse stomach is divided into four regions from the proximal to distal end: forestomach, 
corpus, antrum, and pylorus. The forestomach is lined by squamous epithelium and is absent in 
humans. Mature, differentiated cells that aid in digestion of food are situated in the glandular, 
columnar epithelium of the corpus, which is found in all mammals. A schematic of the 
architecture of a typical mammalian stomach is shown in Fig.1. The corpus epithelium is 
comprised of gastric units which are tubular invaginations that extend into the lamina propria. 
Each gastric unit can be divided into four different regions depending upon the cell types 
occupying each region. The region closest to the gastric lumen is the pit where surface mucous 
pit cells reside. The next is the isthmus where gastric stem/progenitor cells reside, followed by 
the neck which is populated by mucous neck cells. The deepest region is the base which is 
mainly occupied by zymogenic or chief cells. Parietal cells (acid-secreting) and endocrine cells 
are dispersed in all four regions (Fig. 1). The antrum is the distal part of the stomach adjacent to 
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the duodenum and lacks parietal cells and differentiated zymogenic cells. Gastrin secreting G-
cells are found in the antrum. Gastrin stimulates release of histamine and acid in the corpus. The 
pylorus is the distal muscular sphincter that connects the antrum to the duodenum and regulates 
flow of gastric chyme into the intestine.  
In constantly renewing tissues such as the stomach and intestine, mechanisms must exist to 
balance stem cell division and cell lineage allocation, so that the correct number of cells of each 
lineage is constantly generated. This renewal occurs due to the proliferation and differentiation 
of the multipotent stem cells that are present in the isthmus region of the adult gastric unit. The 
stem cells give rise to precursors that move bi-directionally (toward the lumen and toward the 
base) in the unit, giving rise to three main lineages with 11 cell types, that is: 
1. Pit (also known as surface-associated/foveolar) cell lineage: Pre-pit cell precursors, pre-pit 
cells, pit cells [marked by AAA lectin and TFF1] 
2. Zymogenic Cell (ZC) lineage: Pre-neck cell precursors, pre-neck cells, neck cells [marked by 
GSII lectin and TFF2], pre-ZCs, and ZCs [marked by intrinsic factor (GIF), pepsinogen (PGC), 
Mist1] 
3. Parietal Cell (PC) lineage: Pre-PC precursors, pre-PCs, and PCs [marked by H/K-ATPase and 
VEGF-B] 
Secretory granule-free pre-pit cells within the isthmus give rise to mucous secreting pit cells 
when they enter the pit region by upward migration in the gastric unit. 87% of pit cells 
differentiate from pre-pit cells, while the remaining 13% come from their own mitoses [1]. The 
process of pit cell migration to the surface takes 3 days [1]. On the other hand, cells of the 
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zymogenic lineage migrate in the opposite direction from the isthmus, down towards the base of 
the unit.  
Members of the zymogenic lineage differentiate during a downward migration from the isthmus. 
A granule-free pre-neck cell precursor produces pre-neck cells, which are transformed to neck 
cells as they migrate from the isthmus to the neck. Neck cells complete their journey through the 
neck region in 14 days [1]. Upon arrival at the upper portion of the base of gastric units, they 
become pre-zymogenic cells. Terminal differentiation to zymogenic cells occurs during a 
continued downward descent to the lower portion of the base of gastric units. Zymogenic cells 
die by necrosis or apoptosis. The sequence is completed in 190 days [1]. Conversion of 
undifferentiated granule-free cells to pre-parietal cells occurs in the isthmus and takes 1 day [1]. 
Differentiation of pre-parietal to parietal cells also takes place in the isthmus. Parietal cells 
subsequently undergo a bipolar migration to both the pit and base. Death ensues and cells are 
disposed of by extrusion or phagocytosis. The overall turnover time for parietal cells is 54 days 
[1]. 
In addition to these lineages, endocrine cells are also scattered throughout the gastric unit. Even 
though there is emerging literature on the mechanisms by which the different cell types are 
formed, many gaps remain. For example, even though the location of the stem cell within the 
isthmus region of the gastric corpus has been well established by ultrastructure and turnover 
analysis, its molecular identity has not been well characterized [2]. 
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Figure 1.1: Typical anatomy and histology of a mammalian stomach. There are a number of 
variations in mammalian gastric anatomy. For example, mice have a forestomach with 
keratinized squamous epithelium, whereas humans have a pronounced cardiac region with 
simpler mucous glands that mark the transition region between the esophagus and corpus. 
However, the most prominent regions in most mammals are a proximal corpus, encompassing 
most of the stomach volume, and a distal antrum or pylorus. The corpus epithelium is organized 
into repeating gastric units that are invaginations from the surface and contain multiple cell 
lineages in 4 distinct zones. In the diagram, acid-secreting parietal cells are blue, digestive 
enzyme secreting zymogenic (chief) cells are red, mucous neck cells are green, and the mucus-
secreting pit cells nearest the surface are purple. In the antrum, the gastric units are simpler, 
with few parietal or zymogenic cells. Antral units contain 2 distinct types of mucous cells: those 
lining the surface (purple) are similar to the surface cells of the corpus, and those nearer to the 
base have properties intermediate between zymogenic cells and mucous neck cells of the corpus 
(red-yellow). The interfaces between esophagus and corpus and between corpus and antrum are 
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not abrupt but marked by transitional mucosae. Endocrine cells (not depicted) are also present 
throughout the corpus and antrum epithelium. (Adapted from [3]) 
II. The Gastric Epithelial Stem Cell 
It is believed that all gastric mucosal cells originate from stem cells that reside in the isthmus 
region of the gastric unit  [4, [5], because 32P-radiolabeled cycling cells appeared in this region. 
Studies by Leblond in the 1940s showed that one or a few cells in the isthmus constantly 
regenerate cells that migrate bi-directionally, up to the mucosal surface and down to the gland 
base, as they differentiate into mature cells of the gastric unit  [6] (Fig. 1.2).  
 
Figure 1.2: Origins of principal corpus epithelial lineages. The self-renewing stem cell gives 
rise to each of the principal epithelial lineages of the corpus. There is ultrastructural evidence 
for the transient intermediates for each lineage; however, available evidence indicates greater 
complexity in the zymogenic lineage, which arises from a long-lived (≥1 week in mice) 
intermediate, the mucous neck cell, with its own distinct ultrastructure and probable function. 
(Adapted from [3]). 
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In 1966, Robert Corpron identified small, undifferentiated cells, with high nucleus:cytoplasm 
ratio, open chromatin and lack of granules in the isthmus of the gastric units of rats [7], which 
repopulated the entire unit. Karam et al. were able to identify a similar subset of cells in the 
isthmi of human gastric units [8]. In 2002, Bjerknes and Cheng demonstrated that the entire 
gastric unit, corporal and antral, could arise from a single cell, i.e. the stem cell [5]. They utilized 
lineage tracing to identify clones that had lost LacZ expression in the mutagenized ROSA26 
reporter mouse. They found clones that spanned entire gastric units and ones that were long lived 
(48 weeks), confirming that the mutagen hit the stem cell in these instances. Over time, many 
putative stem cell markers have emerged, but none has satisfied the gold standard requirements 
of tracing of all lineages and in vitro gland formation for the gastric corpus. The different 
putative stem cell markers are listed below (adapted from  [9]): 
Table 1: Putative stem cell markers of the gastrointestinal tract 
Marker Location 
Lineage 
tracing 
Life span 
Response to pathogenic 
stimuli 
Ref. 
Villin 
promoter 
Mainly 
antral; below 
isthmus, but 
mobile in 
gland base 
after IFNγ 
Give rise 
to all cell 
types >1 year 
Increased proliferation 
and gland replacement 
after IFNγ  [10] 
Lgr5 
Mainly 
antral; gland 
base 
Give rise 
to all cell 
types >638 days 
Can give rise to tumors 
after conditional Apc 
deletion  [11] 
Mist1 
Mature chief 
cells of 
corpus gland 
Give rise 
to SPEM 
As chief 
cells 
Lost during metaplasia, 
dysplasia, and carcinoma 
 [12, 
[13] 
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Marker Location 
Lineage 
tracing 
Life span 
Response to pathogenic 
stimuli 
Ref. 
base lineage 
Tff2 
Corpus, 
isthmus zone 
(mRNA) 
Give rise 
to mucous 
neck cells, 
chief 
cells, 
parietal 
cells only >200 days Amplified by DMP-777 
 [14, 
[15] 
BMDSC 
Do not 
normally 
engraft in the 
absence of 
injury   
>52 week
s 
Widespread in epithelial 
engraftment after 
extensive chronic injury 
and Helicobacter 
infection  [16] 
Prominin
1 
(CD133) 
Base of 
gastric 
glands N/D N/D 
Highly expressed in 
gastric carcinomas 
 [17, 
[18, 
[19] 
Dclk1 
(DCAM
KL1) 
Corpus, one 
cell per gland 
(at isthmus) N/D N/D 
Amplify in a Kras 
environment 
 [20, 
[21] 
CD44 
Corpus/antru
m; gland 
base N/D N/D 
Increased in tumors. 
Isolated cells give rise to 
tumors in xenograft 
model 
 [22, 
[23, 
[24] 
N/D not done, IFNγ interferon gamma, BMDSC bone marrow derived stem cells. 
 
In spite of identifying the location of the gastric epithelial stem cell within the unit, little is 
known about its niche or markers that label this population specifically.  
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a. Salient features of the stem cell 
The gastric stem cell is different when compared to stem cells of other regions of the digestive 
tract. For one, the gastric stem cell is located much higher in the glandular unit than the intestinal 
stem cell, which is located in the base of the crypt [3]. Due to its location, it is more likely to 
come in contact with external stimuli and react to them. Second, its progeny undergo 
bidirectional migration to fuel the turnover of cells in the gastric unit [3]. Third, life-spans of 
different gastric epithelial lineages are very diverse, ranging from ~3 days for pit cells to several 
months for ZCs, compared to 3-5 days for enterocytes or 2 weeks for paneth cells in the intestine 
[3]. This forces the gastric stem cell to generate different numbers of precursors for each lineage 
in each differentiation cycle. Fourth, the steady-state gastric corpus does not rely on Wnt 
signaling for maintaining homeostasis, like the intestine [3]. However, the antrum or pylorus of 
the stomach might be considered a hybrid between the gastric corpus and intestine, since antral 
stem cells label with LGR5, the Wnt-responsive, intestinal stem cell marker, and depend on Wnt 
signaling for homeostasis [3]. Moreover, ApcMin and Apc1322T mice, which develop intestinal 
polyps due to inactivation of the Wnt-regulatory gene Apc, develop adenomas in the gastric 
antrum but not in the corpus [3]. Loss of Apc in Lgr5+ cells rapidly results in formation of antral 
but not corpus adenomas [3]. These observations indicate that the antrum has Wnt-responsive 
stem cells that are distinct from those that mediate corpus mucosal self-renewal. Also, antral 
stem cells rarely generate PCs or ZCs [3].  Gastric corpus stem cells do not stain with markers of 
intestinal stem cells. While there has been significant advancement in identification of intestinal 
stem cell markers by virtue of lineage tracing, the promoters have failed to trace any of the 
gastric lineages. For example, Lgr5 [25], Bmi1 [26], Prom1/CD133 [27, [28], Sox9 [29] label 
stem cells in the intestine but fail to do so in the gastric corpus. Lgr5 is expressed in antral stem 
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cells, but is conspicuous by its absence in the adult corpus [11]. Identification of a marker to 
trace corpus stem cells will enable us to understand signaling pathways that maintain stem cell 
homeostasis as well as those that respond to external stimuli and injuries.  
b. Response of the gastric epithelial stem cell to injury: 
Although gastric cancer is the second leading cause of cancer related deaths worldwide [30], 
little is known about its cause, pathophysiology and treatment strategies. According to the gastric 
carcinogenesis model proposed by Correa [31], cancer occurs by serial progression from 
superficial gastritis, atrophic gastritis, intestinal metaplasia, finally culminating into gastric 
cancer.  Chronic infection of the stomach with the gram-negative bacterium Helicobacter pylori 
is a major risk factor for developing gastric cancer. Infection with H. pylori causes inflammation 
along with dramatic reorganization of the epithelium by directly or indirectly causing PC death, 
dedifferentiation of ZCs and activation of stem cells. Whether PC death is the causative agent for 
affecting the differentiation state of ZCs and stem cell proliferation remains to be determined.   
Metaplasia is defined as a potentially reversible change from a fully differentiated cell type to 
another. Human gastric metaplasias are of two main types: Intestinal Metaplasia (IM) and 
Spasmolytic Polypeptide Expressing Metaplasia (SPEM). The presence of intestinal goblet cells 
in the gastric epithelium is the hallmark of IM, since goblet cells are not normally present in the 
stomach. Goblet cells in IM are positive for markers such as Muc2 and Trefoil Factor 3 (TFF3) 
[32].  Evidence shows that IM in the stomach has a high risk of developing into cancer and is, 
therefore, defined as a precancerous condition [33]. Epidemiological studies have linked H. 
pylori infection with IM [34] and hence, H. pylori has been implicated as a major cause of IM. A 
second, possibly preneoplastic metaplasia has been identified in the presence of parietal cell 
atrophy, which is known as SPEM (Spasmolytic Polypeptide Expressing Metaplasia). SPEM is 
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characterized by glands that resemble antral glands rather than those of the corpus, and express 
high amounts of Muc6 and TFF2 (Trefoil Factor 2 or Spasmolytic Polypeptide) [35]. SPEM is 
associated with 90% of all resected gastric cancers [36, [37, [38]. Therefore, both, IM and SPEM 
are precancerous gastric lesions and the signaling intermediates that cause the progression from 
metaplasia to cancer remain to be elucidated. 
 
Figure 1.3: Current model for the origin and progression of gastric metaplasias. Chief cell 
transdifferentiation into SPEM is triggered by loss of parietal cells in the corpus mucosa. In the 
presence of inflammation, such as during H. pylori infection, SPEM can expand into a 
proliferative metaplasia. With continued chronic inflammation, intestinal metaplasia (IM) 
evolves in the setting of pre-existing SPEM and can come to dominate the entirety of the glands.  
(Adapted from [39]) 
1. Spasmolytic Polypeptide Expressing Metaplasia (SPEM): 
While infection of human stomachs with H. pylori leads to the development of IM, those of mice 
fail to develop IM when infected with the mouse adapted strain, H. felis. Chronic infection of 
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mice with H. plori or H. felis leads to loss of parietal cells and inflammation throughout the 
mucosa [40, [41, [42].  Mice infected with H. felis develop SPEM after 6 months of infection 
[43] which eventually progresses to dysplasia, without ever developing IM. Since inflammation 
is a confounding factor in Helicobacter dependent development of SPEM, various other non-
pathogenic models have been developed to assess the contribution of PC death alone in SPEM 
development. 
i. Genetic ablation of PCs: In 1996, Li et. al [44]  generated a transgenic mouse line 
containing a fragment of the attenuated diphtheria toxin (DT-A tox176) driven off the 
H+/K+-ATPase β-subunit promoter, which is specifically expressed in PCs. 
Expression of tox176 led to ablation of PCs and development of metaplasia, 
characterized by a 4-5 fold increase in proliferation extending into the base of the 
gastric unit and dedifferentiated zymogenic cells in adult transgenic mice [44]. These 
mice also showed a twofold increase in pit cell number and a modest increase in pre-
pit cells [44]. These data confirm the point of view of PCs being the differentiation 
signaling hub of the gastric unit.  
ii. DMP-777: In 2000, Goldenring et. al [45] identified that DMP-777, a cell-permeant 
inhibitor of neutrophil elastase that caused specific PC death when rats were gavaged 
with 200mg/kg /day of the drug for 3 months. PC atrophy was unaccompanied by 
inflammation. Mice treated with DMP-777 developed SPEM 10-14 days after 
administration, with PC atrophy around day 3, without developing dysplasia even a 
year after administration [45, [46]. This suggests that inflammation might be a key 
determinant of development of neoplasia.  
iii. Tamoxifen: In 2012, Huh et. al [47] identified a tamoxifen induced mechanism for 
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causing PC death and associated metaplasia. Tamoxifen is a selective estrogen-
receptor modulator frequently used in humans for the treatment of breast cancer and 
in mice for spatiotemporally deleting genes using the Cre-ERT/loxP system [47]. 
Mice treated with a single injection of 5mg/20g body weight of tamoxifen undergo 
PC atrophy, expansion of proliferating progenitor cells and dedifferentiation of 
zymogenic cells within 3 days of treatment [47]. This method of SPEM induction is 
completely reversible within two weeks of tamoxifen administration [47]. The 
mechanism by which tamoxifen induces PC atrophy is uncertain, although, the proton 
pump inhibitor, omeprazole, partially rescues the effects of tamoxifen like DMP-777 
[47]. Therefore, it is believed that the mode of action of tamoxifen is similar to DMP-
777 [47]. 
Figure 1.4 demonstrates the epithelial changes characteristic of SPEM caused by the 
above mentioned methods. 
 
Figure 1.4: Cellular mechanisms of SPEM. Chronic inflammation of the corpus in mammals 
leads to characteristic changes in differentiation in the gastric unit. Parietal cells are lost 
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(atrophy), and the zymogenic chief cell lineage is reprogrammed so that genes that are normally 
expressed only in mucous neck cells, such as spasmolytic polypeptide/TFF2 (shown in green), 
are expressed at high levels in cells at the base. Zymogenic cell markers (such as pepsinogen 
C; red) are co-expressed with neck cell markers. Proliferation is increased and occurs more 
basally in the unit. The pattern of basal proliferation and coexpression of neck and zymogenic 
cell genes is similar to the histologic pattern in the normal antrum and pylorus, which is why it is 
called pseudopyloric metaplasia. The most common metaplasia-inducing inflammation is caused 
by H pylori infection, although autoimmune gastritis (in which autoantibodies target parietal 
cells) can cause the same metaplasia pattern. 
2. Intestinal Metaplasia 
Intestinal metaplasia (IM) is considered a preneoplastic lesion of the stomach in which the 
normal gastric mucosa is replaced by mucosa which resembles the intestine. Morphologically, 
IM can be identified by the presence of goblet cells, which are normally absent in the stomach. 
Although IM is considered to be a risk factor for developing gastric cancer, it is unclear whether 
IM causes gastric cancer or is a marker for increased cancer risk [48]. Since infection with H. 
pylori is the greatest predisposing factor for developing gastric cancer, early investigations 
studied the association of infection with presence of IM. However, it was found that IM occurred 
at an equal frequency in patients with dysplasia and gastric cancer regardless of their H. pylori 
status [48]. Also, eradication of H. pylori did not benefit patients whose mucosa had already 
progressed to IM, suggesting that development of IM marks a point of no return in the 
progression to cancer [49].  
The genetic events in IM are not well understood. According to published data, some genetic 
markers that change during progression to IM and cancer are listed below in Table 2. 
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Table 2: Expression of genes during normal turnover, IM and gastric cancer (Adapted from 
[48]). 
Gene Normal Mucosa Intestinal Metaplasia Gastric Cancer 
CDX1 - ↑↑↑↑ ↑↑ 
CDX2 - ↑↑↑↑↑ ↑ 
TFF1 ↑↑↑↑↑ ↑↑↑ ND 
TFF2 - ↑↑ ND 
TFF3 ND ↑↑↑↑↑ ND 
Villin - ↑↑↑ ND 
Sox2 ↑↑↑ ↑↑ - 
Pdx1 ↑ ↑↑ ↑↑↑ 
OCT-1 ↑ ↑↑↑ ↑↑↑ 
RUNX3 ↑↑ ↑ - 
Shh ↑↑↑ - ND 
↑: relative degree of upregulation, ND: Not Defined, -: Absent 
CDX, caudal type homeobox; OCT, octamer binding transcription factor; PDX, pancreatic and 
duodenal homeobox; RUNX3, runt related transcription factor; shh, sonic hedgehog; TFF, 
trefoil factor.  
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Since IM is the conversion of normal gastric mucosa to a more intestinal type, it is expected to 
find upregulation of intestinal genes during IM. Accordingly, the homoeobox developmental 
genes, Cdx1 and Cdx2, which confer intestinal identity, are upregulated in IM. Interestingly, their 
expression is decreased during the progression of IM to cancer [50]. Liu et. al. [50] suggest that a 
sufficiently high expression of Cdx genes converts gastric epithelium to a terminally 
differentiated intestinal epithelium. In order to further progress to gastric cancer, the level of Cdx 
must be decreased to cause sufficient dedifferentiation and proliferation. Another homoeobox 
gene, Sox2, is expressed in the gastric mucosa but is almost absent in the intestinal epithelium 
during development. However, during IM development, Sox2 levels decrease while Cdx2 levels 
increase. While ectopic expression of Cdx2 in gastric tissue leads to the appearance of goblet 
cells [51], ectopic expression of Sox2 in prospective intestinal tissues leads to a more gastric 
phenotype [52].  
The function of the gastric stem cell during development of IM is unknown. Since Helicobacter 
infected mice do not develop IM prior to dysplasia like humans do, they do not serve as ideal 
model organisms for studying IM progression. Other models such as Cdx2 expressing transgenic 
mice or Mongolian gerbils infected with Helicobacter have been used to determine the 
mechanisms responsible for the conversion of the epithelium from gastric to intestinal [48] and 
the response of the stem cell.  
 
Conclusions 
Most gastric injuries, such as SPEM, IM and cancer, depend on the response of the stem cell to 
external stimuli. Therefore, it is imperative to understand mechanisms that lead to stem cell 
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homeostasis during normal turnover and those that lead to stem cell activation during injury. The 
above mentioned models of metaplasia help in determining signaling pathways that regulate stem 
cell proliferation. We have utilized a number of models of metaplasia to understand mechanisms 
that lead to parietal cell atrophy, stem cell activation and entry of cells into the cell cycle. In 
Chapter 2, we have described, in detail, the tamoxifen induced model of metaplasia and its 
advantages over other chronic models of metaplasia. In Chapter 3, we utilize tamoxifen induced 
atrophy in identifying CD44 as a marker of gastric epithelial stem cells, the role of CD44 in 
expansion of stem cell proliferation during metaplasia and the signaling pathways that regulate 
proliferation downstream of CD44. In Chapter 4, we explore the role of circulating factors and 
cytokines that are upstream modulators of parietal cell atrophy, which transduces the first signal 
to stem cells to start proliferating.  
Therefore, in this thesis, we have: 
i. Established a new model for studying parietal cell atrophy and stem cell activation – 
Tamoxifen treatment of mice; 
ii. Determined the signaling cascade by which stem cell proliferation is regulated during 
normal turnover and tamoxifen induced atrophy; 
iii. Determined potential mechanisms by which parietal cells are damaged in different 
models of SPEM: 
iv. Identified potential circulating factors secreted by the innate immune system in 
regulating parietal cell atrophy and subsequent stem cell activation 
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CHAPTER 2: Tamoxifen induces rapid, reversible atrophy, and metaplasia in 
mouse stomach 
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Abstract 
Tamoxifen, a selective estrogen receptor modulator, is widely used in research and clinically in 
patients. We find that treatment of normal mice with a single ≥ 3mg/20g body weight dose of 
tamoxifen leads to apoptosis of > 90% of all gastric parietal cells and metaplasia of zymogenic 
chief cells within 3 days. Remarkably, gastric histology returns to nearly normal by 3 weeks. 
Tamoxifen toxicity occurs by oral and intraperitoneal administration, in both sexes, in multiple 
strains, and does not depend on estrogen, though acid secretion inhibition is partially protective. 
Thus, substantial gastric toxicity is a heretofore unappreciated tamoxifen side effect.  
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Introduction 
Tamoxifen is widely used to spatio-temporally delete mouse genes using the CreERT/loxP 
system [1]. Tamoxifen is also used clinically as a selective estrogen receptor (ER) modulator, in 
chemotherapeutic, anti-osteoporotic, and several other therapeutic regimens [2, [3] . Some 
reports suggest tamoxifen also increases risk for subsequent gastric cancer [4, [5]. Most gastric 
cancers occur in stomachs colonized by Helicobacter pylori [6]. Precancerous effects of 
bacterial colonization include: death (atrophy) of acid-secreting gastric parietal cells (PCs), 
differentiation changes (metaplasia) in the digestive-enzyme secreting zymogenic (chief) cell 
lineage (ZC) and increased stem cell proliferation [7, [8].  
Materials and Methods 
Animals and injections- All experiments involving animals were performed according to 
protocols approved by the Washington University School of Medicine Animal Studies 
Committee. Mice were maintained in a specified-pathogen-free barrier facility under a 12 hour 
light cycle. Wild type C57BL/6, BALB/c and FVB/N mice were purchased from The Jackson 
Laboratory. To trace parietal cells (PCs), H+/K+ATPase-Cre mice [9] were crossed with a 
reporter line,  B6.129-Gt(ROSA)26Sortm1Joe/J (The Jackson Laboratory) [10], which expresses 
floxed β-galactosidase in the nucleus under the control of the Rosa26 promoter. Tamoxifen (1-
5mg/20g body weight, Sigma, St. Louis, MO; and in 1 experiment, 5mg/20g, Cayman Chemical 
Company, MI) was injected intraperitoneally for one or three days to induce SPEM and mice 
were dissected at 12 hours, 3 days, 7 days, 14 days, 21 days and 28 days after treatment. 
Tamoxifen was dissolved in a vehicle of 10% ethanol and 90% sunflower seed oil (Sigma). 
Tamoxifen stock concentrations ranged from 5mg/ml to 2mg/ml; 200μl/20g body weight was 
injected intraperitoneally. Each mouse was orally gavaged with 4mg tamoxifen, prepared in the 
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same vehicle described above, for 3 days and dissected at day 3. Fulvestrant (Sigma; 3mg/20g 
body weight, dissolved in the same vehicle as tamoxifen) and17 β-estradiol (Sigma; 50µg /20g 
body weight, dissolved in the same vehicle as tamoxifen to stock concentration of 100ng/100µl) 
were injected subcutaneously every day for three days, with or without one injection of 5mg/20g 
tamoxifen on the first day; stomachs were harvested 3 days after the first injection. Omeprazole 
(Sigma; 1.5mg/20g body weight) was dissolved in 100 µl DMSO (Sigma) in 90 µl 1% methyl 
cellulose (Sigma) and orally gavaged every day for four days, with or without one injection of 
5mg/20g tamoxifen on the second day of gavaging, with harvesting at 3 days after tamoxifen 
injection. Raloxifene (Sigma; 5mg/20g body weight) was dissolved in 10% DMSO and 90% 
sunflower seed oil and injected into wildtype mice for 3 days and dissected on day 3.To evaluate 
efficiency of recombination, R26CreERT [11] mice were crossed with B6.129-
Gt(ROSA)26Sor
tm1Joe
/J (The Jackson Laboratory) [10] and injected with 2mg/20g body weight 
raloxifene for 5 days, dissected at day 14 and stained for LacZ. 
Immunofluorescence- Stomachs were prepared, and stained, and imaged using methods modified 
from Ramsey et al [12]. Primary antibodies used for immunostaining were:  rabbit (1:10,000), 
goat (1:2000) anti-human gastric intrinsic factor (gifts of Dr. David Alpers, Washington 
University), rabbit anti-H+/K+ ATPase α subunit (1:10,000, Dr. Michael Caplan, Yale 
University), goat anti-BrdU (1:20,000, Jeffrey Gordon, Washington University), rabbit anti-
Cytochrome C (1:100, Cell Signaling Technology). Secondary antibodies, GSII lectin and BrdU 
labeling were as described [12]. 
Genotyping- For PCR, tissue was lysed with 25mM sodium hydroxide (pH 12.0) at 95°C for 25 
minute and neutralized with the same volume of 40mM Tris buffer (pH 5.0) For Cre, PCR was 
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with RedTaq (Sigma), and KlenTaq (DNA Polymerase Facility, Washington University, St. 
Louis, MO) was used for LacZ PCR. Primers: Cre forward: AGG GAT CGC CAG GCG TTT 
TC and reverse: GTT TTC TTT TCG GAT CCG CC, LacZ forward: GTT GCA GTG CAC 
GGC AGA TAC ACT TGC TGA and reverse: GCC ACT GGT GTG GGC CAT AAT TCA 
ATT CGC.  
LacZ staining- LacZ staining was modified from Lobe, et al, 1999 [13]. Tissue was fixed in 
LacZ fix for 4 hours at 4°C and washed in LacZ wash buffer three times. Tissue was equilibrated 
in 30% sucrose/PBS overnight at 4°C, was embedded in O.C.T. (Sakura, Torrance, CA) and was 
frozen in dry ice. The frozen block was cryosectioned at 14 µm thickness. The section was fixed 
again for 10 minutes in LacZ fix and washed in LacZ wash buffer three times. Then the section 
was incubated in LacZ stain 6 hours at 30°C and washed in PBS three times. The section was 
post-fixed in LacZ fix at room temperature for ten minutes, dehydrated through ethanol and 
xylene, counter stained with nuclear fast red (Vector Laboratories Inc., Burlingame, CA) and 
then mounted in Cytoseal XYL (Richard-Allan Scientific, Kalamazoo, MI). 
Tunel Staining - Stomachs were inflated with freshly prepared formalin and suspended in 
fixative overnight at 4°C, followed by multiple rinses in 70% Ethanol, arrangement in 2% agar in 
a tissue cassette, and routine paraffin processing. Sections (5 μm) were deparaffinized and 
rehydrated, and Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
staining was performed using the ‘In Situ Cell Death Detection Kit, Fluorescein’ (Roche) 
according to the manufacturer’s instructions. Sections were counter-stained with GS-II at 594nm 
(1:2000, Invitrogen)  
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Quantitative RT-PCR - For quantitative RT-PCR (qRT-PCR) analysis, total RNAs from stomach 
tissue were extracted by RNAeasy Midi Kit (Qiagen, Valencia, CA). cDNA was synthesized 
with Superscript III (Invitrogen) and random primers. qRT-PCR was performed with SYBR 
Advantage qPCR Mix (Clontech, Mountain View, CA) and gene-specific primers (see table) on 
an Mx3000P (Stratagene, La Jolla, CA). qRT-PCR analysis and standardization was as described 
[14], every run was standardized to 18s rRNA primers: forward CAT TCG AAC GTC TGC CCT 
ATC, reverse CCT GTG CCT TCC TTG GA.  
Gene-specific primers used were as follows:  
Sr. 
No. 
Gene Forward Primer 
5’      3’ 
Reverse Primer 
5’      3’ 
Ref. 
1. Tff1 AGCACAAGGTGATCTGTGTCC GGAAGCCACAATTTATCCTCTCC  [14] 
2. Atp4a TCTGCTTTGCGGGACTTGTA CGGCATTTGAGCACAGCAT  [14] 
3. Tff2 TGCTCTGGTAGAGGGCGAG CGACGCTAGAGTCAAAGCAG  [14] 
4. Pgc ATGAAGAGTATCCGGGAGACC TGGGCTCATAGAGTACACTGTAG  [14] 
5. GIF CCCTCTACCTCCTAAGTGTTCTC CTGAGTCAGTCACCGAGTTCT  [14] 
6. Gast ACACAACAGCCAACTATTC CAAAGTCCATCCATCCGTAG  [15] 
7. Mist1 GCTGACCGCCACCATACTTAC TGTGTAGAGTAGCGTTGCAGG  [14] 
8. He4 AACCAATTACGGACTGTGTGTT TCGCTCGGTCCATTAGGCT  [16] 
9. Lyz GAGACCGAAGCACCGACTATG CGGTTTTGACATTGTGTTCGC  [16] 
 
Western blot - For Western blot analysis, stomach tissue was frozen in liquid nitrogen and 
ground in urea buffer (8 M urea, 0.19 M Tris·HCl pH 6.8, 1% SDS) using PowerGen 700 
homogenizer (Fischer Scientific). Proteins were separated on a 10% polyacrylamide gel 
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(Invitrogen) and transferred to Nitrocellulose membrane (Amersham Hybond ECL). Primary 
antibodies used for blotting were rabbit anti- H+/K+ ATPase α subunit (1:1000, gift from Dr. 
Michael Caplan), rabbit anti-Gastric Intrinsic Factor (1:10,000 gift from Dr. David Alpers), 
rabbit- anti-Chromogranin A (1:1000, DiaSorin, Stillwater, MN), rabbit anti-Cleaved Caspase 3 
(1:1000, Cell Signaling Technology) and rabbit anti-α-tubulin (1:2,000, Cell Signaling 
Technology). Secondary antibody was horseradish peroxidase (HRP)-conjugated donkey anti-
rabbit IgG (1:2,000, Santacruz Biotenchnology, Inc.). Immobilon Western Chemiluminescent 
HRP Substrate (Millipore) was used for detection. 
Parietal cell (Atp4a
+
) and proliferating cell (BrdU
+
) counts – Cell counts were either by 
immunofluorescence or from H&E. For immunofluorescence, stomach sections were costained 
with GS-II, bisbenzimide, and either anti-H+/K+ATPase or anti-BrdU antibody. The numbers of 
PCs or BrdU positive (proliferating) cells in every field were scored for five randomly selected 
fields in the corpus of a single mouse, with three mice in every experimental set. PCs were also 
counted in H&E-stained sections for every mouse used in the study. Fifty well aligned corpus 
gastric units were selected at random from every mouse under study, the total number of PCs 
determined and average PC/unit calculated. H&E counts were indistinguishable from 
immunofluorescence-based counts.  
Microscopy - Light and transmission electron photomicrographs were taken as described [17] 
Graphing and statistics - All graphs and statistics were performed in GraphPad Prism, using one-
way ANOVA with either Dunnett’s or Tukey’s post-hoc multiple comparison tests for cell count 
data. qRT-PCR data significance was assessed by Student’s t test followed by Bonferroni post 
hoc analysis to ensure against multiple comparison bias. Quantification of GSII and GIF 
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immunofluorescent staining was performed using ImageJ software (http://rsbweb.nih.gov/ij/). 
The GSII/GIF positive region of each unit was divided lengthwise into 10 equal sections. The 
images were then thresholded (GSII 4-6 MFI; GIF 10-17 MFI) to subtract background. The 
mean fluorescent intensities (MFI) above the threshold was multiplied by the area of pixels 
above the threshold for both the GSII and GIF channel for each section. For tamoxifen treated 
day 3 and day 21, the data from 20 units from 2 mice were quantified; in untreated mice, data 
from 15 units from one mouse was quantified. The data for each section was averaged and 
plotted. 
 
Results and Discussion 
In control experiments for tamoxifen induction of Cre-recombinase activity [14], we noticed that 
tamoxifen injection (3 consecutive days, intraperitoneal, 5mg/20g mouse body weight) caused 
dramatic rearrangement of the gastric mucosa with loss of > 90% of PCs, a 6-fold increase in 
proliferation in stem/progenitor cells, and morphological changes in the ZCs in the bases of 
gastric-units (Fig. 2.1A-D). By 14-21 days, the epithelium recovered (Fig. 2.1A).  
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Fig. 2.1. Tamoxifen causes rapid, reversible gastric metaplasia in mice, which is highlighted 
by parietal cell death, concomitant increase in proliferation and loss of differentiated cell 
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markers. A) H&E of wild-type mice following intraperitoneal (i.p.) injection of vehicle at day 7 
or 5mg/20g body weight tamoxifen at 3, 7, and 14 days following injection. B) 
Immunofluorescence (green: anti-ATP4A; red:anti-BrdU) at d3, quantified in C,D. E) 
Quantification of mean PCs/unit/individual mouse by H&E; unless otherwise indicated, mice 
were C57/B6 strain; “Tamoxifen II”: tamoxifen from another supplier. F) Whole stomach qRT-
PCR (expressed as Log2 scale. *P<0.05;**P<0.01;***P<0.001) 
 
No other organs had marked phenotypes at this dose or time-schedule (Fig. 2.2). Even a single 
dose of tamoxifen, by intraperitoneal injection or oral gavage, from two different commercial 
suppliers in three different strains of mice caused similar effects in n>63 mice (Fig. 2.1E, 2.3A-
F). By qRT-PCR, PC-specific transcripts (Atp4a) and markers of ZC maturation (Mist1 aka 
Bhlha15, Pgc, GIF) [17] were significantly reduced by d3, whereas the surface/foveolar lineage 
marker (Tff1) and transcripts for gastrin were unchanged (Fig. 2.1F, see Fig. 2.3G for western 
blots of GIF and ATP4A).  
Increased progenitor cell proliferation and changes in ZC differentiation are characteristic of 
spasmolytic polypeptide expressing metaplasia (SPEM) [14, [18]. In SPEM, expression of 
mucous neck cell markers (like spasmolytic polypeptide, aka TFF2) occurs in the base of glands, 
where ZCs normally reside [17, [18]. Tamoxifen increased two SPEM-specific transcripts, He4 
and Lyz [8]; however, transcript levels for spasmolytic polypeptide(Tff2)  itself were unchanged 
(Fig. 2.1F). SPEM is usually diagnosed by histopathological criteria and not transcriptionally [7, 
[8, [17, [18, [19], but we cannot rule out the possibility that the lack of increased Tff2 indicates 
that tamoxifen-induced metaplasia is a SPEM variant. 
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Fig. 2.2. Other organs are not affected by tamoxifen as severely as the stomach. Pancreas (A), 
Liver (B), Heart (C), Spleen (D), Small Intestine (E) and Large Intestine (F) from vehicle treated 
(top) and tamoxifen treated (bottom) wild-type mice 3 days following injection. Note that organs 
exposed to tamoxifen do not differ substantially from those of control mice.  
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Fig. 2.3. Tamoxifen induced SPEM is 
dose dependent. Wild type mice injected 
with 1mg/20g body weight (A), or 
2mg/20g body weight (B) tamoxifen for 3 
days did not show parietal cell death or 
features of SPEM, whereas, mice treated 
with 3mg/30g body weight (C) for 3 days 
or a single injection of 5mg/20g body 
weight (D) tamoxifen show complete 
atrophy of parietal cells and SPEM 
histology. Other strains of mice develop 
SPEM equivalently on tamoxifen 
treatment as shown in BALB/c (E) and 
FVB/N (F) strains after 3 days of 
injection of 5mg/20g tamoxifen. G: 
Western blot showing decrease in H
+
/K
+
 
ATPase and Intrinsic Factor (GIF, 
zymogenic cell marker) protein levels 3 
days after tamoxifen treatment in mice, 
when compared with controls. Chromogranin A levels are slightly higher post tamoxifen 
treatment, which is consistent with previous reports of spasmolytic polypeptide expressing 
metaplasia (SPEM). 
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In humans and mice, metaplasia always occurs in the setting of PC atrophy [8, [17]. To assess 
PC death, we crossed Atp4b-Cre mice, whose PCs constitutively express Cre [9], to nuclear lacZ-
R26R mice. In these mice, all mature PCs had, as expected, nuclear lacZ expression (Fig. 2.4A). 
Tamoxifen caused near complete loss of lacZ, indicating that PCs died and did not give rise to 
other cells with different morphological or molecular characteristics. TUNEL-positive PCs were 
not observed in the vehicle treated controls, whereas they were common within 12 hours after a 
single injection of 5mg/20g tamoxifen (Fig. 2.4B). By 12h, cytochrome C staining could now be 
found leaked into the cytoplasm of the majority of PCs, consistent with early aptoptosis; in 
controls, distribution was still punctate, consistent with retention in the mitochondria (Fig. 2.4B). 
By transmission electron microscopy, PCs showed neither vacuolization nor organellar swelling, 
characteristics of necrotic death, but had apoptotic features like electron-dense inclusions in 
mitochondria and peripheral chromatin condensation (Fig. 2.4D, E). Finally, only tamoxifen-
treated stomachs showed Caspase 3 cleavage (Fig. 2.4C). 
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Fig. 2.4. Tamoxifen results in SPEM by causing death of parietal cells. A) Nuclear LacZ 
labeled PCs following tamoxifen treatment. B) Top: TdT-mediated dUTP nick-end labeling 
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shows dying PCs (arrowheads). Below: Cytochrome C staining is punctate, consistent with 
mitochondrial localization in vehicle-treated (below left) and dispersed throughout the 
cytoplasm tamoxifen-treated PCs (below right) C) Cleaved caspase 3 western blot with tubulin 
loading control. D) At 2.5d following tamoxifen, PCs show chromatin condensation (arrows with 
black outline), consistent with early apoptosis. E) Another degenerating PC exhibits 
mitochondria ranging in morphology from normal (dashed arrow) to electron-dense-inclusion-
containing (white solid arrow) to electron-dense and degenerating (arrowheads). 
Tamoxifen can function as both an estrogen receptor (ER) agonist and antagonist depending on 
tissue type; however, neither treatment with the pure ER agonist 17-β-estradiol nor the specific 
antagonist fulvestrant induced atrophy/metaplasia. And neither blocked tamoxifen effects (Fig. 
2.5A, B).  The sex of the mice also did not affect tamoxifen effects (Fig. 2.5C), nor did 
ovarectomy of females to block endogenous estrogen production (Fig. 2.5C; data not shown).  
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Fig. 2.5. SPEM induction by 
tamoxifen is not estrogen receptor 
(ER) or sex dependent. Mice treated 
with ER agonist, 17-β-estradiol did 
not develop SPEM (A) and neither did 
estradiol rescue SPEM induced by 
tamoxifen (right). Similarly, mice 
treated with ER antagonist, 
Fulvestrant did not develop SPEM (B) 
and neither did it rescue SPEM induced by Tamoxifen (right).  
Ovarectomized (C) and female (right) 
mice also developed SPEM like their 
male counterparts (male mice used for 
all other experiments in the current 
study) on injection with tamoxifen. D: 
Raloxifene does not show toxicity, like 
tamoxifen, at the same dose and time 
course. E: Cre-recombinase driven by 
the R26 promoter, in a R26-Reporter 
background, is induced by Raloxifene. Blue depicts LacZ staining in cells with Cre-recombinase 
activity. The staining pattern is similar to what we see with tamoxifen in other experiments (not 
shown) using R26-Cre: nearly all mesenchymal cells and many ZCs show induced.  
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However, tamoxifen effects could largely be reversed by blocking the PC proton pump with 
omeprazole (Fig. 2.6), suggesting a role for active acid secretion in tamoxifen toxicity to PCs. 
Finally, another SERM family member, raloxifene, which also has both pro and anti-estrogenic 
effects, did not cause atrophy up to a dose of 5mg/20g (Fig. 2.5D), indicating toxicity is not a 
general feature of SERMs. On the other hand, intraperitoneal injection of raloxifene induced Cre 
recombinase-mediated lacZ activation in mice expressing Rosa26-Cre fused with a modified ER 
(Fig. 2.5E), indicating that raloxifene can be used to induce Cre recombinase activity to obviate 
the off-target toxicity of tamoxifen in Cre-loxP inducible systems. 
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Fig. 2.6. SPEM induction by tamoxifen is ameliorated by omeprazole treatment. A: Wild-type 
mice injected with the proton pump inhibitor, omeprazole, in conjunction with tamoxifen (right) 
are partially protected from SPEM induced by tamoxifen alone (center). Omeprazole, by itself, 
does not have any effect on the stomach mucosa (left). B: Tamoxifen and omeprazole co-treated 
mice show higher numbers of H
+
/K
+
 ATPase expressing parietal cells (right) when compared to 
those treated with only tamoxifen (center). Omeprazole alone does not alter the number of H
+
/K
+
 
ATPase (Atp4) expressing parietal cells (left). These results are quantified in (D). C: Tamoxifen 
and omeprazole co-treated mice show lower numbers of BrdU positive proliferating cells (right) 
when compared to those treated with only tamoxifen (center). Omeprazole alone does not alter 
the number of BrdU positive proliferating cells (left). These results are quantified in (E). 
Tamoxifen is a chemotherapeutic drug that has toxic effects on cancer cells from diverse tissues. 
In osteoclasts (which, like PCs, are large, mitochondria- and proton pump-rich cells), toxicity is 
caused by disrupting proton gradients and, thereby intracellular pH [20]. The drug DMP-777 
causes PC death the same way [19]. Omeprazole is partially protective against both DMP-777 
and tamoxifen toxicity, suggesting a similar mode of action [19]. The minimal dosing that causes 
metaplasia in the current study is an order of magnitude more than the equivalent (40 mg/day) 
used therapeutically in humans [21]. Acute loss of PCs in patients taking tamoxifen might be 
beneficial for acid-reflux associated illness but could also predispose, long-term to gastric 
cancer. Further experiments are clearly needed to address effects of tamoxifen on the human 
stomach. 
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CHAPTER 3: The hyaluronic acid receptor CD44 coordinates normal and 
metaplastic gastric epithelial progenitor cell proliferation 
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Abstract 
The stem cell in the isthmus of gastric units continually replenishes the epithelium. Atrophy of 
acid-secreting parietal cells (PCs) frequently occurs during infection with Helicobacter pylori, 
predisposing patients to cancer. Atrophy causes increased proliferation of stem cells, yet little is 
known about how this process is regulated. Here we show that CD44 labels a population of 
small, undifferentiated cells in the gastric unit isthmus where stem cells are known to reside. 
Loss of CD44 in vivo results in decreased proliferation of the gastric epithelium. When we 
induce PC atrophy, by Helicobacter infection or tamoxifen treatment, this CD44+ population 
expands from the isthmus towards the base of the unit. CD44 blockade during PC atrophy 
abrogates the expansion.  We find that CD44 binds STAT3, and inhibition of either CD44 or 
STAT3 signaling causes decreased proliferation. Atrophy-induced CD44 expansion depends on 
pERK, which labels isthmal cells in mice and humans.  Our studies delineate an in vivo signaling 
pathway, ERK→CD44→STAT3, that regulates normal and atrophy-induced gastric 
stem/progenitor-cell proliferation. We further show that we can intervene pharmacologically at 
each signaling step in vivo to modulate proliferation. 
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Introduction 
Tumors of the stomach are the second leading cause of cancer-related death worldwide  [1, [2]. 
Most of these tumors occur in the setting of chronic infection with the bacterium Helicobacter 
pylori, which causes atrophy (death) of the acid-secreting parietal cells (PC). PC atrophy, in turn, 
causes precancerous, metaplastic changes in other epithelial cells  [3, [4, [5, [6].  In normal 
corpus gastric units, PCs concentrate in the middle (neck) portion amongst mucous neck cells 
(NCs)  [7] and below the isthmus that houses the stem cell. Classical 32P-radiolabeling studies 
indicate that one or a few cells in the isthmus constantly regenerate cells that undergo 
bidirectional migration, up to the mucosal surface and down to the gland base, as they 
differentiate into mature cells of the gastric unit  [4, [8].  NCs migrate slowly from their birth 
into the base, where they rapidly transition into digestive enzyme-secreting zymogenic cells 
(ZCs).  
PC atrophy in humans, mice and other model animals causes existing ZCs to re-express NC 
markers  [6, [9, [10, [11]. This aberrant ZC differentiation pattern is known as Spasmolytic 
Polypeptide Expressing Metaplasia (SPEM) due to greatly increased expression of the NC 
marker Spasmolytic Polypeptide (TFF2). PC atrophy also causes increased proliferation of 
normal stem/progenitor cells in the isthmus  [6, [7]. The pattern of chronic PC atrophy and 
SPEM has been associated with 90% of resected gastric cancers and is thought to be a key 
predisposing factor, but the molecular mechanisms causing SPEM as well as progenitor 
expansion have not been elucidated  [12, [13, [14]. Given that eradication of H. pylori seems to 
cause only partial reversion of metaplasia and risk for cancer  [15, [16, [17, [18], developing 
additional treatment strategies that would encourage reversion of these lesions can potentially 
greatly decrease the risk for gastric cancers worldwide. 
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Our understanding of the molecular regulation of gastric corpus isthmal stem cell proliferation, 
even under normal homeostasis, is still rudimentary despite considerable recent work having 
elucidated gene products marking stem cells in the intestines (e.g. LGR5  [19], LRIG1  [20], 
BMI  [21]) and even in the more distal gastric antrum  [19, [22]. A handful of molecular 
pathways and markers  [23, [24, [25]  have been proposed for the gastric epithelium, but no 
mechanistic studies revealing molecules that regulate proliferation of the canonical isthmal stem 
cell either under normal conditions or in response to injury have been reported  [4]. Furthermore, 
the mechanisms underlying altered patterns of stem cell behavior during precancerous conditions 
in any tissue are only beginning to be explored. 
We have recently shown that a ≥3mg/20g body weight dose of tamoxifen is toxic specifically to 
PCs, in an estrogen receptor independent manner, within the mouse stomach  [26]. Nearly all 
PCs atrophy by 3 days after a single intraperitoneal injection of tamoxifen, and death begins 
within hours, leading to SPEM  [26] that eventually reverses several weeks later if no more 
tamoxifen is injected. PC death is accompanied by a rapid activation of stem and progenitor cells 
in the isthmus region  [26]. Thus, tamoxifen causes PC atrophy and isthmal stem cell activation 
that is rapid, synchronous, and robust, affording us a novel tool to study the induction of stem 
cell activity in response to PC atrophy within an animal model.  Here, we report the signaling 
mechanisms by which gastric corpus epithelial stem cells maintain homeostasis. We find that 
CD44 labels undifferentiated, proliferating cells within the isthmus, which expand dramatically 
during atrophy induced by Helicobacter infection and tamoxifen. Baseline isthmal progenitor 
proliferation is reduced in Cd44−/− mice. Moreover, wild-type (WT) mice treated with PEP-1, a 
peptide that blocks the interaction between hyaluronic acid (HA) and CD44, also show both 
inhibited normal proliferation as well as blocked expansion during atrophy. We next show that, 
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along with CD44, STAT3 phosphorylation is critical for isthmal cell proliferation in response to 
injury and that STAT3 activation depends on CD44. We find ERK signaling is activated almost 
immediately following PC damage and acts as the upstream modulator of Cd44 and the atrophy 
induced proliferative response, as determined by a kinase activation screen. Finally, we show that 
cells expressing pERK in their nuclei expand in the isthmus of mice during PC atrophy and in 
atrophic and metaplastic lesions in human patients. Our results identify for the first time an in 
vivo signaling pathway that mediates the response of the normal stem/progenitor cell 
compartment to a metaplasia inducing injury. 
 
Materials and Methods 
Animals and injections- All experiments involving animals were performed according to 
protocols approved by the Washington University School of Medicine Animal Studies 
Committee. Mice were maintained in a specified-pathogen-free barrier facility under a 12 hour 
light cycle. Wild-type C57BL/6 and CD44─/─ mice were purchased from The Jackson 
Laboratory. Mice from all treatment groups were given an i.p. injection of a mixture of 5-bromo-
2’-deoxyuridine (BrdU, 120 mg/kg) and 5-fluoro-2’-deoxyuridine (12 mg/kg) 90 minutes before 
sacrifice to label S-phase cells. Vehicles used for all injections are: sterile water, sterile saline, 
ethanol in sunflower seed oil, or DMSO in sunflower seed oil; no phenotypes were induced by 
injection of any of the vehicles alone.   
Table 3.1: Mice treatments and injections 
Treatment Dose 
(body weight) 
Vehicle Injection 
Scheme 
Source 
Tamoxifen 5mg/20g 10% ethanol + 
90% sunflower 
seed oil 
i.p. one day, 
sacrificed as 
indicated 
Sigma 
U-0126 50mg/kg 10% DMSO 
(Sigma) + 90% 
i.p. one hour 
before and 
Sigma 
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sunflower seed 
oil 
every two hours 
after tamoxifen 
WP1066 2mg/20g 20% DMSO + 
80% sunflower 
seed oil. 
i.p. one hour 
before and 
every 12 hours 
after tamoxifen 
EMD 
Millipore 
Hyaluronan 
(HA) 
30mg/kg 0.9% sterile 
saline 
i.p. twice a 
week since 
weaning, for 5 
weeks 
Sigma 
PEP-1  
(5 week) 
40mg/kg Sterile water i.p. twice a 
week since 
weaning, for 5 
weeks 
New 
England 
Peptide, 
Gardner, 
MA 
PEP-1  
(3 days) 
40mg/kg Sterile water i.p. once a day 
for 3 days, 
starting one day 
before 
tamoxifen 
injection 
New 
England 
Peptide, 
Gardner, 
MA 
 
H. pylori growth conditions and murine infection- The wild-type rodent-adapted cag+ H. pylori 
strain PMSS1 was cultured on trypticase soy agar with 5% sheep blood agar plates (BD 
Biosciences) for in vitro passage, as previously described [27]. It was then cultured in Brucella 
broth (BB, BD Biosciences) supplemented with 10% fetal bovine serum (FBS, Atlanta 
Biologicals) for 16 to 18 hours at 37°C with 5% CO2. Male C57BL/6 mice were purchased from 
Jackson Laboratories and housed in the Vanderbilt University Animal Care Facilities in a room 
with a 12-hour light-dark cycle at 21°C to 22°C. Mice were orogastrically challenged with either 
Brucella broth (BB), as an uninfected (UI) control, or with the mouse-adapted wild-type cag+ H. 
pylori strain PMSS1. Mice were euthanized at 4 and 8 weeks post-challenge and gastric tissue 
was harvested for immunohistochemistry. 
Human Tissues- Examination of human gastric pathological tissue specimens was approved by 
the Institutional Review Board of Washington University School of Medicine, the Comité de 
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Bioetica of Nicaragua for Universidad Nacional Autonoma De Nicaragua – Facultad De Ceincias 
Medicas Managua, and the Research Ethics Board Manager for Health Sciences at the University 
of Toronto.  Serial sections (4–6 μm thick) obtained from paraffin-embedded tissue samples 
(H&E and alcian blue–periodic acid–Schiff stains) were reviewed by two pathologists in Italy 
(M.F., and M.R.) with specific expertise in gastrointestinal diseases, and a consensus on the score 
for each pertinent histologic variable was reached. Diagnoses and selection of specific regions of 
transitions among normal stomach, atrophic stomach, and intestinal metaplasia was performed 
by a third pathologist in the US (JCM). 
Immunofluorescence and Immunohistochemistry- Stomachs were prepared, and stained, and 
imaged using methods modified from Ramsey et al [28]. Immunohistochemistry was performed 
using ABC reagent and DAB substrate kits (Vector Labs) as per the manufacturer’s instructions. 
For BrdU/Ki67 quantifications, positive cells were counted in >50 gastric units per mouse and 
>3 mice per experiment. Total number of positive cells was divided by the total number of 
gastric units for each mouse. Stomachs were prepared, and stained, and imaged using methods 
modified from Ramsey et al  [28].  Primary antibodies used for immunostaining are listed in 
Table 3.2: Primary antibodies used for immunostaining  
Serial No. Antibody Dilution Source 
1 Goat α-BrdU 1:20,000 Jeffrey Gordon, Washington University 
2 Rabbit α-pERK1/2 1:100 Cell Signaling Technology, Danvers, MA 
3 Rabbit α-Ki67 1:100 Abcam, Cambridge, MA 
4 Rat α-CD44 1:50 BD Biosciences, San Jose, CA 
5 Mouse α-E-cadherin 1:200 BD Biosciences, San Jose, CA 
6 Rabbit α-Atp4a 1:10,000 Dr. Michael Caplan, Yale University 
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Hyaluronan-binding protein staining was performed as described [29].  Secondary antibodies, 
lectins and BrdU labeling were as described [28]. 
Western Blotting – Western Blotting –Western blot analysis was performed as described [26]. 
Antibodies used for blotting are listed in Table 3.3. Immobilon Western Chemiluminescent HRP 
Substrate (Millipore) was used for detection. 
Table 3.3: Primary antibodies used for Western blotting 
Serial No. Antibody Dilution Source 
1 Rabbit α-Cyclin D1 1:1,000 Cell Signaling Technology, Danvers, MA 
2 Rabbit α-pERK1/2 1:1000 Cell Signaling Technology, Danvers, MA 
3 Rabbit α-p-p38MAPK 1:1000 Cell Signaling Technology, Danvers, MA 
4 Rabbit α-SAPK/JNK 1:1000 Cell Signaling Technology, Danvers, MA 
5 Rabbit α-pAKT 1:1000 Cell Signaling Technology, Danvers, MA 
6 Rabbit α-PLCγ 1:1000 Cell Signaling Technology, Danvers, MA 
7 Rabbit α-Egr1 1:1000 Cell Signaling Technology, Danvers, MA 
8 Rabbit α-pSTAT3 1:1000 Cell Signaling Technology, Danvers, MA 
9 Rabbit α-STAT3 1:2000 Cell Signaling Technology, Danvers, MA 
10 Rat α-CD44 1:500 BD Biosciences, San Jose, CA 
11 Goat α-HAS1 1:1000 Santacruz Biotechnology Inc., CA 
12 Goat α-HAS2 1:1000 Santacruz Biotechnology Inc., CA 
 
Secondary antibodies were horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG 
(1:2,000, Santa Cruz Biotenchnology, Inc.), goat anti-rat IgG (1:1000, Santa Cruz Biotechnology, 
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Inc.) and donkey anti-goat IgG (1:1000, Santa Cruz Biotechnology, Inc.). 
Flourescence Activated Cell Sorting - Gastric corpora were collected, washed in PBS, dissected 
into ~1mm2 pieces, suspended in 1mL HBSS, and mechanically disaggregated with two 20 
second pulses in a Medimachine (BD). Tissue was incubated for 1h with vigorous shaking at 37° 
C in 10mL HBSS supplemented with 1mM DTT and 5mM EDTA. The cell suspension was 
filtered (50μm filter, Partek) and the filtrate incubated at 37° C, 5% CO2 until staining. The 
remaining mucosa/tissue left on  the filter was rinsed in 10mL RPMI, then incubated at 37° C 
with vigorous shaking in 10mL RPMI containing 5% BSA and 1.5mg/mL Dispase II (Stem Cell 
Technologies) for 1.5 h. This cell suspension was filtered, and the second filtrate pooled with the 
first, washed, and surfaced labeled for flow cytometry. Cells were stained with Alexa Fluor™ 
647-conjugated with either anti-mouse Epcam (Cell signaling) or Alexa Fluor™ 647-conjugated 
anti-mouse E-cadherin (for some experiments), and APC-Cy™7-conjugated anti-mouse CD44. 
Labeled cells were analyzed with a FACScan (BD) flow cytometer. The use of high wavelength 
fluorophores avoided considerable autofluorescence of living gastric epithelial cells. 
Immunoprecipitation – Immunoprecipitation was performed using the Pierce Crosslink IP Kit 
(Thermo Scientific, Rockford, IL) using the manufacturer’s instructions. Rabbit anti-Stat3 
(1:200, Cell Signaling Technology) was used for pull down and western blots analysis was done 
as described above. 
Microscopy - Light and epifluorescence micrographs were taken as described [7]. 
Graphing and statistics - All graphs and statistics were performed in GraphPad Prism, using 
Student’s t test (one-tailed or two-tailed, as appropriate) for comparison of two groups of data 
and one-way ANOVA with either Dunnett’s or Tukey’s for multiple comparison tests. 
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Results 
CD44 is expressed in isthmal cells and regulates normal baseline proliferation 
CD44 is a cell-surface adhesion molecule, widely described as a marker of cells with highest 
proliferative capacity in cancers of the breast   [30, [31], colon  [32, [33], and stomach  [34]. 
CD44 is highly expressed in gastric cancer cell lines  [34], Helicobacter pylori infected human 
patient epithelia  [34, [35], gastric carcinomas  [36, [37], intestinal metaplasia  [37, [38] and 
dysplasia  [39]. Though CD44 is expressed in gastric tumors  [34, [35, [40], its expression has 
not been characterized in normal mouse corpus gastric epithelial tissue  [41], but it has been 
observed in the antral epithelium  [34] and at the squamous-corpus junction  [42]. We found that 
CD44 was expressed throughout the scant interglandular mesenchymal cells (Fig. 3.1A), but 
CD44+ epithelial cells could also be found in epithelial cells within the isthmus (Fig. 3.2A) and 
in the foveolar/pit region of wild-type mice (Fig. 3.1A, white bracket).  
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Fig. 3.1: The CD44+ cells expanding from the isthmus upon tamoxifen induced parietal cell 
atrophy were epithelial. In vehicle treated mice, there was little overlap between CD44 (red) and 
the epithelial marker, E-cadherin (green) (A, note only one isthmal cell with partial CD44- 
partial E-cadherin label in magnified box at right), but this population expanded gradually over 
3 days after tamoxifen treatment (B, C). Mesenchymal CD44+ cells are labeled with a white 
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bracket, and CD44+ immune cells are marked by white arrowheads. Insets show magnified 
images of the cells showing overlap between CD44 and E-cadherin (yellow). 
 
CD44+ isthmal epithelial cells were small and undifferentiated, as they did not co-stain with 
markers of differentiated cells, such as AAA and GSII (Fig. 3.2A). Since CD44 is known to 
affect proliferation  [43], we next investigated the requirement for CD44 signaling in gastric 
epithelial stem cell proliferation. In mice lacking Cd44, the basal rate of proliferation was half of 
the wild type (WT) controls (Fig. 3.2B, C; n=10), suggesting a role for CD44 in normal stem cell 
homeostasis. CD44 can interact with multiple ligands in the extracellular matrix such as 
osteopontin, collagen, fibronectin, laminin, and chondroitin sulfate, but its principal ligand is 
hyaluronan (HA) [44]. HA activates CD44 by binding to its N-terminal functional domain  [45]. 
To determine whether direct CD44 activation was required for isthmal cell proliferation, we next 
treated adult mice with PEP-1 twice a week for 5 weeks. PEP-1 inhibits CD44-mediated 
signaling by blocking the binding of its ligand, HA. Blocking the CD44-HA interaction with 
PEP-1 caused statistically significant decrease in proliferation of normal stem cells to levels 
phenocopying Cd44−/− mice (Fig. 3.2D n= 12 mice total, 3 mice per experiment, 50 gastric units 
analyzed per mouse).  
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Fig. 3.2: CD44 labels undifferentiated cells in the normal stem cell zone, i.e. the isthmus, of 
the gastric unit, and its loss stunts basal rates of proliferation. In the normal mouse gastric 
unit, CD44 labeled small, distinct cells in the isthmus region (A). Mice lacking the Cd44 gene 
have about half the number of proliferating cells per gastric unit compared to WT controls (B, 
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C). PEP-1 is a peptide inhibitor which blocks the interaction between hyaluronic acid and 
CD44. Treatment with PEP-1 for 5 weeks reduces basal rates of proliferation (D), and results in 
lower numbers of pit cells (E), similar to the Cd44−/− animals (E). In all figures: *P<0.05, 
**P<0.01, ***P<0.001. 
 
Cd44−/− gastric units also showed stunting of the gastric unit zone between the gastric lumen and 
the isthmus, the pit/foveolar zone (Fig. 3.3A,B) and overall decreased census of pit cells (Fig. 
3.2E), a phenotype that was recapitulated by 5-week treatment of WT mice with PEP-1 (Fig. 
3.2E, 3.3C). Pit cells slough rapidly after emergence from the isthmal stem cell zone (half-life of 
~3 days [46]) and would be expected to be most affected by decreased stem cell proliferation due 
to their high turnover rate. We also treated mice for 5 weeks with HA, which caused statistically 
significant increased isthmal cell proliferation (Fig. 3.3E, n=7) and pit/foveolar zones relative to 
wild type (Fig. 3.2E), showing that injection of the CD44 activating ligand was sufficient to 
induce increased proliferation and further confirming a direct role of CD44 signaling in 
regulating isthmal stem cell proliferation. PCs and other non-pit cell epithelial lineages did not 
differ in their baseline census whether CD44 was activated, inhibited or deleted (Fig. 3.3F). 
Taken together, our data indicate that CD44 is expressed in undifferentiated epithelial cells 
within the isthmus and regulates normal rates of gastric epithelial stem cell proliferation. 
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Fig. 3.3: Loss of functional CD44 caused abbreviated pit/foveolar regions. While wildtype mice 
showed long pit regions (A) with ~11 pit cells per unit (Fig. 1D), Cd44─/─ mice showed shorter 
pits with almost 2-fold reduced number of normal foveolar cells per unit (B, Fig. 1D). Mice 
treated with PEP-1, showed a similar foveolar phenotype as Cd44─/─  (C), whereas, those treated 
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with the CD44 ligand HA showed longer pit regions (D) with an average of ~13 foveolar cells 
per unit (Fig. 3.2D) and almost twice the rate of proliferation of WT mice (E). None of the 
conditions changed the parietal census significantly (F). In all figures: *P<0.05, **P<0.01, 
***P<0.001. 
 
Infection with Helicobacter pylori causes PC atrophy and expansion of CD44 into the base of 
gastric units 
We sought to determine whether CD44 expression in gastric epithelial cells was affected by PC 
atrophy, which induces proliferation in mice and humans. Infection of humans with CagA+ 
strains of H. pylori is a major predisposing factor for the development of gastric adenocarcinoma  
[47]. We infected WT mice with a CagA+ strain of H. pylori, PMSS1, for 8 weeks (n=5 mice). As 
expected, in uninfected mice, there was no parietal cell death (Fig. 3.4A, left green arrowhead 
indicates a PC), and CD44 was expressed in the epithelium in the isthmus (Fig. 3.4B, C, left; 
orange arrowhead). In contrast, 8 weeks after H. pylori infection, most PCs were atrophic (Fig. 
3.4A, right, note only rare residual PCs in a section of the gastric corpus, green arrowheads), and 
CD44 expression was found diffusely in the base of gastric units (Fig. 3.4B, C) in zymogenic 
cells which co-expressed the neck cell marker, GSII (yellow arrowheads), indicating they were 
metaplastic.  
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Fig. 3.4: Helicobacter pylori infection causes parietal cell atrophy and expansion of CD44 
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expression. Hematoxylin and eosin stained sections of wild-type, uninfected mice show healthy 
parietal cells (A, left, green arrowhead), whereas, those infected for 8 weeks with the cag+ 
PMSS1 strain of H. pylori show diffuse loss of parietal cells (A, right). The gastric unit is largely 
replaced with metaplastic cells (A, right; brown arrowheads), and only a few parietal cells 
remain (A, right; green arrowheads). CD44 also labels occasional immune cells infiltrating 
interglandular regions (B, right; beige arrowheads). CD44 is expressed in the uninfected gastric 
epithelium in the isthmus (B,C blue box; orange arrowheads) but expands to the base of the unit 
upon infection with H. pylori (B, right, yellow box). In uninfected mice, the zymogenic cells do 
not express CD44 (C, left, white arrowheads), however, upon infection, they become metaplastic 
and express neck cell markers such as GSII (red) as well as CD44 (C, right, yellow arrowheads). 
In mice infected with H. pylori for a shorter time period of 4 weeks, (D), CD44 expansion can be 
seen to extend from the isthmus (purple box) and into the base (orange box) in some gastric 
units. Exemplar CD44+ cells are marked with purple arrowheads (D, insets); gastric units are 
outlined by dashed white line. 
 
Tamoxifen induced parietal cell atrophy causes a burst of CD44+ progenitor cell proliferation 
H. pylori infection in mice and humans is chronic and often focal and asynchronous across the 
stomach. Elucidation of the molecular mechanisms underlying atrophy-induced proliferation in 
the stomach requires a system for inducing atrophy that is synchronous, rapid, and global 
throughout the whole stomach. We have shown that a single injection of 5mg/20g body weight of 
tamoxifen causes dramatic rearrangement of the gastric mucosa, an effect that does not depend 
on the estrogenic or anti-estrogenic effects of tamoxifen but instead causes direct PC toxicity 
[26]. Fig 3.5 shows how within 3 days, over 90% of PCs atrophied, yet complete recovery of PC 
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census occurred by 21 days (Fig. 3.5A and [26]). As PCs atrophied, proliferation accelerated in 
the normal stem cell region, the isthmus, reaching 6-fold baseline levels by day 3 (Fig. 3.5B, C 
and ref [26]). Even by 12h, almost half of the PCs had atrophied, and isthmal progenitor cells 
could be seen expanding towards the base of the unit, the region vacated by dying PCs (Fig. 
3.5B, C). Western blots showed that CD44 and the proliferation markers, PCNA and cyclin D1, 
increased throughout the gastric corpus (Fig. 3.5D).  
In short, tamoxifen causes PC atrophy, increased CD44 expression, and proliferation, similar to 
infection with Helicobacter but has a rapid and synchronous timeframe for atrophy and injury 
response across the whole stomach allowing for biochemical analysis of the process. 
Furthermore, we have shown previously that tamoxifen treatment does not cause substantial 
inflammatory cell infiltrate [26]. Unlike infection with CagA+ Helicobacter; the changes are 
almost wholly confined to the mucosal cells already present at time of treatment, reducing 
confounding variables in analyzing differences in global analysis of changes in signaling 
pathways and gene expression.  
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Fig. 3.5: CD44 expands and labels proliferating cells upon parietal cell atrophy and is 
required for this injury induced expansion of progenitor cells. Hematoxylin and eosin stained 
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sections of wild-type mice at 3 days (A, left) following intraperitoneal (i.p.) injection of vehicle, 
and, at 12 hours (A, middle) and 3 days (A, right) following i.p. injection of 5mg/20g body 
weight of tamoxifen. Wild-type mouse stomach treated with vehicle shows normal stomach 
epithelium, whereas, those injected with tamoxifen show a progressive loss of PCs. PC loss is 
coupled with an expansion in proliferation, measured by BrdU incorporation (stained in red), at 
12 hours (B, middle; C) and 3 days (B, right; C) after tamoxifen treatment, compared to vehicle 
controls (B, left; C). Cyclin D1 and PCNA, which are markers of proliferation, are also 
increased on PC atrophy at 12h and day 3 by western blot of whole corpus stomach regions (D). 
The blot also shows that CD44 expression increases upon atrophy.  A CD44+ epithelial 
population starts expanding from the time-point (6h) when PCs first begin to die (E) and reaches 
the base of the unit by day 3 (E). The number of CD44+ epithelial cells expands ~3-5 fold during 
this time, as shown by multiple FACS experiments (F). One of the FACS plots graphed in F is 
shown in G. Many CD44 expressing cells co-stain with Ki67 after treatment with tamoxifen (H, 
yellow box is magnified in inset at right). 
 
We next set out to use tamoxifen-induced atrophy as a tool to determine the origin of CD44+ 
cells following PC atrophy. CD44+ isthmal cells began to expand as early as 6h after tamoxifen 
injection (Fig. 3.5E). The initial increase in CD44-positive epithelial cells occurred in the isthmal 
progenitor zone, from which they expanded into the base until there were CD44 and E-cadherin 
double positive epithelial cells from isthmus to base by D3 (Fig. 3.5E, Fig. 3.1B,C). This pattern 
was similar to the chronic CD44 labeling that occurred in the base of Helicobacter-infected 
corpus units. By day 3, many of the CD44+ cells in the base labeled SPEM-type metaplastic 
cells, co-labeling with GSII (Fig. 3.5E). We next decided to look at an earlier time point in our 
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Helicobacter infected mice (4 weeks post infection) to determine whether, in certain units, 
CD44+ cells could also be identified expanding from the isthmus as occurred shortly after 
tamoxifen-induced atrophy. Fig. 3.4D shows that, whereas many units already show full 
metaplasia with GS-II+/CD44+ cells only at the base, as in the 8-week post-infection animals, 
some units showed CD44 extending from isthmus to the base. 
We next quantified the expansion of CD44+ epithelial cells. Their census increased ~3 to 5-fold 
over the course of the three day tamoxifen treatment, as determined by flow cytometry (n= 18 
mice across 9 experiments) (Fig. 3.5F, G, Fig. 3.6).  
 Fig. 3.6: CD44+ epithelial cells 
expand 5-7 fold upon parietal cell 
atrophy as quantified by FACS. A 
representative FACS graph from an 
experiment shows that CD44+ 
epithelial cells increase ~5-7 fold 
upon treatment with tamoxifen for 
12h and day 3 compared to vehicle 
controls. 
Furthermore, there was extensive co-labeling of the CD44+ population (at 12h) with the 
proliferation marker Ki67 (Fig. 3.5H). CD44’s activating ligand, HA, was found in the 
mesenchyme between gastric glands (Fig. 3.7A) and increased following atrophy, as did the 
enzymes that synthesize it, HAS1 and HAS2 (Fig. 3.7B).   
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Thus, both CD44 and HA were increased in expression in tandem, following atrophy, with HA 
present in the region of the basement membrane of the epithelial cells expressing CD44. During 
response to PC atrophy, Cd44─/─ mice showed a statistically significant reduction in isthmal 
proliferation compared to controls (n=6 mice, 2 experiments) (Fig. 3.8A), and a short, 3 day 
pretreatment with PEP-1 was sufficient to nearly completely abrogate the proliferative response 
Fig. 3.7: Hyaluronic acid (HA), a ligand of CD44, was 
increased upon atrophic injury with tamoxifen. HA 
(stained using Hyaluronan-binding protein; in green) 
and CD44 (red) were increased in expression towards 
the base of the gastric unit during tamoxifen induced 
metaplasia (A, arrowheads). HAS1 and HAS2, enzymes 
that synthesizes HA, were also increased by 12h of 
tamoxifen treatment (B). 
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induced by PC atrophy (Fig. 3.9; n=5, 2 experiments).  
 
Fig. 3.8: Cd44─/─ mice have compensatory mechanisms for increasing proliferation following 
tamoxifen induced atrophy. When treated with tamoxifen, Cd44─/─ mice were able to increase 
proliferation to almost normal levels (A; one-tailed, paired Student‟s t test), despite the defect in 
basal levels of proliferation. Although there was a decrease in pSTAT3 in the Cd44─/─ mice (B), 
similar to PEP-1 treatment (Fig. 6E), Cyclin D1 levels did not change in the Cd44─/─ mice (B), 
suggesting that there might be a CD44-STAT3 independent compensatory mechanism in these 
mice that regulates proliferation in the face of atrophy. 
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Thus, both stem cell normal homeostasis and response to PC atrophy are mediated by HA-CD44 
interactions, though in mice null for Cd44 from conception, compensatory mechanisms allow for 
some degree of non-CD44-mediated proliferation increase (note in Fig. 3.8B that atrophy still 
caused an increase in cyclin D1 expression in Cd44−/− mice).  
Therefore, our data show that CD44: (a) is expressed by cells in the normal stem cell 
compartment; (b) marks proliferating progenitor cells during injury, and; (c) is necessary for 
Fig. 3.9: CD44 is necessary for elevating the 
rate of progenitor cell proliferation upon 
induction of atrophy. PEP-1 blockade of 
CD44 activation halves atrophy induced 
proliferation (B, C), measured by BrdU 
incorporation (red, B), whereas parietal cells 
still die upon PEP-1 inhibition of CD44 (A).  
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maintaining the normal and injury-responsive proliferative capacity of the gastric units. We next 
sought to determine the mechanism by which CD44 regulates progenitor cell proliferation. 
 
CD44 regulates gastric progenitor cell proliferation through STAT3 
 Signal transducer and activator of transcription 3 (STAT3) controls diverse cellular functions, 
such as growth, differentiation and apoptosis [48]. When activated by cytokines and growth 
factors, STAT3 localizes to the nucleus and regulates transcription of target genes that control 
proliferation and apoptosis [34, [48, [49]. STAT3 increases normal and cancer stem cell 
proliferation [50] by inducing its targets survivin and cyclin D1 [51, [52] and is activated by 
cagA+ strains of H. pylori in host cells, in vitro and in vivo [53]. CD44 increases cyclin D1 
expression by directly interacting with active STAT3 [54]. As we observed increased 
proliferation and cyclin D1 expression in the CD44-dependent response of the gastric unit to PC 
atrophy, we hypothesized that the mechanism of CD44 action might be via STAT3-cyclin D1. 
Consistent with our hypothesis, we found that while activated STAT3 (STAT3 phosphorylated on 
Tyr 705) was at low levels in normal mucosa, there was abundant p-STAT3 during atrophy (Fig. 
3.10A). We then checked whether STAT3 bound CD44 by co-immunoprecipitation and found 
indeed that there was more CD44 associated with STAT3 in response to atrophy (Fig. 3.10B) 
when compared to controls. Immunoprecipitated STAT3 was phosphorylated only in tamoxifen 
treated samples and not in control or Cd44─/─ stomachs (Fig. 3.10B). STAT3 phosphorylation 
was also decreased in the absence of CD44 or when CD44-HA interactions were blocked by 
PEP-1 (Fig. 3.10C, 3.8B). CD44 expression was also reduced by PEP-1 blockade of its HA 
ligand (Fig. 3.10C). When we blocked STAT3 activation by injecting its specific inhibitor, 
WP1066 [55], with and without tamoxifen, we found that STAT3 inhibition greatly reduced 
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atrophy-induced cyclin D1 expression and stem cell proliferation (Fig. 3.10D,E), without 
affecting CD44 expression (Fig. 3.10E). Hence, we conclude that STAT3 is activated upon injury 
in the gastric epithelium, and CD44 binds to STAT3 to regulate the injury-induced burst of 
proliferation of progenitor cells.  
 
Fig. 3.10: CD44 regulates gastric progenitor 
cell proliferation through STAT3. STAT3 is 
activated by tyrosine phosphorylation after 
atrophy induction with tamoxifen (A).  
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IP with antibody against STAT3 followed by Western blot for CD44 shows increased association 
between CD44 and STAT3 during tamoxifen-induced atrophy, compared to controls; also 
phosphorylated STAT3 was pulled down only during tamoxifen induced atrophy (B). Inhibition of 
STAT3 and CD44 functions (using WP1066 and PEP-1 respectively) causes decreased Cyclin D1 
expression (C, E) and proliferation as quantified in tissue using BrdU (D); “D1”= 1 day post 
tamoxifen; “D2” = 2 days. CD44 levels were not affected by STAT3 inhibition, whereas, pSTAT3 
was significantly reduced upon CD44 inhibition with PEP-1 (C, E). CD44 expression is reduced 
upon blocking interaction with its HA ligand by PEP-1 (C). 
 
ERK signaling regulates progenitor cell proliferation through CD44 
To determine the upstream signal causing CD44 expansion and increased proliferation, we 
surveyed multiple signaling pathways known to affect proliferation, such as the MAP kinases 
(p38MAPK, ERK, and JNK), AKT, and PLCγ in tamoxifen-induced atrophy. Whereas most 
proliferation mediators were either not substantially or only marginally increased, there was a 
dramatic increase in active ERK at the time of peak atrophy (Fig. 3.11A). ERK is known to 
increase proliferation in normal [56] as well as neoplastic cells [56, [57], though its role in 
gastric stem cell homeostasis has not previously been assessed. Accordingly, ERK was strongly 
activated as early as 6 hours after treatment with tamoxifen (Fig. 3.11B), which was further 
confirmed by the concomitant increase in expression of its downstream target, EGR1 as well as 
CD44 (Fig. 3.11B)  [58]. If ERK signaling was indeed involved in regulating proliferation in the 
gastric epithelium following PC atrophy, blocking it should block atrophy-induced proliferation. 
ERK phosphorylation can be blocked with the kinase-specific inhibitor of MEK, U-0126 [59]. 
We co-injected mice intraperitoneally with U-0126 along with tamoxifen.  Fig. 3.11C shows that 
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U-0126 successfully blocked ERK phosphorylation in the stomach during tamoxifen-induced 
atrophy and prevented a downstream increase in ERK’s transcriptional target EGR1 [60, [61]. 
Confirming our hypothesis that pERK mediates PC-atrophy induced CD44, U-0126 injection 
into mice blocked the increase in CD44 (n= 10 mice across 3 experiments) (Fig. 3.11C). We 
observed similar results with another inhibitor of ERK activation, PD 98059 [62] (unpublished 
data; n= 3 mice, two experiments). As expected, ERK inhibition also blocked the proliferative 
response to atrophy (Fig. 3.11D, E), much like loss or inhibition of CD44. BrdU incorporation 
per gastric unit, at 12h post tamoxifen treatment, was reduced by 56 ±5% (n=3 mice; 50 gastric 
units counted per mouse) in mice treated with U-0126 compared to those receiving tamoxifen 
and vehicle.  
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Fig. 3.11: ERK signaling is activated early upon 
induction of injury and is required to induce CD44.  
Western blots of candidate signaling pathways that might 
be involved in increasing the proliferative response after 
PC atrophy by tamoxifen (A). Of the pathways analyzed, 
only ERK signaling shows a dramatic increase in 
activation after tamoxifen, compared to vehicle controls. 
ERK1/2 are tyrosine phosphorylated soon after PC 
damage ensues (6 hours after tamoxifen treatment); 
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EGR1 and CD44, downstream targets of ERK signaling, are already increased in expression at 
this early time point (B). Co-injection of tamoxifen with U-0126, a specific inhibitor of ERK 
phosphorylation, mutes the metaplastic induction of pERK along with downstream targets, EGR1 
and CD44 by western blot (C), and mutes the proliferative response shown by BrdU 
immunostaining in red (D), quantified in (E). 
 
ERK signaling is increased in multiple models of gastric metaplasia and labels isthmal cells  
If ERK activation mediates the expansion of stem/progenitor cells, then phosphorylated ERK 
should be identifiable within those cells. In agreement, Fig. 3.12A, B show that, whereas control 
mice showed no detectable pERK, 6 hours following induction of atrophy, we identified 2-3 
undifferentiated cells per unit with nuclear pERK within the canonical isthmal stem cell zone 
(Fig. 3.12A, B). pERK could also be detected in multiple cell nuclei per unit in  tox176 mice  
[63] that show constitutive PC atrophy due to PC-specific expression of attenuated diphtheria 
toxin (unpublished data) and in mice 8 weeks after infection with Helicobacter (Fig. 3.14A, right 
panels) whereas pERK was completely absent in uninfected controls (Fig. 3.14A, left panels).  
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Fig. 3.12: pERK labels metaplasia-associated cells in mice and humans. pERK labels nuclei of 
isthmal progenitor cells (orange arrowheads) at 6 hours of tamoxifen treatment (A, B), whereas, 
there is no pERK signal in vehicle treated controls. PCs do not stain positive for pERK in either 
vehicle or tamoxifen treated mice. Gastric units of human patients showing focal intestinal 
metaplasia (C, right) in a region with mixed gastric and intestinal differentiation (magnified in 
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E), indicating transitional/early metaplasia (goblet cell is marked with a yellow arrowhead) 
stain positive for pERK (green arrowheads). Quantification of pERK expression in human IM 
patients (n=3) displaying such a transitional epithelium by counting the number of pERK+ cells 
in the „intestinal metaplasia (IM)‟ regions and in residual gastric-differentiation regions 
„adjacent to IM‟ epithelium vs. those in normal humans, shows a dramatic increase in pERK+ 
cells in IM regions, with a significant increase in pERK+ cells even in gastric regions adjacent to 
IM when compared to normal human patients (D). 
Serial histological sections immunostained with anti-pERK and anti-CD44 from mice injected 
with tamoxifen for 12h showed a population of positive cells in the same location in the isthmus 
(Fig. 3.13).  
 
Fig. 3.13: CD44 and pERK label the same population of cells as they start expanding from the 
isthmus during tamoxifen induced metaplasia. Immunohistochemical staining of serial sections 
of mouse stomachs treated for 12h with tamoxifen show that CD44 (yellow arrowhead) and 
pERK (green arrowheads) label a similar, overlapping population of isthmal cells during 
atrophy. 
Finally, we examined a small cohort (n=3) of human gastric resection specimens for pERK 
staining [10]. pERK+ cells were almost never observed in normal control stomach specimens 
(Fig. 3.12C) or in regions without atrophy. However, pERK+ epithelial cells could be found in 
regions of gastric differentiation neighboring or contiguous with intestinal metaplasia (Fig. 
3.12C, magnified in 3.12E). pERK+ cells were also particularly prominent in intestinal 
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metaplasia lesions that neighbored regions of gastric differentiation. To test this pattern of pERK 
staining in regions of transition between normal and metaplastic differentiation in a broader 
cohort of samples, we extended our study to include ten more gastric specimens with chronic 
parietal cell atrophy and inflammation caused by infection with Helicobacter pylori.  
The specimens were acquired in collaboration with an international consortium studying gastric 
carcinogenesis in Nicaragua (http://gcbiomarkers.org/). 8/10 of these specimens showed the 
same pattern of pERK staining, with high pERK staining in transition regions adjacent to 
metaplastic tissue. One specimen did not display metaplasia nor did it stain with pERK. The 
remaining sample did not stain with pERK even though it displayed intestinal metaplasia. We 
took 3 random pERK stained patient slides and quantified regions showing transitions between 
gastric and intestinal differentiation. In regions of intestinal metaplasia with residual gastric 
epithelium, there were 11±3.46 pERK+ cells per high power field of 60X magnification 
(quantification from n=3 different patient specimens, representative of staining patterns observed 
in 9/11 specimens; p<0.01). In the gastric epithelium adjacent to intestinal metaplasia, pERK-
positive cells were also increased significantly (3.67±1.15 per hpf, p<0.05) compared to regions 
in the same specimens that had residual normal differentiation patterns with preserved parietal 
cells (~0.33 pERK+ cells per hpf) (Fig. 3.12D; Fig. 3.14B,C).   
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Fig. 3.14: ERK signaling is activated after parietal cell atrophy in both, humans and mice. 
Immunohistochemical staining for pERK showed numerous positive nuclei of metaplastic cells in 
mice infected with the PMSS1 strain of H. pylori (A; green arrowheads), whereas uninfected 
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controls did not stain positive for pERK (A). pERK staining was also observed in gastric tissues 
of human patients undergoing intestinal metaplasia (B, C; green arrowheads) in regions of 
transition between normal gastric tissue and glands developing early intestinal metaplasia with 
appearance of goblet cells (yellow arrowhead). 
 
Given the data in humans and mice, we posit that activation of ERK signaling plays a key role in 
the cell proliferative response to PC atrophy and is the upstream regulator of the CD44-STAT3 
proliferation axis. 
 
Fig. 3.15: Model for stem/progenitor cell renewal during normal and atrophic injury 
conditions. The isthmal stem cell (SC) is self-renewing and also gives rise to acid-secreting 
parietal cells (PCs), among other cell-types within the stomach. Upon atrophy of PCs, by toxins 
or H. pylori infection, the SCs activate ERK to ramp up proliferation. ERK activation is required 
for expanded CD44 expression and the association between CD44 and pSTAT3, which in turn, 
upregulates Cyclin D1 to drive proliferation. 
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Discussion 
Here we demonstrate that parietal cell atrophy, which increases the risk for gastric cancer [64], 
causes increased isthmal stem/progenitor cell proliferation, which depends on activation of ERK. 
ERK induces CD44, which is critical for both normal proliferation and the atrophy-induced 
expansion. CD44 signaling maintains normal proliferation and increases proliferation following 
PC atrophy via interaction with its ligand HA. STAT3 binds CD44 and is phosphorylated only 
when CD44 is present and can interact with its ligand HA. Inhibition of STAT3 phosphorylation 
inhibits atrophy-induced stem cell proliferation but does not affect increased expression of 
CD44. Thus, we conclude that atrophy-induced proliferation depends on an 
ERK→CD44→STAT3 axis. 
To our knowledge, this is the first report delineating an in vivo mechanism for isthmal cell 
expansion almost immediately after PC damage and atrophy. We utilize tamoxifen treatment as a 
rapid, synchronous, and inducible model for PC atrophy that recapitulates what we observe in 
mice in chronic Helicobacter pylori infection. Soon after PC atrophy begins, there is a dramatic 
increase in activation of ERK in isthmal cells, possibly due to release of a damage-induced pro-
proliferative signal or loss of a proliferation-inhibiting signal from the surrounding PCs. Our 
finding that ERK is critical for inducing stem cell proliferation is consistent with other reports. In 
the juvenile rat, premature weaning also induces isthmal proliferation that depends on ERK 
signaling [65]. In patients infected with H. pylori, it has been proposed that bacterial CagA 
activates the ERK cascade in gastric epithelial cells, which initiates the development of gastric 
cancer [66]. It has also been shown that systemic constitutive activation of the K-ras oncogene, 
which is upstream of ERK in the ERK-MAPK pathway, causes gastric hyperplasia and increased 
proliferation [67]. It appears that ERK is a consistent injury-induced proliferative signal in 
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precancerous lesions of the gastrointestinal tract, such as esophageal dysplasia [68], Barrett’s 
adenocarcinoma cells [69] and pancreatic ductal adenocarcinoma [70]. 
Once active, ERK increases the expression of its target CD44. CD44 expression expands from 
the isthmus soon after PC damage. CD44 is a well-known cancer stem cell marker and co-labels 
proliferating cells in the gastric epithelium upon injury. CD44 labels a population of cells that 
includes the LGR5+ population in the bases of the pyloric glands [19] (unpublished data); 
however, we show here it also labels occasional, small epithelial cells in the corpus gastric unit 
isthmus. Lack of CD44 signaling, in Cd44−/− mice and in mice treated with PEP-1, stunts stem 
cell proliferation. Cd44−/− mice display a defect in the numbers of pit cells possibly due to faster 
turnover rate of these cells compared to parietal and other epithelial cells, which leads to an 
accumulation of the deficit over time. Another explanation for this observation could be that 
CD44 might regulate pit cell progenitor proliferation selectively, since we do observe 
mesenchymal CD44 accumulation adjacent to pit cells.   When subjected to PC injury by 
tamoxifen, the PEP-1 mice are unable to elicit the same proliferative response as control mice, 
whereas Cd44 nulls are better at coping with PC atrophy, probably due to compensatory 
mechanisms established during lifelong lack of CD44. This is confirmed by the fact that while 
PEP-1 treated mice do not show an expansion in cyclin D1 expression following injury, the 
Cd44−/− mice are still able to elevate cyclin D1 to control levels, suggesting they have developed 
other ways of responding to injury that are independent of the normal CD44-dependent 
mechanism. Both PEP-1 treated and Cd44−/− mice, when injured with tamoxifen, undergo PC 
atrophy, establishing that the proliferative response is downstream of the initial attack of 
tamoxifen, i.e. the ablation of PCs (note in Fig. 3.9C, PEP-1 treated mice have lower 
proliferation, even though there are almost no PCs remaining). It will be interesting to see 
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whether loss of CD44 in Cd44−/− or PEP-1 inhibited mice affects the course of H. pylori 
infection. In addition to its role in proliferation, CD44 has recently been shown to impart cells 
with resistance against reactive oxygen species (ROS) [71]. As most gastric pathology involves 
inflammatory responses, and inflammation induces the release of ROS, CD44 might play a dual 
role in overcoming such injurious stimuli – by increasing proliferation and protecting the 
dividing cells from the surrounding toxicity, thereby increasing their lifespan. 
CD44 induces cyclin D1 by associating with active STAT3 [54]. Abolishing STAT3 activity 
decreases proliferation in spite of PC atrophy, without affecting Cd44 expression. Tamoxifen 
treated Cd44−/− and PEP-1 injected mice show reduced pSTAT3, establishing a role for CD44 in 
STAT3 activation in a feed-forward proliferation circuit. Interestingly, Cd44−/− mice are able to 
increase cyclin D1 without the presence of active STAT3, confirming that the CD44-independent 
mechanism regulating proliferation in cases of acute PC injury is also STAT3-independent. As 
PEP-1 has a more dramatic effect on atrophy induced proliferation than loss of CD44, it is 
possible that HA signaling through its other receptors, such as TLR4 [72], which would be 
blocked by PEP-1 but would still function in Cd44−/− mice, might compensate loss of CD44. 
However, treating Cd44−/− mice with PEP-1 does not further reduce the rate of proliferation in 
uninjured mice (unpublished data), suggesting that HA receptors other than CD44 might not play 
key roles in maintaining normal stem cell turnover.   Taken together, it appears that the 
ERK→CD44→STAT3 axis is involved in expansion of proliferating isthmal stem/progenitor 
cells under conditions of acute injury.  
There is only a scant literature on the intracellular signaling pathways that regulate non-
neoplastic turnover of progenitor cells in the corpus [4].  On the other hand, some of the signals 
regulating stem cell response extrinsically have been identified. For example, Sonic hedgehog 
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and BMP2/4/7 are critical for regulation of normal stem cell turnover because deficiencies in 
those factors cause increased isthmal proliferation [73, [74], though those effects might be 
indirect via loss of PCs causing decreased acid and increased gastrin, which is a known corpus 
stem cell mitogen [75, [76]. Gastrin works in part by stimulating histamine release by 
enterochromaffin cells, which also regulates proliferation of isthmal stem cells [77, [78, [79]. 
EGFR stimulating factors like EGF, TGFα, and Amphiregulin work through ERK and other 
downstream signaling pathways; all cause increased proliferation [80, [81].  
It is unclear which ligand stimulates activation of ERK in the responsive isthmal cells. It might 
be derived from neighboring dying PCs. We do not believe the early stem cell response to 
atrophy we observe depends on gastrin, as gastrin transcript levels are unchanged until at least 3 
days following tamoxifen treatment [26]. Signaling through the EGFR receptor tends to cause 
pit/foveolar cell specific proliferation as opposed to stimulation of the multipotent, isthmal stem 
cell [82]. Thus, EGF family ligands are less likely candidates.  
Inhibition of the ERK pathway decreases proliferation and CD44 expression. Though regulation 
of biological processes like proliferative response to injury in vivo is undoubtedly complex, we 
posit three possible, non-mutually exclusive mechanisms by which ERK could mediate increase 
in CD44. First, ERK activation could increase CD44 transcriptionally leading to an increase in 
CD44+ cell proliferation. Second, ERK could increase proliferation of CD44+ isthmal cells, 
without increasing CD44 expression directly. Third, ERK signaling could increase HA in the 
basement membrane/mesenchyme by directly activating HAS, which in turn would increase 
CD44-dependent proliferation. Our data support the first interpretation. The second mechanism 
does not seem plausible because if it were true, then blocking CD44 action would not affect 
proliferation, yet our data show that CD44 is necessary for atrophy-induced increase in 
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proliferation. The third interpretation seems less likely because we observe pERK in isthmal 
cells in the epithelium as early as 6h after atrophy induction, just before CD44+ cells start 
expanding from the same region. We do not observe pERK in the mesenchyme, so there are 
likely to be other mechanisms leading to upregulation of HAS. 
It is intriguing to speculate that the resident CD44+ epithelial population in wild-type mice might 
mark a normal corpus stem cell, as these cells are isthmal, occasional, have high N:C ratio under 
normal conditions and expand greatly upon injury. CD44+ cells also co-label with LGR5+ cells in 
the antrum/pyloric region of the stomach, which can regenerate the entire pyloric unit, consistent 
with multipotency.  
One seeming paradox in our CD44 data is that loss of CD44 under homeostatic conditions 
decreases census of surface/pit cells, whereas, during response to parietal cell atrophy, it affects 
proliferation of cells expanding away from the pit zone and into the base.   One explanation is 
that in homeostasis, pit cells turnover far more rapidly than any other cells in the gastric unit, so 
defective CD44 signaling manifests as decreased census of those cells. During parietal cell 
atrophy, there is rapid turnover of parietal cells, deeper in the unit, so CD44 mediates expansion 
of cells towards the base of the unit to replace the lost parietal cells. 
Lifetime risk for development of gastric cancer has been reported to be decreased only partially 
by eradication of Helicobacter pylori [15, [16, [17]. It is likely that aberrant epithelial 
differentiation patterns, such as atrophy, metaplasia and increased proliferation, persist after 
treatment and must also be treated to reduce cancer risk substantially. The experiments in the 
current study identify both the novel role of a specific signaling pathway involved in the 
proliferative response to PC atrophy and show, as a proof of principle, that those pathways can 
be pharmacologically inhibited at multiple steps. Ultimately, the identification of clear 
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pharmaceutical targets in the metaplasia/atrophy sequence might be critical for reversing the risk 
for cancer progression from precursor lesions. 
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CHAPTER 4: Metaplasia in the stomach is induced by cytokines produced by 
macrophages 
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Abstract 
Atrophy of acid secreting parietal cells in the stomach is the first step towards developing 
metaplasia, which eventually progresses to gastric cancer. Gastric cancer is the second largest 
cause of cancer related deaths worldwide. Parietal cell death is accompanied by a rapid 
remodeling of the gastric epithelium, characterized by stem cell activation, dedifferentiation of 
post-mitotic zymogenic cells and their re-entry into the cell cycle. However, the origin of parietal 
cell atrophy and metaplasia remain obscure.  
We have previously established that the breast cancer treatment drug, tamoxifen, causes prompt 
parietal cell death within 3 days of administration. Atrophy is accompanied by an increase in 
stem cell proliferation by activation of the ERK→CD44→STAT3 signaling cascade. 
Nevertheless, the upstream signal that leads to parietal cell death and the communication 
between damaged parietal cells and the neighboring stem cells that lead to their activation are 
unknown.  Here we find that, within a few hours, there is a dramatic increase in the levels of 
circulating IL-6 in the sera of mice treated with tamoxifen. Although inflammation is absent, 
there is an increase in F4/80+ macrophages in the mesenchymes of tamoxifen treated mice. When 
challenged with tamoxifen ex vivo, primary macrophages secrete IL-6.  Depletion of 
macrophages in tamoxifen treated mice blocks parietal cell atrophy and associated expansion in 
stem cell proliferation. Factors secreted by macrophages lead to the activation of ERK in stem 
cells and increase in iNOS in parietal cells. ERK causes a burst of stem cell proliferation, 
whereas, iNOS activates the parietal cell death cascade. When iNOS signaling is blocked, 
parietal cell atrophy and proliferation expansion are rescued. In conclusion, we propose a 
mechanism by which the innate immune system signals to the gastric epithelium to initiate 
parietal cell death and metaplasia.   
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Introduction 
When acid-secreting parietal cells (PCs) in the gastric epithelium atrophy (die) by genetic 
ablation [1], infection with Helicobacter pylori [2] or by chemical means such as treatment with 
tamoxifen [3], it causes a stereotypic response in the remaining epithelial cells known as 
spasmolytic polypeptide expressing metaplasia (SPEM). SPEM is characterized by expanded 
stem cell proliferation and dedifferentiation of enzyme secreting zymogenic cell (ZCs)s. The ZC 
dedifferentiation is characterized by re-expression of markers like TFF2 (spasmolytic 
polypeptide) that are usually expressed only during the ZC precursor stage [4]. Healthy PCs 
secrete a number of factors, such as amphiregulin, transforming growth factor α (TGF-α), 
heparin binding-epidermal growth factor-like growth factor (HB-EGF), Sonic hedgehog (Shh), 
that aid in differentiation of other mucosal lineages [4].  It is not clear which, if any, of the 
known growth factors normally elaborated by PCs might regulate the dedifferentiation of ZCs 
into SPEM cells. Presumably, loss of the PC-elaborated signal might affect ZC differentiation 
either directly or via an intermediary cell type. Alternatively, injured or dying PCs might 
elaborate a stress signal that causes metaplasia of ZCs. 
H. pylori infection related PC atrophy is associated with inflammation, which makes 
mesenchyme to epithelial signaling fairly complicated. Hence, we utilize the tamoxifen induced 
PC atrophy model to determine signals from them mesenchyme to the epithelium that cause PC 
stress and eventual death. Tamoxifen does not cause inflammation, but displays all the epithelial 
changes of H. pylori SPEM. Therefore, we analyzed circulating cytokines that were elevated 
upon tamoxifen treatment that could signal to the epithelium and lead to PC atrophy and stem 
cell expansion.  
Several cytokines are implicated in mediating PC death upon infection with H. pylori. 
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Interleukin-1β (IL-1β), IL-6, tumor necrosis factor alpha (TNF-α), IL-8, IL-21, gamma interferon 
(IFN-γ), and transforming growth factor β (TGF-β) are found at increased levels in the gastric 
mucosa of patients with H. pylori-associated gastritis compared with levels in healthy controls 
[5]. Antigen presenting cells (APCs) such as dendritic cells and macrophages are present in H. 
pylori infected mucosa and are likely involved in secreting some of the above mentioned 
cytokines [5]. Along with the function of eradicating the bacterial infection, these APCs might 
release cytokines that lead to epithelial remodeling and metaplasia. Most studies focus on the 
role of immune cells and cytokines in eliminating H. pylori. Here we are interested in 
determining the effect of these cytokines on PC death and stem cell expansion. 
Our study shows that macrophages are increased in the mesenchymes of tamoxifen treated 
mouse stomachs and these macrophages secrete IL-6 when challenged in vivo and ex vivo with 
tamoxifen. We also find that depletion of macrophages rescues tamoxifen induced PC death and 
stem cell expansion and this occurs by blocking iNOS expression and ERK activation 
respectively. Increasing nitric oxide (NO) by injecting NO donors increases proliferation, 
whereas blocking NO with scavengers reduces PC death and proliferation.   
 
Materials and Methods 
Animals and injections- All experiments involving animals were performed according to 
protocols approved by the Washington University School of Medicine Animal Studies 
Committee. Mice were maintained in a specified-pathogen-free barrier facility under a 12 hour 
light cycle. Wild-type C57BL/6 and iNOS─/─ mice were purchased from The Jackson Laboratory. 
Mice from all treatment groups were given an i.p. injection of a mixture of 5-bromo-2’-
deoxyuridine (BrdU, 120 mg/kg) and 5-fluoro-2’-deoxyuridine (12 mg/kg) 90 minutes before 
sacrifice to label S-phase cells. Vehicles used for all injections are: sterile saline, ethanol in 
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sunflower seed oil, or DMSO; no phenotypes were induced by injection of any of the vehicles 
alone.  Table 1 enumerates the treatments given to mice. 
 
Table 4.1: Mice treatments and injections- 
Treatment Dose 
(body weight) 
Vehicle Injection 
Scheme 
Source 
Tamoxifen 5mg/20g 10% ethanol + 
90% sunflower 
seed oil 
i.p. once a day, 
sacrificed as 
indicated 
Sigma 
Clodronate 100µL  Solution from 
manufacturer 
i.p. twice a day 
until sacrifice 
Encapsula, 
Nano 
Sciences 
Control 
Liposomes 
100µL Solution from 
manufacturer 
i.p. twice a day 
until sacrifice 
Encapsula, 
Nano 
Sciences 
Aminoguanidine 400mg/kg 0.9% saline s.c. once a day 
until sacrifice 
Sigma 
SNAP 20mg/kg 20% ethanol + 
80% sunflower 
seed oil 
i.p. 3 times a 
day until 
sacrifice 
Sigma 
DetaNONOate 0.4mg/kg 0.9% saline i.p. once a day 
until sacrifice 
Sigma 
Curcumin 100mg/kg 25% ethanol + 
75% sunflower 
seed oil 
i.p. 3 times a 
day until 
sacrifice 
Sigma 
Human Tissues- Examination of human gastric pathological tissue specimens was approved by 
the Institutional Review Board of Washington University School of Medicine, the Comité de 
Bioetica of Nicaragua for Universidad Nacional Autonoma De Nicaragua – Facultad De Ceincias 
Medicas Managua, and the Research Ethics Board Manager for Health Sciences at the University 
of Toronto.  Serial sections (4–d6 μm thick) obtained from paraffin-embedded tissue samples 
(H&E and alcian blue–periodic acid–Schiff stains) were reviewed by two pathologists in Italy 
(M.F., and M.R.) with specific expertise in gastrointestinal diseases, and a consensus on the score 
for each pertinent histologic variable was reached. Diagnoses and selection of specific regions of 
transitions among normal stomach, atrophic stomach, and intestinal metaplasia was performed 
by a third pathologist in the US (JCM). 
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IL-6 ELISA- Wildtype mice were injected i.p. with either vehicle (10% ethanol + 90% oil; n=3) 
or tamoxifen (n=3) and blood was collected by retro-orbital bleeding. Blood was allowed to clot 
at 37°C for 30 minutes, centrifuged at 2000g for 10 minutes at 4°C and aliquoted and stored at -
20°C. Aliquots were shipped to the Cytokine Core Laboratory of the University of Maryland for 
performing IL-6 ELISAs. 
Macrophage collection and culture- Peritoneal macrophages were isolated and cultured as per  
[6]. Briefly, wildtype mice were each injected with 4mL thioglycollate medium 5 days prior to 
sacrifice. 10mL of ice cold DMEM was injected into the peritoneal cavity immediately after 
sacrifice, and collected into the same syringe. Media along with suspended macrophages were 
centrifuged at 1200 rpm for 10 minutes at 4°C. Supernatant was discarded and the pellet was 
suspended in DMEM/F12-10 media and plated into a 6-well plate at the concentration of 2*106 
cells per well. Cells were allowed to adhere to the plate overnight at 37°C, 5% CO2 in an 
incubator. Media was changed the following day to discard dead cells and debris. The wells were 
treated with either DMSO alone or tamoxifen in DMSO (2mg/mL) for 1hr. at 37°C.  
IL-6 RT-PCR- Cultured and treated macrophages were washed with PBS and mRNA was 
extracted using the Qiagen RNeasy Mini Kit using the manufacturer’s instructions. RNA was 
quantified using Biotek ELISA plate reader and Gen5 software. 1µg RNA was synthesized to 
cDNA using the protocol described in [3] and PCR was performed using the primers for IL-6 
(Forward Primer 5’→3’ CCAAGAGGTGAGTGCTTCCC; Reverse Primer 5’→3’ 
CTGTTGTTCAGACTCTCTCCCT) and 18S (Forward Primer 5’→3’ 
CATTCGAACGTCTGCCCTATC; Reverse Primer 5’→3’ CCTGTGCCTTCCTTGGA [3]. 
Immunofluorescence and Immunohistochemistry- Stomachs were prepared, and stained, and 
imaged using methods modified from Ramsey et al [7]. For BrdU/Ki67 quantifications, positive 
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cells were counted in >50 gastric units per mouse and >3 mice per experiment. Total number of 
positive cells was divided by the total number of gastric units for each mouse. Stomachs were 
prepared, and stained, and imaged using methods modified from Ramsey et. al. [7].  Primary 
antibodies used for immunostaining are listed in Table 4.2:  
Table 4.2: Antibodies used for immunostaining 
Serial No. Antibody Dilution Source 
1 Goat α-BrdU 1:20,000 Jeffrey Gordon, Washington University 
2 Rabbit α-pERK1/2 1:100 Cell Signaling Technology, Danvers, MA 
3 F4/80 1:100 BD Biosciences, San Jose, CA  
4 Rabbit α-GIF 1:20,000 David Alpers, Washington University 
5 Rabbit α-iNOS 1:100 Abcam, Cambridge, MA 
Secondary antibodies, lectins and BrdU labeling were as described [7]. 
Western Blotting – Western Blotting –Western blot analysis was performed as described [3]. 
Antibodies used for blotting are listed in Table 4.3. Immobilon Western Chemiluminescent HRP 
Substrate (Millipore) was used for detection. 
Table 4.3: Primary antibodies used for Western blotting 
Serial No. Antibody Dilution Source 
1 Rabbit α-pERK1/2 1:1000 Cell Signaling Technology, Danvers, MA 
2 Rabbit α-Tubulin 1:2000 Cell Signaling Technology, Danvers, MA 
3 Goat α-HAS2 1:1000 Santacruz Biotechnology Inc., CA 
Secondary antibodies were horseradish peroxidase (HRP)-conjugated donkey anti-rabbit IgG 
(1:2,000, Santa Cruz Biotenchnology, Inc.), goat anti-rat IgG (1:1000, Santa Cruz Biotechnology, 
Inc.) and donkey anti-goat IgG (1:1000, Santa Cruz Biotechnology, Inc.). 
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Microscopy - Light and epifluorescence micrographs were taken as described [8]. 
Graphing and statistics - All graphs and statistics were performed in GraphPad Prism, using 
Student’s t test (one-tailed or two-tailed, as appropriate) for comparison of two groups of data 
and one-way ANOVA with either Dunnett’s or Tukey’s for multiple comparison tests. 
 
Results 
IL-6 is produced and secreted into the serum immediately after treatment with tamoxifen 
High levels of circulating IL-6 are associated with advanced gastric cancer [9]. IL-6 is a major 
mediator of inflammation and activator of STAT3, which enhances proliferation and helps cells 
progressing towards neoplastic growth [10]. In chapter 3, we have shown increased STAT3 
activation associated with increased stem cell proliferation following treatment with tamoxifen. 
Accordingly, we find an increase in circulating IL-6 in sera of mice treated with tamoxifen 
within 6 hours of injection (Fig. 4.1A). Activated peritoneal macrophages frequently secrete IL-6 
in other disease models such as endometriosis [11], stress [12], treatment with LPS [13], and so 
on. Therefore, we isolated peritoneal macrophages from mice, cultured and treated them with 
tamoxifen ex vivo. While IL-6 transcripts were absent in mice treated with DMSO control, we 
found IL-6 mRNA expression in macrophages treated with tamoxifen for 1h (Fig. 4.1C). In 
inflammatory diseases of the gastrointestinal tract, such as ulcerative colitis and Crohn’s disease, 
there is enhanced secretion of IL-6 by mononuclear cells of the lamina propria [14]. Although 
tamoxifen does not produce classical inflammation in our model of gastric metaplasia, we 
observed an increase in F4/80+ macrophages in the mesenchyme adjacent to the base of the 
gastric units (Fig. 4.1B). These macrophages presumably secrete IL-6, along with other 
cytokines and factors that increase STAT3 activation and proliferation of cells at the base of the 
unit.  
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Fig. 4.1 Tamoxifen increases IL-6 secretion by macrophages. In mice treated with vehicle, 
there was undetectable IL-6 in the sera, whereas tamoxifen treated mice showed a dramatic 
increase in IL-6 concentration in their sera (A). Macrophages are important secretors of IL-6 
and are increased in the mesenchymes of tamoxifen treated mouse stomachs, labeled in green 
with F4/80 (B). Arrowheads point to green macrophages in the mesenchyme and dashed lines 
outline gastric units (B). When cultured peritoneal macrophages are treated with tamoxifen, they 
increase their expression of Il-6 transcripts, shown in (C) by RT-PCR, when compared to DMSO 
treated controls.   
 
Macrophages secrete IL-6 when treated with tamoxifen ex vivo and are necessary for 
developing metaplasia 
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IL-6 is typically secreted by either T-cells or macrophages. To rule out the possibility of the 
involvement of T-cells, we treated Rag1─/─ mice with tamoxifen and found that they developed 
metaplasia like the wildtype controls (data not shown). Therefore, we focused our next 
experiments on macrophages. In order to determine the role of macrophages in inducing 
metaplasia, we depleted macrophages using clodronate before treating mice with tamoxifen. 
Mice that received clodronate in addition to tamoxifen had a blunted proliferative response when 
compared with those that received tamoxifen alone (Fig. 4.2A). Moreover, clodronate also 
blocked PC death and dedifferentiation of ZCs at the base of the unit (Fig. 4.2B). In Fig. 4.2B, 
the orange bracket shows dedifferentiated ZCs expressing both neck and ZC markers (purple and 
red overlap) in the tamoxifen treated mice whereas the clodronate + tamoxifen treated mice show 
distinct regions of neck cells (white bracket) and ZCs (yellow bracket).  
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Fig. 4.2 Depletion of macrophages by treatment with clodronate rescues SPEM development 
induced by tamoxifen. Pre-treatment of mice with clodronate before inducing atrophy with 
tamoxifen blocks the proliferative expansion of stem cells (A) as measured by counting BrdU+ 
proliferating cells per gastric unit. Clodronate pretreated mice also show lower degree of GSII 
(neck cell marker) and GIF (zymogenic cell marker) overlap signifying lesser dedifferentiation of 
zymogenic cells in these mice compared to tamoxifen treated positive controls (B).   
GSII (Neck Cells) 
101 
 
Macrophages induce ERK activation and iNOS expression following treatment with 
tamoxifen 
We next determined at what stage clodronate affected the ERK-CD44-STAT3 proliferation 
cascade outlined in Chapter 3. We performed western blots for each signaling intermediate and 
found that ERK activation was affected by macrophage depletion by clodronate (Fig. 4.3). 
Clodronate treatment did not affect HA production as its synthesizing enzyme HAS2 remained 
unchanged (Fig. 4.3). Since we have shown earlier that macrophages secrete IL-6 upon treatment 
with tamoxifen (Fig. 4.1) and IL-6 is known to activate STAT3, we expected a block in STAT3 
phosphorylation in presence of clodronate. However, pSTAT3 levels remained unchanged (Fig. 
4.3) suggesting that there might be IL-6 independent methods of activating STAT3. Another 
possible explanation is that IL-6 might activate STAT3 by phosphorylating Ser727 [15] while we 
have analyzed phosphorylation at the Tyr705 residue.  
  
+ 
Fig. 4.3: Clodronate blocks ERK 
activation and iNOS expression 
in tamoxifen induced SPEM. 
Western blots show that while 
STAT3 activation and HAS2 
expression are unchanged upon 
clodronate treatment, pERK and 
iNOS expressions are blocked by 
depletion of macrophages. 
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These data show that depletion of macrophages blocks ERK activation, which explains the 
decrease in proliferation. However, we also observe a decrease in PC death with clodronate 
treatment. Therefore, we assayed for the stress signal, i.e. expression of iNOS and found that 
while iNOS was increased in tamoxifen treated mice, clodronate inhibited the expression of 
iNOS (Figure 4.3). Expression of iNOS could be the source of the parietal cell atrophy signal 
downstream of factors secreted by macrophages. 
 
iNOS is expressed in damaged parietal cells of mice and humans 
Nitric oxide (NO) is an endogenous mediator of a number of physiological functions and stress 
responses. It is a vasodilator that protects gastric mucosa by reducing acid secretion and 
increasing blood flow and epithelial alkaline secretion [16]. NO is a short-lived molecule that 
can cause local effects in cells, including proliferation, apoptosis, migration, invasion and 
angiogenesis [17]. The literature on the role of NO in cancer tumorigenesis is dichotomous, with 
some reports arguing about its pro-tumorigenic functions and others suggesting that it is anti-
tumorigenic [17]. NO is generated by three isoforms of NOS (nitric oxide synthase) enzymes: 
neuronal NOS (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS) [17]. eNOS and 
nNOS produce low concentrations (nanomolar) of NO for short durations, wheras iNOS is 
capable of producing large amounts (micromolar) of NO over hours or days [17]. At low 
concentrations, NO acts as a signal transmitter and aids maintenance of homeostasis; whereas, at 
higher concentrations, such as those produced during injury by iNOS, it is cytoprotective against 
pathogens and tumors [17]. In humans, H. pylori infection is associated with higher levels of 
iNOS and NO [18]. Moreover, increased risk of developing gastric cancer has been reported in 
populations with higher consumption of nitrate and nitrite from animal sources, which 
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decompose in the stomach to give rise to reactive nitrogen species such as NO [19]. Furthermore, 
tamoxifen increases iNOS expression and NO production by myoepithelial cells when they are 
co-cultured with conditioned media from or breast carcinoma cells [20]. Therefore, we tried to 
elucidate the role of iNOS and NO in parietal cell death and stem cell proliferation upon 
induction of metaplasia by tamoxifen. 
While iNOS is normally absent in the gastric mucosa, we found an increase in iNOS expression 
in PCs of mice injected with tamoxifen (Fig. 4.4). iNOS labeled individual PCs which is in 
accordance with the  trend of asynchronous PC death.  
  
Figure 4.4: iNOS labels parietal cells in tamoxifen treated mice. While vehicle control 
stomachs do not show any iNOS expression (red; left panel), mice treated with tamoxifen start 
expressing iNOS as early as 6 hours after treatment with tamoxifen (middle panel) and continue 
expressing iNOS at 12 hours of treatment (right panel). The expression of iNOS is limited to 
parietal cells, shown in insets.  
 
We also observed an increase in iNOS staining in human gastrectomy samples that exhibited 
SPEM (Fig. 4.5A, right). In tox176 mice, where PCs are killed by diphtheria toxin as soon as 
they differentiate, we saw rare iNOS staining in pre-parietal cells (Fig. 4.5A, left). iNOS staining 
by immunohistochemistry was prominent in parietal cells of metaplastic human stomachs (Fig. 
4.5B). 
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Fig. 4.5: iNOS is expressed in pre-parietal 
cells of tox176 mice and in PCs of humans 
with gastric metaplasia. Pre-parietal cells of 
tox76 mice express iNOS (A, left), as do 
parietal cells of humans with metaplasia (A, 
right; B, right and below). Normal human 
stomachs do not express iNOS (B, left) 
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Nitric oxide signaling is necessary and sufficient for inducing parietal cell death and 
expansion of proliferation 
In order to delineate the role of NO in inducing or protecting from PC atrophy and stem cell 
expansion, we performed loss of function and gain of function experiments, using NO donor and 
NO scavenger injections in mice. We injected SNAP (S-Nitroso-N-acetyl-DL-penicillamine) and 
DetaNONOate NO donors into mice and observed a slight increase in proliferation at Days 1 and 
3 respectively (Fig. 4.6A, B).  
 
Figure 4.6: Effect of nitric oxide donors on epithelial proliferation. While administration of the 
NO donor, DetaNONOate, for 3 days did not significantly increase proliferation (A), treatment 
with another NO donor, SNAP, caused a doubling of proliferating cells within a day of treatment 
(B). 
We then injected mice with tamoxifen in the presence of an iNOS specific inhibitor, 
Aminoguanidine, and found a decrease in the expansion of proliferation induced by tamoxifen 
alone (Fig.  4.7A). When treated with an NO scavenger, curcumin, we observed a more 
substantial decrease in proliferation compared to tamoxifen alone (Fig. 4.4B).  
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Figure 4.7: Blocking iNOS activity and scavenging nitric oxide inhibits the expansion of 
proliferation during metaplasia. Mice pre-treated with the iNOS inhibitor, aminoguanidine, 
before injury with tamoxifen showed a blunting of the proliferative response (A), as did mice pre-
treated with the NO scavenger, curcumin (B). 
However, multiple experiments with treatment of iNOS─/─ mice with tamoxifen did not 
consistently show a decrease in proliferation or parietal cell protection compared to WT mice 
treated with tamoxifen (Fig. 4.8) and we reckon this defect is due to compensation by other NOS 
enzymes (eNOS and nNOS) in these mice. Also, since curcumin affects multiple signaling 
pathways, including ERK, we believe that part of the proliferation dampening effect of curcumin 
might be due to blocking of ERK signaling, which we have proved earlier to be involved in stem 
cell proliferation (Chapter 3). In conclusion, NO produced by iNOS in parietal cells might be 
necessary and sufficient in causing stem cell expansion upon metaplasia.   
*** 
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Discussion 
Here we demonstrate that signaling initiated by macrophages leads to parietal cell death and 
development of metaplasia, which is a known precancerous lesion [4]. In the presence of 
tamoxifen, macrophages secrete IL-6 and other factors which begin the cascade of parietal cell 
death and expansion of proliferation. Parietal cell death is mediated by the expression of iNOS. 
Inhibition of macrophages and iNOS decrease parietal cell death, stem cell proliferation and 
associated metaplasia. Hence, we conclude that the initiation of metaplastic changes in the 
gastric epithelium is brought about by factors released by elicited macrophages. 
Infection with Helicobacter pylori, which is the main predisposing factor for developing gastric 
cancer, results in inflammatory infiltration in the gastric mesenchyme [5]. Patients with H. pylori 
infection show myeloid antigen presenting cells, such as macrophages and dendritic cells, in 
their gastric mucosa [5]. H. pylori infected monocytes in vitro secreted more proinflammatory 
cytokines such as IL-12p40, IL-23, IL-1β, IL-6, and IL-10 compared to uninfected controls [5]. 
Fig. 4.8: iNOS
─/─
 mice treated with 
tamoxifen display a threshold 
phenomenon whereby they either 
lose all their parietal cells or none. 
Parietal cell counts show that 
wildtype mice lose all their PCs 
upon tamoxifen treatment, whereas 
iNOS─
/─ mice either lose PCs or 
completely rescue their loss. 
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Our model of tamoxifen induced parietal cell atrophy displays all the hallmarks of metaplasia 
associated with H. pylori infection, except the development of classical inflammation [3]. 
However, we do observe the presence of CD45+/F4/80+ myeloid cells in the mesenchymes of 
mice treated with tamoxifen, while these cells are absent in vehicle treated samples (Fig. 4.1). 
Moreover, of all the cytokines assayed, we observe an increase in circulating levels of IL-6 in 
tamoxifen treated mice compared to controls (Fig. 4.1). Isolated and cultured macrophages 
express IL-6 when treated with tamoxifen, whereas vehicle treated macrophages fail to do so 
(Fig. 4.1). Therefore, even in the absence of inflammation, factors secreted by macrophages, 
including IL-6, are increased in the sera of mice treated with tamoxifen. 
Macrophages regulate injury induced stem cell proliferation by modulating the activation of 
ERK. We have shown in Chapter 3 that ERK activation initiates a CD44-STAT3 proliferation 
signaling cascade. Loss of ERK activation in mice lacking functional macrophages is responsible 
for the inhibition of stem cell proliferation and we predict that this is accomplished by a block in 
the CD44-STAT3 signaling downstream of pERK. We do not observe any change in the 
expression of HAS2, an enzyme that synthesizes hyaluronic acid, upon macrophage depletion. 
Therefore, hyaluronic acid activated CD44 is not a critical modulator of proliferation 
downstream of macrophage signaling. It is intriguing that even though macrophages secrete IL-6 
ex vivo and in vivo, and that IL-6 is the main upstream activator of STAT3, we do not find 
deactivation of STAT3 upon macrophage depletion. This could either be due to an IL-6 and 
macrophage independent mechanism of STAT3 activation or due to its activation via 
phosphorylation or acetylation of a different amino acid reside of STAT3 that we did not test for.  
Another very interesting observation is that macrophage depletion blocks parietal cell death, 
which is the first response of the gastric mucosa to injury. Our data show that this blockage 
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occurs by inhibition of iNOS signaling by clodronate. iNOS is expressed in parietal cells of mice 
treated with tamoxifen and humans with gastric metaplasia. Nitric oxide release is necessary and 
sufficient to cause PC death and expansion of proliferation as shown by NO donors and 
scavengers. iNOS─/─ mice showed variability in loss of PCs upon tamoxifen treatment, perhaps 
due to a threshold effect of NO concentration on PC loss or due to compensation by eNOS and 
nNOS in producing sufficient amounts of NO to cause PC atrophy.  
Our observations delineate an interplay between circulating factors, mesenchymal signals and 
epithelial responders that lead to all aspects of metaplasia development, i.e. parietal cell loss, 
expansion of proliferation and dedifferentiation of ZCs. Future studies identifying the specific 
factors that cross talk from the mesenchyme to the epithelium to initiate the metaplastic cascade 
will prove critical in understanding the source of stem cell activation in the stomach. 
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
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Conclusions 
The goal of my thesis has been to understand mechanisms that regulate gastric epithelial stem 
cell proliferation during normal homeostasis and preneoplastic metaplasia. The main 
predisposing factor for developing gastric metaplasia and cancer is infection with Helicobacter 
pylori. H. pylori infection leads to parietal cell atrophy and an associated expansion in progenitor 
cells. However, there is a large amount of inflammation associated with infection, which makes 
it difficult to separate the individual signals responsible for atrophy and increase in proliferation 
respectively. Hence, to analyze different signaling pathways that are induced early following 
atrophy of parietal cells, we first identified a model for inducing atrophy in a rapid and 
synchronous manner, without a substantial inflammatory component.  
 
In Chapter 2, we showed that a single injection with a high dose of the breast cancer 
chemotherapeutic drug, tamoxifen, induces rapid parietal cell atrophy within three days of 
administration [1]. Moreover, tamoxifen induced atrophy is not accompanied by substantial 
inflammation but does cause an expansion in the proliferative progenitor cell compartment, 
along with dedifferentiation of zymogenic cells [1].  Parietal cell loss is reversible within two 
weeks of cessation of tamoxifen treatment [1]. Although the mechanism of tamoxifen toxicity on 
parietal cells in unknown, treatment with the proton pump inhibitor, omeprazole, partially 
rescues atrophy; suggesting that tamoxifen may act by disrupting the proton gradient [1].  
In Chapter 3, we utilized the ability of tamoxifen to kill parietal cells and remodel the gastric 
epithelium to determine mechanisms that modulate progenitor cell expansion. We found that the 
proliferating isthmal cells label with the cell surface receptor, CD44 [2]. CD44 is normally 
expressed in the immune cells and mesenchyme, but also labels small, undifferentiated isthmal 
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cells in the normal, uninjured gastric epithelium [2]. Upon treatment with tamoxifen, CD44+ 
cells from the isthmus start expanding towards the base of the unit until day 3 of the treatment, 
when all cells in the gastric unit label with CD44 [2]. We found that loss of CD44, either by 
deletion of the Cd44 gene or by blocking its activation using PEP-1, reduced the number of 
proliferating cells at baseline when compared to wildtype controls [2]. Accordingly, Cd44─/─ and 
PEP-1 treated mice were unable to dramatically increase proliferation when challenged with 
tamoxifen. Conversely, when CD44 was activated by treating mice with its ligand hyaluronan, 
there was an increase in proliferation [2]. Thus, CD44 interaction with its normal extracellular 
matrix binding partner is necessary and sufficient for proliferation under normal and injury 
conditions. We then determined the mechanism by which CD44 regulates proliferation. We 
found that CD44 binds to pSTAT3 and regulates the transcription of the proliferation gene, 
CyclinD1 [2, [3]. When STAT3 activation is blocked pharmacologically and challenged with 
tamoxifen, there is a dampening of the proliferative response and expression of CyclinD1 [2]. 
Therefore, CD44 enhances progenitor cell proliferation following injury by binding to STAT3 
and controlling the expression of CyclinD1. Since we found CD44 is induced at the 
transcriptional level, we then determined which signaling pathway might induce Cd44 gene 
expression. We found that ERK was activated by phosphorylation early upon treatment with 
tamoxifen, and blocking of ERK activation inhibited proliferation and Cd44 expression [2]. 
Hence, we concluded that atrophy-induced CD44 expansion depends on pERK, which, 
accordingly, also labels the proliferating isthmal cells that respond to atrophy.  
 
We have shown that even though we inject mice systemically with tamoxifen, the stomach is 
specifically sensitive to injury when compared to other organs [1]. Therefore, in Chapter 4, we 
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analyzed signals from the circulation, which could cause parietal cell death and increased 
proliferation. We found that mice that were treated with tamoxifen showed a dramatic increase in 
IL-6 in their sera. Since IL-6 is generally secreted by T-cells and macrophages, we looked for the 
presence of these cells in the stomachs of mice treated with tamoxifen. While control mice did 
not show cells labeling with the macrophage specific marker, F4/80, we found scant F4/80+ 
macrophages in the mesenchymes of tamoxifen treated stomachs. When cultured and treated 
with tamoxifen, peritoneal macrophages showed an increase in the expression of Il-6. Depletion 
of macrophages with clodronate not only reduced the proliferative response to tamoxifen, but 
also blocked atrophy of parietal cells. Therefore, we next identified the signal from the 
macrophages to the parietal cells that causes atrophy upon tamoxifen treatment.  
 
iNOS expression is increased in parietal cells upon treatment with tamoxifen and in humans with 
intestinal metaplasia. When treated with nitric oxide donors, the mice showed parietal cell 
damage and a concomitant increase in proliferation, reminiscent of tamoxifen treatment. 
Blocking of iNOS with its pharmacological inhibitor or scavenging of nitric oxide rescued the 
increase in proliferation. Hence, we conclude that factors secreted by macrophages upon 
tamoxifen challenge are sufficient to induce parietal cell atrophy by increasing the expression of 
iNOS. Nitric oxide (NO) is a diffusible gas that can signal to cells locally. Depending upon the 
concentration of NO, it is capable of inducing proliferation in stem cells via the MAPK pathway 
independent of EGFR [4]. Furthermore, NO causes dedifferentiation of articular chondrocytes by 
increasing ERK signaling and inhibiting p38MAPK [5]. Therefore, NO serves as an ideal 
signaling intermediate released by PCs during injury that can signal to adjacent stem cells to 
proliferate and zymogenic cells to dedifferentiate and re-enter the cell cycle. 
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In conclusion, in this thesis, we have outlined a tamoxifen induced mechanism by which parietal 
cells undergo atrophy and initiate the development of metaplasia. Metaplasia is associated with 
an expansion in stem cell proliferation brought about by an ERK→CD44→STAT3→cyclin D1 
signaling cascade. Once challenged with tamoxifen, macrophages secrete cytokines that induce 
parietal cell death, in a mechanism that depends on parietal cell induction of iNOS, and stem cell 
proliferation, through the activation of ERK signaling.  
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Future Directions 
I) Determining the role of the CD44 ligand, hyaluronan, in regulating CD44 expression 
and proliferation of isthmal cells 
Hyaluronan (HA) is a component of the extracellular matrix and is found in connective, 
epithelial and neural tissues, forming large networks in the extracellular compartment [6]. Each 
HA molecule consists of on average 10,000 repeating disaccharide units of D-glucuronic acid 
and N-acetylglucosamine, synthesized by the action of three HA synthesizing enzymes (HAS1, 2 
and 3) [6]. HA accumulates at sites of inflammation and tumor progression [6]. Although HA 
accumulation is not a universal characteristic of all tumors, many cancers contain increased 
amounts of HA compared to normal tissues [7]. It is also believed that HA surrounding cancer 
cells helps in increasing their spread and migration [8].The stroma surrounding gastric tumors 
shows increased staining of HA relative to normal gastric mesenchyme [7]. We found that HA 
staining was found in the mesenchyme surrounding the gastric unit in normal wildtype mice [2]. 
However, there was also an increase in HA in the mesenchyme of tamoxifen treated mice 
(Chapter 3 [2]). The expression of HA synthesizing enzymes, HAS1 and HAS2 was also 
increased (Chapter 3 [2]). Fig. 5.1 (adapted from Chapter 3) shows the expression of HA and 
HAS1, 2 in normal and tamoxifen treated mice.  
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Moreover, we observed an increase in HA staining in human biopsies of patients who had 
developed intestinal metaplasia (Fig. 5.2). In normal human stomachs, HA stained the 
mesenchymes in between gastric units; however, in humans with intestinal metaplasia, these 
regions of HA staining in the mesenchyme were greatly expanded (Fig. 5.2). 
Fig. 5.1: Hyaluronic acid (HA), a ligand of CD44, was 
increased upon atrophic injury with tamoxifen. HA 
(stained using Hyaluronan-binding protein; in green) 
and CD44 (red) were increased in expression towards 
the base of the gastric unit during tamoxifen induced 
metaplasia (A, arrowheads). HAS1 and HAS2, enzymes 
that synthesizes HA, were also increased by 12h of 
tamoxifen treatment (B). 
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Fig. 5.2: Hyaluronic acid (HA) is increased in human patients with gastritis and intestinal 
metaplasia. HA (stained using Hyaluronan-binding protein; in green) and GSII (red) were 
increased in expression in the mesenchyme surrounding the gastric unit during intestinal 
metaplasia (yellow bracket).  
 
Since atrophy and metaplasia are accompanied by a surge in proliferation that are regulated by 
the HA receptor, CD44 (Chapter 3), we next looked at whether HA was sufficient to induce 
proliferation. We injected 3-week old mice with HA twice a week for 5 weeks and found that 
they had increased proliferation, with increased pit cell census (Chapter 3) compared to wildtype 
controls. Since the mouse gastric epithelium continues to develop and differentiate for a few 
weeks after birth, our data show that HA is an important regulator of proliferation during this 
developmental period. To assess whether HA is involved in adult gastric epithelial proliferation, 
we injected adult wildtype mice with HA every day for 3 days and 10 days and found a 
significant increase in proliferation (Fig. 5.3).  
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We then tested for sufficiency of HA in inducing proliferation, by blocking the interaction of HA 
with its receptors using the peptide PEP-1 (Fig. 5.4 and Chapter 3).  
 
Fig. 5.4. HA is necessary for normal and injury induced expansion of proliferation. Mice 
treated with the HA blocking peptide, PEP-1, for 5 weeks showed half the number of 
proliferating cells compared to wildtype controls (A). When PEP-1 treated mice were injected 
with tamoxifen, they were able to expand proliferation to only half of that of mice treated with 
tamoxifen alone (B). 
 
Fig. 5.3: HA is sufficient to induce 
expansion of stem cell proliferation. 
Mice treated every day with HA for 3 days 
and 10 days showed significant increase 
in proliferation, stained with BrdU, 
compared to vehicle treated control mice. 
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Since HA is necessary and sufficient for inducing proliferation but does not lead to parietal cell 
death or zymogenic cell dedifferentiation (data not shown), stem cell proliferation must be 
uncouplable from parietal cell death. While pERK induced CD44 expansion and interaction with 
HA appears to be the mechanism adopted by injured stem cells to increase proliferation, HA 
induced proliferation even in the absence of pERK can modulate normal proliferation in the 
gastric epithelium. Thus, if we can understand the mechanisms that regulate HA synthesis, we 
should have a strong foothold into the pathways that feed into both normal cell turnover and 
atrophy induced expansion of gastric stem cells.  
 
II) Determining the factors secreted by activated macrophages that lead to parietal cell 
atrophy and proliferation expansion 
We have shown in Chapter 4 that macrophages secrete IL-6, among other factors, which increase 
parietal cell death and associated expansion of proliferation. However, it is unlikely that IL-6 is 
the only factor responsible for rescuing the metaplastic changes in the epithelium during injury. 
Our collaborative work with Dr. Richard DiPaolo, as well as the work of others [9], has shown 
that IL-11 is involved in inducing PC injury during autoimmune gastritis, along with IL-6 [10]. 
Moreover, loss of EBI3, which forms have the heterodimeric cytokines IL-27 and IL-35, 
accelerates the development of metaplasia in mice with autoimmune gastritis (DiPaolo lab, 
unpublished data). To identify factors responsible for PC atrophy and stem cell proliferation, we 
will first determine whether macrophage secreted factors are sufficient for development of 
metaplasia. For this, we will isolate peritoneal macrophages, culture and treat them with 
tamoxifen, and then adoptively transfer them into clodronate treated or irradiated mice and assess 
whether the recipient mice develop metaplasia. Once we have established sufficiency, we can 
determine which proteins and cytokines have higher expression in tamoxifen treated macrophage 
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cultures using qRT-PCR. Finally, we can test sufficiency of individual factors by injecting 
recombinant versions of these factors into mice or transducing them using adenovirus vectors 
and assessing whether they undergo PC atrophy or expansion in proliferation or ZC 
dedifferentiation or all of the aforementioned processes. 
 
III) Determining the mechanism by which zymogenic cells undergo dedifferentiation 
following parietal cell atrophy 
Along with proliferation expansion, another epithelial remodeling process associated with 
parietal cell death is the dedifferentiation of zymogenic cells. Zymogenic cells are largely post-
mitotic and normally do nothing but their physiological duty of elaborating enzymes critical for 
digestion. Upon parietal cell atrophy, zymogenic cells start re-expressing markers of their 
precursors, i.e. neck cells, such as TFF-2, represented by GSII in Figure 5.5 [1].  
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Fig. 5.5 Tamoxifen induces spasmolytic polypeptide-expressing metaplasia (SPEM). A: 
photomicrographs of basal and neck zones of gastric units with mucous neck cells (green, GS-II 
lectin) and zymogenic cells (red, GIF) taken 3 days after vehicle treatment (above); 3 days 
(middle) and 21 days (below) after tamoxifen treatment. B: Neck and base zones of gastric units 
were analyzed for expression of neck and zymogenic cell markers as a function of distance 
(0=first cell positive for neck/zymogenic markers; 100 = basal-most neck/zymogenic cell). For 
each unit, distance was normalized into bins representing 10% of total distance. Plotted are the 
products of the mean fluorescent intensity and the total area that is either GS-II (neck cell) or 
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GIF (zymogenic cell) positive (means±SD, across all gastric units). Note how normal neck cell 
differentiation peaks, then falls off toward the base, whereas, zymogenic cells are found in the 
base and not the neck. Tamoxifen treatment causes neck cell marker expression in the base. The 
changes in neck cell (C) and zymogenic cell (D) markers for all conditions are plotted on the 
same axes. 
 
Blocking of PC atrophy inhibits the dedifferentiation of ZCs. This could be caused by one of 
three mechanisms: 
i. Healthy PCs constantly engage in homeostatic signaling with ZCs, the loss of 
which during atrophy leads to ZC dedifferentiation 
ii. Injured PCs release stress signals that cause ZCs to dedifferentiate 
iii. A common upstream stress signal leads to death of PCs and dedifferentiation 
of ZCs 
While the nature of signaling between PCs and ZCs is not extensively elucidated, our data with 
blocking iNOS and macrophage activation show that either the PC stress signals or common 
activators or both might be involved in orchestrating epithelial remodeling during injury. 
Whatever the nature of the PC to ZC signaling might be during atrophy, it results in ZC 
dedifferentiation. We observe an increase in CD44+ cells at the base of the gastric units during 
atrophy (Fig. 3.1). These CD44+ cells could either originate from CD44+ isthmal cells that 
proliferate and occupy the base and/or from the dedifferentiation of ZCs which causes them to 
reduce their size, express the stem cell marker, CD44, and enter the cell-cycle. It is technically 
challenging to establish the relative contribution to the CD44-positive cells from expanded 
isthmal stem cells vs. dedifferentiating ZCs. Once CD44 is expressed, it imparts the ZCs with 
124 
 
proliferative (and potentially stem/progenitor) cell capabilities, because it has been well 
established that. ZCs act as cryptic progenitors during atrophy and give rise to metaplastic cells 
[11].  
 
An important developmental pathway that regulates dedifferentiation is the Hippo pathway [12]. 
Inactivation of the hpo kinase cascade in drosophila larval eye imaginal dics increases the rate of 
cell duplication, protects cells from apoptosis, and delays the cell cycle exit of the uncommitted 
cells [13]. The Hippo pathway restricts organ growth and size by phosphorylating and 
inactivating the transcription factor YAP (Yes-Associated Protein). Inactivation of the tumor 
suppressors of the Hippo pathway or activation of the oncogene YAP results in massive tissue 
overgrowth characterized by increased cell proliferation and diminished cell death [14]. YAP1 
dephosphorylation is a reliable metric for assessing Hippo activation. Hence, we determined the 
status of YAP1 phosphorylation in our model of tamoxifen induced atrophy in Figure 5.6. We 
found a decrease in pYAP1 at Day 3 of tamoxifen treatment, which coincides with the highest 
number of proliferating cells during tamoxifen induced atrophy, as well as the appearance of 
proliferating ZCs [1]. Therefore, to reiterate, we find an increase in YAP1 activation and Hippo 
signaling coinciding with increased proliferation and ZC dedifferentiation in our model of 
tamoxifen induced atrophy. 
 
Fig. 5.6. YAP1 is activated upon treatment with 
tamoxifen. Phosphorylation of YAP1, which 
deactivates it, is decreased 3 days after treatment 
with tamoxifen, which coincides with maximum 
parietal cell atrophy and CD44 expression 
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CD44 has been shown to interact with merlin, a product of the Nf-2 gene, which is a component 
of the Hippo tumor suppressor pathway and interacts with cytoskeletal components [15]. In 
schwannoma cells, merlin binds to the cytoplasmic tail of CD44 and this binding inhibits the 
association between CD44 and HA [15]. It will be interesting to determine whether CD44 
increase in ZCs during atrophy causes ZC dedifferentiation and proliferation via the Hippo 
pathway. This can be studied using null mutants of the Hippo kinases Mst1 and Mst2. Pdx1-Cre 
driven Mst1─/─ X Mst2fl/fl mice have shown to cause dedifferentiation in pancreatic acinar cells 
[9]. In order to adapt these mice to our system, we can generate β-actin-Cre; Mst1─/─/Mst2fl/fl 
mice or Mist1-Cre; Mst1─/─/Mst2fl/fl mice which should over-activate the Hippo pathway in the 
entire epithelium or zymogenic cells, respectively. If these mice show dedifferentiation of 
zymogenic cells and increase their proliferation, it will confirm the role of Hippo in developing 
metaplasia. 
 
A recent study in Drosophila larval imaginal discs showed a link between Hedgehog (Hh) 
signaling and the Hippo pathway in regulating cell proliferation [16]. The authors showed that 
the Hh inhibitory receptor, Patched (PTCH1) acts as a tumor suppressor, and loss of Ptch1 leads 
to hyperactivation of YAP1, resulting in excess proliferation [16]. In humans, PTCH1 is highly 
expressed in the gastric epithelium and especially in the membrane compartment of ZCs (Human 
Protein Atlas). In the stomach, Shh is expressed highly,  though recent studies using Shh-Cre 
lineage tracing have shown that all major corpus lineages express Shh [17]. Hedgehog signaling 
is frequently associated with advanced gastric adenocarcinomas [18]. Although, during 
metaplasia there is a loss of Shh due to death of parietal cells, there is an increase in the 
expression of the Hh target, Gli1, when compared to controls (data not shown). This indicates 
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that either other cell lineages increase expression of Shh during PC atrophy or that Shh 
molecules are released by dying PCs which enables signaling to other cells in the unit, including 
ZCs. Increased Gli1 expression is a readout of increased Shh signaling and mirrors the result of 
loss of Ptch1. I hypothesize that increased Hh signaling results in hyperactivation of YAP1 and 
increased proliferation via the Hippo pathway. This is an unexplored area of research and can be 
beneficial in understanding mechanisms that lead to ZC dedifferentiation and entry into the cell 
cycle.  
 
VII. Determining the role of CD44 in Helicobacter pylori niche establishment 
Helicobacter pylori infection in humans is the major risk factor for developing gastric cancer 
[19]. Once H. pylori colonizes the stomach, it persists for the lifetime of the host. Although 
infection is associated with inflammation, it typically does not clear the bacteria [19]. In mice, 
the CagA+ strain of H. pylori, PMSS1, colonizes the antrum of the stomach [20], which is devoid 
of acid secreting parietal cells. This enables H. pylori to evade the harsh acidic environment of 
the stomach corpus and phenocopies the way infection is thought to occur in humans. The 
bacteria survive as two major populations: first, freely swimming in the mucus gel and using its 
motility, chemotaxis and stress responses to survive and swim towards the shelter of the 
epithelium; and second, adhered to epithelial cell surface through various adhesins [20]. Howitt 
et. al. [21] found that H. pylori utilizes a novel family of chemotactic proteins called ChePep for 
colonizing the stomach. ChePep is necessary for H. pylori flagellar rotation, which enables it to 
evade acidic regions within the stomach, which act as chemorepellants [21]. ChePep also 
regulates its ability to colonize deeper into antral glands [21]. Thus, H. pylori is presumably 
attracted to some moiety on the surface of gastric epithelial cells, eventually attaches to the cell 
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surface and establishes a colony. H pylori preferentially adhere to intercellular junctions between 
epithelial cells [20]. Tan et. al. found that the bacteria adhered to the intercellular junctions were 
able to undergo several rounds of replication while being adhered to their original point of 
attachment [20]. Moreover, H, pylori colonization is typically adjacent to a dividing cell (Manuel 
Amieva, Stanford University; personal communication). It is unclear whether bacterial 
attachment promotes epithelial cell proliferation or whether H. pylori is chemically attracted to 
dividing cells within the gastric unit. Either scenario presents interesting, addressable questions 
in order to understand the nature of host-pathogen interactions. 
 
Once attached to the host cell, H. pylori deliver the cytotoxin-associated gene A (CagA) protein 
into the host cell [22]. CagA is one of the most important links between infection and 
development of gastric cancer [22]. Once inside the host cell, CagA localizes to the plasma 
membrane and interacts with host cell junctional complex machinery, such as ZO-1, Jam and E-
cadherin [22]. Moreover, kinases from the host cell, such as c-Src/Lyn and Abl, phosphorylate 
tyrosines on the CagA protein and activate a receptor tyrosine kinase signaling cascade [22]. 
These events lead to loss of host cell polarity and increased invasiveness [22]. Recent studies 
have shown that in an attempt to protect host cells from the infection, intracellular CagA is 
degraded by autophagy induced by accumulation of reactive oxygen species (ROS) [23]. The 
accumulation of CagA is restricted to cells deficient in autophagy [23]. Tsugawa et. al. found that 
cells expressing CD44 (specifically, the variant CD44v9) were resistant to ROS and, therefore, 
deficient in autophagic degradation of CagA [23]. This observation is important in understanding 
the relation between H. pylori infection and CD44 in gastric metaplasia, since presence of both 
leads to gastric cancer. 
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We have shown in Chapter 3 that CD44 labels proliferating cells, normally and during parietal 
cell atrophy by tamoxifen and H. pylori infection [2]. The human Cd44 gene contains 20 exons 
[24]. Exons 1-5 and 16-20 are typically spliced together to form standard CD44 or sCD44, which 
forms a 37kDa protein and is ubiquitously expressed [24]. Exons 6-15 can be variably spliced 
into the standard exons to give rise to CD44 variants in the N-terminal extracellular domain [24]. 
Certain CD44 isoforms, such as CD44v6 and CD44v9, are overexpressed in gastric cancer [25]. 
As mentioned before, CD44v9 enables resistance to ROS and promotes H. pylori infection in 
hosts [23]. 
These observations raise a number of interesting questions: 
1. Is H. pylori chemically attracted to CD44+ cells in the normal gastric epithelium, by 
virtue of specific sugar moieties on the CD44 extracellular domain? 
2. Does attachment of H. pylori to potentially CD44+ stem cells lead to an increase in stem 
cell proliferation? 
3. Does H. pylori attachment selectively increase expression of CD44v9 over CD44s? 
4. Are Cd44─/─ mice resistant to H. pylori colonization and persistence?  
5. Is ROS induction sufficient to induce CD44+ stem cell proliferation? 
Addressing these questions will provide key insights into the mechanisms by which H. pylori 
modulates the host epithelium to establish its niche. Moreover, since host cell changes persist 
after eradication of the bacterium, understanding the role of CD44 will facilitate devising 
therapeutic strategies post H. pylori clearance in patients. 
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APPENDIX 1: The Gastric Mucosa: Development and Differentiation  
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Abstract 
The development and differentiation of the gastric mucosa are controlled by a complex interplay 
of signaling proteins and transcriptional regulators. This process is complicated by the fact that 
the stomach is derived from two germ layers, the endoderm and the mesoderm, with the first 
giving rise to the mature epithelium and the latter contributing the smooth muscle required for 
peristalsis. Reciprocal epithelial–mesenchymal interactions dictate theformation of the stomach 
during fetal development, and also contribute to its continuous regeneration and differentiation 
throughout adult life. In this chapter, we discuss the discoveries that have been made in different 
model systems, from zebrafish to human, which show that the Hedgehog, Wnt, Notch, bone 
morphogenetic protein, and fibroblast growth factor (FGF) signaling systems play essential roles 
during various stages of stomach development. 
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Introduction 
Evolutionarily, the stomach as a functional organ, with its acid and digestive enzyme-secreting 
properties, emerged well after the development of the intestine, and was more or less 
concomitant with the evolution of jaws. Its final, adult form is similarly slow to develop, 
occurring, for example, several weeks after birth, in rodents. Like the rest of the epithelium of 
the luminal gastrointestinal (GI) tract, the gastric epithelium exhibits continual cell loss 
throughout adult life [1]. To replace the lost cells, resident stem cells continually differentiate 
into multiple cell lineages. Thus, in terms of cell fate specification decisions, developmental 
processes never stop in the stomach. In this chapter, we examine the embryonic specification of 
the stomach from the luminal GI tract, its subsequent development into a mature organ, and, 
finally, the differentiation processes that continue into adulthood. More specifically, we examine 
the development of cell lineages and the role of signaling pathways at each step. 
 
I. Early Foregut Development 
We first briefly review early development, to put the emergence of the stomach in its proper 
context. In the mouse embryo, gastrulation begins at E6.25, with the formation of a thickening 
on the posterior side of the epiblast, called the ―primitive streak‖. Epiblast cells ingress through 
the primitive streak and the node, and undergo an epithelial-to-mesenchymal transition (EMT) to 
gradually form the endoderm and the mesoderm. During the formation of the vertebrate GI tract, 
the endoderm and mesoderm undergo extensive regionalization and elongation to give rise to 
organs with specific structures and functions. The vertebrate embryonic GI tract consists of an 
endodermally derived epithelium and a mesodermally derived mesenchyme. Eventually, the gut 
tube is patterned along the anterior–hindgut (which forms the distal transverse, descending, and 
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rectosigmoid segments of the colon) [2]. After this initial patterning, the fate of the endoderm, 
although broadly determined, is still only partially specified and depends on patterning factors 
secreted by the underlying mesoderm. As we will discuss, the fact that factors from the 
mesenchyme direct epithelial fate decisions remains relevant, to some degree, throughout adult 
life. Key regulatory pathways that are developmentally critical, such as the Hedgehog, Wnt, bone 
morphogenetic protein (BMP), and FGF systems, send signals across the epithelial–
mesenchymal boundaries throughout the nascent luminal GI tract and thus contribute toward 
patterning of the gut tube along the left–right, A–P, dorsal–ventral, and radial axes.  
 
II. Specification of the Stomach as a Separate Organ: An Overview 
Following gastrulation, the primitive gut tube is formed from the endoderm, and it encircles the 
inner leaflet of the lateral plate mesoderm, which then forms the visceral mesoderm [2]. The 
formation of a solid gut tube at the dorsal midline by the convergent-extension of the sheet of 
endodermal cells requires both the vascular endothelial growth factor (VEGF) and Wnt/PCP 
(planar cell polarity) pathways, as studied in zebrafish [3]. The transcription factor HNF1b/Tcf2 
aids in the formation of a single gut tube lumen by inducing genes whose expression results in 
apical fluid secretion into the developing luminal space [4]. The primitive gut tube endoderm is 
broadly partitioned antero-posteriorly, with the anterior half of the embryo expressing the 
transcription factors Hhex, Sox2, and Foxa2 and the posterior half expressing Cdx1, 2, and 4 [5]. 
The anterior half forms the foregut while the posterior half forms the hindgut. Between E8.0 and 
E9.5, broad foregut and hindgut territories become divided into organ-specific zones and 
lineages in the mouse embryo. Gastric epithelial cytodifferentiation is initiated around E13.5. 
Unlike humans—who have entirely glandular stomachs—mice have a stomach in which the 
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proximal third is lined by a stratified, keratinized squamous epithelium (the region known as the 
forestomach). By E16.5, the morphological differences between the forestomach and glandular 
epithelia are evident in mice. Recombination experiments have shown that the presumptive 
stomach endoderm might have some plasticity until E11.5/E12.5, but at E14.5, the endoderm no 
longer requires mesenchymal instructive signals for its A–P patterning [6]. This finding is 
corroborated by studies in the chick, which also show that most of the endoderm is capable of 
self-differentiation even from the early stages of development and that it does not require 
mesodermal inputs to do so. However, mesodermal signals are crucial for early specification and 
patterning [7]. 
 
III. Morphogenetic Codes Involved in Stomach Specification 
In the 1960s, Lewis Wolpert hypothesized that molecules could affect target tissues by traveling 
over distances in a gradient, much like the color gradients on the French Flag (thus called the 
French Flag model). Morphogens are such molecules, which originate in a specific tissue, and 
travel over some distance to act on specific receptors with progressively decreasing signal 
strength. The dose or strength of the ligand molecule binding to its receptor determines the 
output of gene expression in the target tissue, and it is, therefore, the decisive factor in 
establishing positional information. A limited number of morphogenetic signaling pathways that 
play crucial roles in determining the different axes during development of an organ have been 
identified. The four principal signaling pathways are the Hedgehog, Wnt, transforming growth 
factor (TGF), and receptor tyrosine kinase (such as fibroblast growth factor (FGF), epithelial 
growth factor (EGF), and platelet derived growth factor (PDGF)) systems. These four pathways 
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coordinate the spatiotemporal expression of transcription factors that impart foregut or hindgut 
identity to the GI tract [5]. 
A. The Hedgehog Signaling Pathway – Early Events 
1. Left-Right Axis Formation 
Correct patterning of the left-right axis is essential for the proper development of gut-derived 
organs such as the pancreas and liver and for leftward looping of the gut tube. During 
gastrulation, a group of ciliated cells at the anterior end of the primitive streak form a notch 
called the node, which is believed to regulate left-right axis formation of the gut, by generating a 
leftward flow of the extraembryonic fluid [8]. Hedgehog signaling is involved in gut tube 
formation as Smo and Shh/Ihh mutant mice fail to close the midgut, probably due to leftward gut 
malrotation [9]. Shh is expressed at E7.75 in the anterior endoderm [10, [11] and later expands to 
the posterior part of the gut, whereas Ihh is expressed in the posterior endoderm and spreads 
anteriorly [12, [13]. Shh and Ihh play redundant roles in left-right axis formation, and both 
mutants lack Nodal expression in the left lateral plate mesoderm and fail to specify the left side 
program. It has been proposed that hedgehog has an indirect role in this process in that it 
becomes distributed asymmetrically to one side of the embryo secondary to impaired nodal flow 
[13, [14]. This asymmetrical flow of Hh is thought to be dependent on FGF signaling [14].   
 
2. Anterior-Posterior Endodermal Patterning in the Gut 
Patterning of the endoderm along the A-P axis occurs after gastrulation, as early as E6.7. The 
first endodermal cells to exit the primitive streak move anteriorly and express the Hex gene, 
whereas later-exiting endodermal cells express FoxA2 (Hnf3β), and those exiting last form the 
posterior endoderm and express Cdx2 [15, [16]. However, the timing of the exit of cells from the 
137 
 
primitive streak is not the only determinant early of A-P patterning. At this stage, patterning 
factors secreted by the mesenchyme are essential to provide hindgut. Hex, FoxA2 and Sox2 are 
required for foregut development, while Cdx1, 2 and 4 are required for hindgut development and 
defining the foregut-hindgut boundary [5, [17]. At later stages of development, the endoderm 
plays an instructive role in patterning the mesoderm [18]. 
 
3. Hedgehog in Stomach Development 
Shh is expressed at high levels in the forestomach epithelium and at low levels in the glandular 
part of the stomach epithelium from E11.5 to 15.5 [19]. Ihh has a reciprocal expression pattern to 
that of Shh, in that it is highly expressed in the glandular stomach and to a lesser extent in the 
forestomach [20]. The expression of Ptc1, which is both the receptor for and a target of 
Hedgehog signaling, in the underlying mesenchyme closely follows the expression of Shh [20]. 
Ihh mutants do not show any gross abnormalities in glandular stomach development [9], which 
suggests that in spite of high amounts of message in the glandular stomach, Ihh might not be 
translated or active, or may be compensated by Shh. Ihh expression in the hindstomach depends 
on the mesenchymal/epithelial signaling brought about by FGF10 binding to the FGFR2b 
receptor (Spencer-Dene et al., 2006). Inhibition of Shh signal in the glandular epithelium in these 
earlier stages is blocked by FGF10 through Gata4 [18, [20]. At later stages of development, i.e. 
E18.5, Shh expression expands to include the glandular stomach epithelium and results in 
signaling within the epithelium itself and to the mesenchyme [9]. Shh null mice display a small, 
malformed forestomach which is in accordance with its early expression pattern. Shh apparently 
does not play a major role in governing development of gastric epithelial cell lineages, and 
glands form normally in the posterior stomach, though with reduced gland branching [18]. Shh 
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and Ihh double null embryos arrest shortly post-gastrulation, and as Shh and Ihh may have 
redundant functions, single null alleles do not yield an accurate analysis of overall Hh signaling 
during gastrointestinal morphogenesis. To fully understand the function of Hedgehog signaling 
in the developing GI tract, Mao and coworkers [21] used conditional gene targeting to ablate 
both Shh and Ihh at E9.5, and found that Hh signaling plays a critical role in promoting the 
survival and proliferation of mesenchymal progenitors underlying the gastric epithelium. 
 
B. The Wnt Signaling Pathway 
Wnt ligands are secreted glycoproteins and have been shown to govern important developmental 
processes such as cell fate determination, tissue patterning, cell proliferation and morphogenesis 
[22]. Wnt signaling occurs by two pathways, the canonical Wnt/β-catenin signaling pathway 
(Wnt1, 3 and 8) which brings about activation and nuclear translocation of β-catenin, and the 
non-canonical Wnt/Ca2+ and Wnt/Fz planar cell polarity pathways (Wnt 5a and 11). Wnt 
signaling is also regulated by various secreted Wnt antagonists, the Soluble Frizzled Related 
Proteins (Sfrps), which bind to and block Wnt ligands from binding to Frizzled receptors [23], 
the WIF-1 protein, which has a similar mechanism of action as SFRPs but is structurally 
different and has been studied extensively in Drosophila and Xenopus [24], and Cerberus, a Wnt 
antagonist similar to SFRP and WIF-1 that has been studied principally in Xenopus.  At present, 
it is not clear whether the mouse Cerberus like protein, mCer1, funtions as a true orthologue of 
Cerberus [25]. Finally, there are the Dickkopf (Dkk1-4) proteins that act by binding to the Wnt 
co-receptors LRP5/6 rather than by interacting with the Wnt ligands directly [21, [26, [27].  
At stage E12.5 of mouse embryonic development, Wnt4, 5a and 11 exhibit specific and partially 
overlapping expression patterns in the stomach: Wnt11expression is strong in the esophageal-
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pyloric junction and in part of the forestomach around the lesser curvature; Wnt5a is expressed 
in the entire forestomach and part of the corpus; Wnt4 expression is confined to the pyloric 
region of the stomach epithelium and is weakly present in the esophagus. Wnt5b and 6 might be 
expressed in the esophageal epithelium at this stageas well [28]. The non-canonical Wnt5a is 
diffusely expressed in the mesenchyme at E12.5 and more specifically in the ectomesenchyme 
just underlying the epithelium at E14.5. Decreasing Wnt5a expression results in repression of the 
intestinal marker Cdx2 and posterior expansion of Sox2, the foregut marker [29]. In the chick 
embryo, Wnt5a is expressed in the presumptive stomach mesenchyme, and overexpression of 
Wnt5a causes increased and ectopic expression of some of the marker genes of the luminal and 
glandular epithelial cells, the former characterized by the expression of Spasmolytic Polypeptide 
and thus analogous to neck cells in the mammalian gastric corpus, and the latter marked by by 
the expression of pepsinogen, analogous to the zymogenic or chief cells in mammals. In 
particular, the overexpression of Wnt5a markedly enhances the expression of ECPg (Embryonic 
Chicken Pepsinogen), indicating its role as a mesenchymal factor that regulates the 
differentiation of the proventricular epithelium [30]. Wnt/β-catenin signaling is necessary and 
sufficient to promote hindgut development of the endoderm and repress foregut formation in frog 
and zebrafish embryos [31].  
Given the interdependence of Wnts and their receptors, it is also important to understand the 
spatio-temporal expression of Sfrps and other inhibtors when evaluating Wnt signaling in the 
developing stomach. Recent studies have shown that Sfrp1, Sfrp2 and Sfrp5 are redundant in 
function and required for forestomach morphogenesis [22]. Sfrp1 expression starts in the 
splanchnic mesoderm around E10.5, extending from the caudal region of the presumptive 
stomach up to the midgut. Sfrp1 and 2 are targets of Barx1, a homoeodomain transcription 
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factor, which is specifically expressed in the presumptive stomach mesenchyme from E9 until 
E15, with a peak at E13.5 [32]. Barx1 acts by inhibiting the canonical Wnt pathway in the 
stomach. Using TOP-GAL reporter mice, the authors showed that canonical Wnt signaling is 
active in the presumptive intestine but not the presumptive stomach endoderm. Wnt signaling 
initiates around E9.5, persists through E12.5, and is attenuated by E14. Barx1 upregulates the 
expression of Sfrp1 and 2 in the mesoderm, which in turn compete with the Wnt ligands, 
blocking signaling to the epithelium. The attenuation of Wnt is required for specification of the 
stomach-specific program in the epithelium. Since Barx1 is not expressed in the intestinal 
mesenchyme, Wnt signaling in the intestinal epithelium is not attenuated and the epithelium 
continues to follow the default intestinal specific program [32]. That the intestinal program is in 
fact, the default pathway, has also been suggested by studies in chick embryos [33]; although in 
these studies, Wnt involvement was not specifically addressed. Barx1 also regulates the 
expression of Bapx1 (Nkx3.2) in the mesenchyme, which is required for the formation of the 
pyloric sphincter [34]. Overall, the literature indicates that Wnt signaling promotes posterior 
fates in the gut endoderm, with inhibition of Wnt promoting foregut marker expression 
posteriorly and overexpression leading to intestinal differentiation (posteriorization) of the 
stomach.  
 
C. The FGF pathway: 
FGFs (through FGF receptors) have been shown to signal across epithelial-mesenchymal borders 
to promote cell proliferation, migration, and differentiation during the development of the lung, 
intestine, and stomach [35, [36, [37]. The mouse and human FGF families consist of 23 members 
that are structurally related and are either secreted or act as intracellular ligands. Nyeng and 
141 
 
colleagues analyzed the expression of all 23 FGF ligands in later stages of the developing 
stomach (E14.5-E18.5) on the messenger RNA level and found that FGF1-3, FGF7, FGF9 and 
FGF10 were expressed above a baseline control gene [36]. Earlier, Bhushan and coworkers [38]  
had shown that FGF10 was expressed in the posterior part of the stomach mesenchyme at E11.5, 
before cytodifferentiation had occurred. FGF10 is a ligand for FGFR2-IIIb, which is expressed 
on the epithelium. During these later stages of embryonic gastric morphogenesis, FGFR2b 
expression in the corpus and antrum was more or less constant over time with a slight increase at 
E15.5, coinciding with the timing of the highest expression of FGF10 and, interestingly, was 
more prominent in newly forming glands.  
In chick embryos, overexpression of FGF10 in the presumptive stomach mesenchyme results in 
excessive cell proliferation of the overlying epithelium and affects its differentiation, leading to 
the expression of cSP (spasmolytic polypeptide – luminal marker) as well as Smad8 (a glandular 
marker) in epithelial cells [7]. In mouse and chick embryos, FGF4 is expressed in the mesoderm, 
and signals to the endoderm to promote the expression of Cdx genes in the presumptive hindgut 
region and to repress the expression of Hhex and Foxa2 in the presumptive foregut [39, [40, [41].  
 
D. The BMP/TGF Signaling pathway 
Bone morphogenetic proteins (BMPs) are multi-functional growth factors that belong to the 
transforming growth factor beta (TGFβ) superfamily. BMPs have been shown to play critical 
roles in heart, neural, cartilage, postnatal bone development and other organs such as kidney, 
lung, liver, limb, amnion, eye, teeth, pituitary, and testes. Smad1, 5 and 8 are the immediate 
downstream signaling molecules of BMP receptors. BMP signaling promotes posterior 
endoderm development [5]. Danesh and colleagues  studied the expression patterns of different 
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BMP ligands in the early developing murine embryo (E7.25-E10.5) (Danesh et al., 2009). They 
found that BMP2 is absent from the gut tube at this time. At E8.25, BMP4 is expressed in the 
posterior lateral plate mesoderm; whereas at E10.5, it extends to dorsal gut mesoderm [42]. 
BMP7 is expressed at low levels in the foregut endoderm at E8.75, and by E10.5, its expression 
in the posterior stomach is highly intensified. BMP2 is expressed in the mesenchyme of the 
developing proventricular mesenchyme of the chick. Overexpression of BMP2 leads to an 
increase in the number of glands expressing ECPg (embryonic chicken pepsinogen), whereas 
overexpression of Noggin (a BMP antagonist) completely inhibits gland formation [7]. On the 
other hand, overexpression of BMP4 does not lead to any change in gland formation [7].  
 
E. The Retinoic Acid Signaling pathway 
Retinoic Acid (RA), the active derivative of Vitamin A, is a diffusible embryonic signaling 
molecule that has a wide array of target molecules in a variety of different organs. In the GI tract, 
RA signaling is important in establishing the foregut-hindgut boundary [5]. Retinoic Acid 
activity depends on the RA-synthesizing enzyme, retinaldehyde dehydrogenase (RALDH). 
Raldh1 is weakly expressed in the stomach epithelium at E12.4-14.5; whereas Raldh2 has a 
stronger expression in the stomach mesenchyme at E10.5-E12.5 [43]. Raldh2-/- mouse fetuses 
exhibit a smaller, rudimentary stomach than wild type littermates, with a columnar epithelium 
lacking squamous or glandular differentiation [44].  These knockout mice have lower FGF10 
expression in the mesenchyme, but Hoxa5 expression is unaffected. It has been proposed [45] 
that Hoxa5 regulates FGF10 expression, but the above results indicate that there might be other 
upstream players controlling FGF10.  
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F. The Notch Signaling System 
While Notch signaling has been shown to play important roles in controlling cell fate decisions 
during development of various tissues, including the intestinal epithelium, its role in the 
development of the mammalian stomach has not been fully explored, although it has been shown 
that the differentiation of multiple enteroendocrine cell lineages in the stomach is dependent on 
the transcription factor Ngn3, and important effector of the pathway [46] In the developing 
chicken proventricular epithelium, Notch signaling acts as a binary switch between choosing the 
luminal (cSP expressing) or glandular (Smad8/ECPg expressing) cell fate [47]. Nyeng and 
colleagues [36] studied the cross talk between Notch and FGF signaling in the mouse embryonic 
gut development and found Notch1, its downstream bHLH transcription factor Hes1, and its 
ligand Jagged2 to be expressed in the gastric epithelium in the corpus and antrum at high levels. 
and in the forestomach at a basal level from E14.5 through E18.5 [36]. They also found that 
Hes1 expression was upregulated in response to FGF10, thus implying that FGF10 positively 
regulates Notch signaling in the developing stomach epithelium [36]. 
 
IV. Transcription Factors 
In an attempt to identify marker genes for the development of each organ of the GI tract in 
chicks, Yasugi and Mizuno identified groups of genes expressed in the epithelium at different 
times around gland formation, i.e. when the epithelium invaginates into the mesenchyme to form 
gastric glands  [7]. The first group includes genes which are expressed prior to and during gland 
formation, i.e.  foxa2, cSox3, cfos and junD. The second group of genes, cSox2, Shh, cSP,and 
PPARγ, are expressed prior to but not after gland formation . The last set of genes is expressed 
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specifically after gland formation, i.e.  Smad8 and Gata5. Delta and Notch are expressed 
sporadically. ECPg is expressed after gland formation and specifically in the gland epithelium. 
A. The Hox Genes 
The Hox transcription factors share a common DNA-binding motif called the homeodomain. 
These proteins are involved in regional specification along the A–P axis during embryonic 
development and are expressed in lateral plate mesoderm.48 As the gut derivatives are locally 
specified along the A–P axis, it is expected that the Hox genes will play a role in establishing 
regional identities. Kawazoe and coworkers48 examined the expression of the different Hox 
genes in the developing GI tract at E12.5. Among the HoxA cluster, in situ hybridization studies 
showed that Hoxa-4 and Hoxa-5 were expressed in the distal part of the stomach, whereas Hoxa-
6 is expressed in the entire stomach mesenchyme. Hoxb-4 also has a distal stomach expression 
pattern, whereas Hoxb-5 and Hoxb-7 are expressed over the entire stomach. No expression of 
Hoxc-4, Hoxc-5 and Hoxd-4 was observed in the stomach at E12.5. The authors hypothesize that 
a different Hox code exists in different regions of the gut, which regulates regional specification, 
with the HoxA cluster predominating the foregut domain. Hoxa-5 is expressed as early as E9.0 in 
the caudal segment of the foregut and by E15.5 its expression follows a gradient, with highest 
levels in the hindstomach mesenchyme. Hoxa-5 expression vanishes after birth, around P15 in 
mice. Hoxa5-/- mice, at age P15, display a thinner stomach epithelium and hypertrophied 
submucosa. Aubin and colleagues  proposed that Hox5a acts by negatively regulating Fgf10 
expression in the hindstomach mesenchyme, which then decreases Ihh in the hindstomach 
epithelium and increases Shh in the forestomach epithelium  [45]. Hoxa5 also increases Tgfb1 
and Tgfb3 in the mesenchyme. Overall, Hoxa5 appears to provide a posteriorization signal to the 
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gastric epithelium and mesenchyme. Finally, a study on Hoxb1 expression in the gut 
mesenchyme revealed that it is regulated by retinoic acid signaling  [48].  
B. COUP-TFII 
COUP-TFs (COUP-TFI or NR2F1 and COUP-TFII or NR2F2) are highly conserved nuclear 
orphan receptors that are expressed in the mouse embryonic stomach mesenchyme  [49].   At 
E12.5, COUP-TFII is expressed in the mesenchyme adjacent to the endoderm but not distally, 
and regulates radial and A-P patterning of the stomach  [50]. Ablation of COUP-TFII 
specifically in the mesenchyme leads to the formation of a thicker epithelium, an anterior shift of 
the limiting ridge that divides the fore- and hind-stomach, reduction in the size of the 
forestomach, and expansion of the hindstomach. COUP-TFII may be regulated by Hh signaling 
from the overlying epithelium and it, in turn, might regulate the expression of Bmp4 in the 
mesenchyme  [50]. Since COUP-TFII may be downstream of Shh, it acts as an anteriorization 
signal like Shh. In the adult, COUP-TFII is expressed in the gastric epithelium, specifically in the 
parietal cells and the base of the gastric unit  [50]. 
C. Sox2 
Sox2 is a transcription factor that is important to maintain pluripotency of the epiblast and 
embryonic stem cells. At E9.5 in the mouse embryo, Sox2 is expressed in the endoderm of the 
entire foregut. However, its expression is gradually localized to the esophageal endoderm as the 
embryo develops. In the stomach, Sox2 is initially expressed in the stomach epithelium as 
distally as the pylorus but is later downregulated in the glandular corpus and antrum and 
expressed only in the forestomach by E18.5 (Que et. al., 2007). Hypermorphic Sox2 allele 
expression causes the forestomach epithelium to resemble that of the glandular stomach due to 
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the expression of mucin and trefoil factor genes  [51]. This suggests that Sox2 might act in the 
developing fetus by inhibiting the expression of the hindstomach genes in the forestomach. 
D. Barx1:  
Barx1 is a mouse homeodomain transcription factor, a member of the Bar subclass of 
transcription factors, which is expressed in restricted areas of the head and neck mesenchyme 
and that of the developing stomach from E9.5 to E16.5  [52]. Kim and coworkers  [32] observed 
that Barx1 had a high enrichment of RNA message in the stomach mesenchyme as compared to 
the intestine in E12 mouse embryos. Inbred Barx1-/- embryos and outbred Barx1-/- neonates 
(since inbred Barx1-/- embryos die at E12.5) show stomach defects, with much smaller stomachs 
than wild type littermates and lack of leftward rotation  [32, [53]. Moreover, the mucosa is 
highly thickened and disorganized and the posterior 3rd of the Barx1-/- neonate stomach 
undergoes intestinal homeotic transformation, showing expression of intestinal markers and true 
villus morphology  [53]. As outlined above, Barx1 acts by upregulating the expression of soluble 
Wnt antagonists Sfrp1 and Sfrp2, which in turn bind to Wnt ligands and limit their availability to 
engage Frizzled receptors on endodermal cells of the presumptive stomach. Since Barx1 is not 
expressed in the presumptive intestinal mesenchyme, Wnt signaling is not inhibited in this region 
and it follows an intestinal specific program  [53]. Thus, Barx1 acts as an anteriorizing signal and 
in its absence, the gastro-duodenal boundary are shifted anteriorly. 
E. Bapx1 
Bapx1 is a homeodomain transcription factor that specifies gut smooth muscle in Drosophila  
[54]. In the chick embryo, Bapx1 is expressed in the gizzard mesenchyme and inhibits the 
expression of Bmp4 and Wnt5a  [55]. Bapx1 is presumed to be regulated by Shh and controls the 
patterning of the gizzard  [55]. Studies in mouse embryos show Bapx1 to be activated at E8.5 in 
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the lateral plate mesoderm adjacent to the endoderm  [34]. Embryos lacking Bapx1 show a defect 
in the expansion and morphogenesis of the antral-pyloric segment, rendering it an important 
factor for pyloric sphincter development  [34]. 
F. Forkhead-box (FOX) family: 
Forkhead transcription factors belong to the winged helix family of factors and are so named due 
to the appearance of their DNA binding motifs when bound to DNA  [56]. Kaestner and 
colleagues  [57] identified Fkh6 (forkhead homologue 6, now termed FoxL1) as being 
specifically expressed in the gastrointestinal mesoderm just underlying the endoderm. FoxL1-/- 
mice show an expanded glandular epithelium, extensive branching within the mucosa and 
vacuolated pit cells  [57] Absence of FoxL1 caused decreased Bmp2 and Bmp4 expression. The 
phenotype implies a role for FoxL1 in epithelial proliferation  [57]. Another interesting study 
done by Fukamachi and colleagues  [58] suggested a role for FoxL1 in the differentiation of 
oxynticopeptic cells (which are cells combining the separate roles of parietal cells and 
zymogenic cells that characterize mammalian stomachs) into parietal cells, since eliminating 
FoxL1 in mice caused parietal cells to stain positively for pepsinogen.  
In evolution, the first species to display two different cell types, i.e. the parietal cell and 
zymogenic cell, for the secretion of hydrochloric acid and digestive enzymes may be found in the 
elasmobranch Hexanchus griseus, but the molecular mechanism governing this lineage 
differentiation (e.g., whether a FoxL1 ortholog plays a role) during evolution is unknown  [59]. 
Loss of FoxL1 severely abrogates basal and histamine-stimulated gastric acid secretion without 
affecting the cellular canaliculi architecture  [58]. A related transcription factors, FoxF1, is co-
expressed with FoxL1 in the developing gut mesoderm, and both are direct targets of Hedgehog 
signaling through Gli2 and Gli3  [60]. In the adult, FoxL1 indirectly targets Wnt/β-catenin 
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signaling by upregulating extracellular matrix heparin sulfate proteoglycans, which in turn 
increase the local concentration of Wnt ligand for binding to Frizzled receptors which are 
expressed in the epithelium  [61]. Wnt signaling provides a positive signal for cell proliferation, 
suggesting that FoxL1 may have opposing roles in the fetus and the adult. 
 
 
Fig. A1.1. Epithelial-mesenchymal interactions during early foregut/stomach development in 
the embryo. The gut tube is formed by the juxtaposition of an endodermally derived epithelial 
later and a mesodermally derived mesenchymal later. Post-gastrulation, important signaling 
interactions occur bidirectional across the epithelial-mesenchymal boundary, which help in 
specifying the different organs of the gut tube along the different axes. Depicted is a schematic of 
the cross talk occurring between the two tissue layers during the specification of the stomach.  
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V. Postnatal Gastric Development 
The source of nutrients for an embryo is obviously different from that of a neonate. Until birth, 
the developing embryo procures its nourishment from the placenta and substances from 
swallowed amniotic fluid, which also might contain factors that aid in development  [62]. As the 
newborn develops, maturation and gland formation of the gastrointestinal tract continue, peaking 
its rate of growth at around three weeks in rodents. The stomach grows at a more rapid rate just 
after birth as compared to the rest of the body  [63]. Gastric epithelial cells differentiate into and 
establish different lineages – the pit, zymogenic, enteroendocrine and parietal cell lineage  [64]. 
At birth, gastric acid secretion capacity is low, but it rapidly increases about three-fold during the 
first three days post partum  [65], coupled with a proportionate increase in the number of parietal 
cells per unit volume of gastric mucosa (Xu et. al., 1992). The low pH of the stomach 
immediately after birth equips the neonates with the first line of defense against ingested 
microorganisms as the pups change their environment from a sterile to an open one  [66]. Gastric 
acid secretion is responsive to levels of the hormone gastrin (secreted by G-cells of the antrum). 
Gastrin expression increases shortly after birth, in correlation with the observed increase in acid. 
Gastrin gene expression responds to EGF via cAMP activation  [67]. Interestingly, there is 
>1,000 times more EGF in colostrum and milk consumed by neonates as compared to plasma 
levels, and ingested EGF might act as the trigger for gastrin release, subsequent parietal cell 
proliferation, and acid secretion immediately after birth  [68].  
Studies in neonatal rats have shown that changes in suckling of new born pups, such as weaning, 
have an impact on proliferation of gastric mucosal cells  [69].  Gama and Alvarez showed that if 
pups are early-weaned, the basal proliferation in the gastric mucosa is higher, suggesting that 
milk plays an important role in maintaining the desired proliferative rate and homeostasis. 
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Indeed, the mitogen TGFβ is found in rat milk and its concentration decreases towards weaning  
[70]. TGFβ receptors I and II are also expressed in the gastric epithelial cells at E20 until 
weaning  [71]. This timing coincides with the proliferation of the cells in the developing gastric 
unit. Post-weaning, the proliferative zone of the unit is restricted to the isthmus region where the 
stem cell is believed to reside.  
Ghrelin is a growth-hormone-releasing peptide released by the endocrine cells of the rat fetal 
stomach from E18 onward,  and its expression peaks during the second and third weeks after 
birth  [72]. Ghrelin is also released by other tissues in the pregnant mother (such as the brain, 
hypothalamus, pituitary, immune cells, ovary, placenta and others), in the fetus during 
development (such as in the stomach, intestine, pancreas, lungs), and in the neonate (such as the 
stomach and lungs)  [73]. For the newborn, the sources of circulating ghrelin include secretion 
by the stomach mucosa and the maternal contribution in colostrum and milk  [74]. Ghrelin may 
play a role in postnatal gut development as it leads to an increase in total body weight and the 
weight of the stomach (Hayashida et. al., 2002).  
VI. Adult Gastric Homeostasis 
The gastric epithelium undergoes continuous renewal throughout the life span of the animal  [1]. 
This renewal occurs due to the proliferation and differentiation of multipotent stem cells that are 
present in the isthmus region of the adult gastric unit. The stem cell gives rise to precursors that 
move bidirectionally (towards the lumen and towards the base) in the unit, giving rise to three 
main lineages with eleven cell types, i.e.  
1. Pit (also known as surface-associated/foveolar) cell lineage – Pre-pit cell precursors, 
Pre-pit cells, Pit cells 
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2. Zymogenic cell lineage – Pre-neck cell precursors, Pre-neck cells, Neck cells, Pre-
zymogenic cells, Zymogenic cells 
3. Parietal cell lineage - Pre-parietal cell precursors, Pre-parietal cells, Parietal cells 
In addition to these lineages, endocrine cells are also scattered throughout the gastric unit. Even 
though there is emerging literature on the mechanisms by which the different cell types are 
formed, many gaps remain. For example, even though the location of the stem cell within the 
gastric corpus has been well established by ultrastructure and turnover analysis, its molecular 
identity has not been well characterized (Huh et. al., 2006).  
 
Fig. A1.2. Normal architecture and organization of different cell types in the gastric unit of 
the adult mouse. The corpus (body) of the adult stomach consists of repeating invaginations 
called gastric units, each of which can be divided into four regions characterized by the presence 
of specific cell types in each region. Depicted is an H&E stained slide of the adult mouse 
stomach showing a single gastric unit outlined in white, with each region labeled: 1, Pit region, 
which lines the stomach lumen, consists of mucus-secreting pit aka foveolar cells, and narrows 
152 
 
deeper in the unit into the isthmus region; 2, the isthmus region, characterized by the presence of 
multipotent gastric stem cell; 3, neck region, where mucus-secreting neck cells and most of the 
acid-secreting parietal cells reside; and 4, base region, where enzyme producing zymogenic cells 
are present. 
1. The Pit cell lineage: The stem cell in the isthmus region gives rise to a pit cell precursor, 
which is devoid of secretory granules. The precursor then differentiates into pre-pit and 
ultimately into pit cells, which migrate into the pit region. Pit cells contain mucous 
granules (characterized by Muc5AC, Gkn1, Tff1) and degenerate upon reaching the 
luminal surface. This entire process takes place over three days  [75, [76, [77, [78]. Verzi 
and colleagues showed that the forkhead transcription factor FoxQ1 is expressed 
specifically in the stomach in the adult GI tract and within the stomach, its expression is 
limited to pit cells  [79]. However, this finding is controversial as another report claims 
that FoxQ1 is expressed exclusively in parietal cells  [80]. Verzi and coworkers find that 
FoxQ1 is required for the expression of Muc5AC but not Gkn1 in pit cells  [79]. FoxQ1 
mutant stomachs also have dysregulation of genes involved in assembly and function of 
membranous organelles, such as Rpgrip, Sec22 and Stk25, suggesting that it may play a 
crucial role not only in the expression of Muc5AC, but also in imparting this cell with its 
specific architecture  [79]. Gastrin has been implicated in increasing proliferation of pit 
cells, leading to an extended pit region  [81]. Ihh may also play a role in pit cell 
differentiation and maintenance  [82].  
 
2. The Zymogenic cell lineage: The pre-neck cell precursors that arise from the stem cell in 
the isthmus give rise to mucus-secreting neck cells, which eventually mature to form 
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enzyme-secreting zymogenic cells (ZC), which occupy the base of the unit. Neck cells 
are characterized by the expression of TFF2 (also known as spasmolytic polypeptide) and 
the expression of TFF2 is expanded during SPEM (spasmolytic polypeptide expressing 
metaplasia)  [83]. The journey of the neck cell to the base to form zymogenic cells takes 
around 14 days, and zymogenic cells at the base of the gland have a half life of 194 days  
[84]. The improbability of a terminally differentiated, post-mitotic mucus secreting neck 
cell maturing into an enzyme secreting zymogenic cells was highlighted by Hanby and 
colleagues  [85]. However, Ramsey and co-workers presented the first molecular 
evidence that zymogenic cells, in fact, arise from neck cells, and that this maturation is 
controlled by the bHLH transcription factor, Mist1  [86]. Recent studies by Tian and 
colleagues  show that Mist1 facilitates structural maturation of zymogenic cellsin part by 
regulating the expression of Rab proteins, which control the formation of serous secretory 
granules  [87]. Another pathway that expands the zymogenic cell population is the 
retinoic acid pathway  [88].  
 
3. The Parietal cell lineage: Parietal cells (PCs) arise from pre-parietal cells in the isthmus 
region, function in acid secretion, and contain a highly dense canalicular network  [89]. 
Aside from their acid secretion function, parietal cells also produce growth factors that 
maintain normal patterns of cell differentiation and proliferation within the gastric unit  
[90]. Most of the PC transcriptional machinery is centered around regulating the 
expression of genes that keep the cell functional, such as Arf1, Sod2, Mucdhl, Fads1,and 
Calm2  [90]. The PC also elaborates growth factors such as Igfbp2 and Pthlh that can 
have an effect on the differentiation and proliferation status of other cell types in the 
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gastric unit  [90, [91]. The aforementioned transcription factor FoxQ1 appears to be 
unique in that it  controls gastric acid secretion, but not the development of parietal cells, 
and FoxQ1-/- mice show a defect in the development of canaliculi and are less responsive 
to gastrin  [80].  
Hormonal regulation of gastric acid secretion is performed by peptides such as gastrin (secreted 
by the G-cells of the antrum), ghrelin (produced by Gr cells), natriuretric peptides (produced in 
the central nervous system), orexins (neuropeptides), histamine and others,  either alone or in 
combination  [92]. Gastrin is the main stimulant for acid secretion after a meal, and its 
mechanism of action is via the activation of the CCK-2 (cholecystokinin) receptor, which in turn 
activates the PLC and/or MAPK pathways, causing the release of histamine from ECL cells 
(endocrine cells) of the stomach  [93]. Histamine diffuses to parietal cells, where it binds to H-2 
receptors and activates cAMP production, ultimately resulting in the recruitment of the 
H+/K+ATPase to the canalicular membrane to enable acid secretion  [94]. 
 
VII. Morphogenetic pathways in maintaining adult gastric homeostasis: 
A. The Hedgehog Pathway 
Studies by Van den Brink and colleagues first catalogued Shh expression in the adult gastric 
fundus  [95]. Ptc-1, a target of hedgehog signaling, is also expressed in parietal cells and 
epithelial cells at the base of the unit. There are contrasting observations relating to the 
expression of Shh in the pit region, and it is not yet certain if Shh is, in fact, expressed in these 
cells  [96]. Within the epithelium, the targets of hedgehog signaling are parietal cells at the 
cellular leve,l and FoxA2, Isl-1, the H+/K+ATPase, and BMP4 at the molecular level  [18, [95, 
[97]. Shh is in turn regulated by EGF signaling  [97]. While  FoxA2, Isl-1 and H/KATPase are 
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expressed in the epithelium, BMP4 is expressed in the interstitial myofibroblast like cells  [95]. 
However, studies by Fukaya and coworkers showed that Ptc-1 expression was absent from the 
isthmus region suggesting that hedgehog does not act directly on stem/progenitor cells  [82]. In 
contrast, Ihh is expressed in differentiated pit cells and may play a role in the differentiation and 
maintenance of this lineage  [18, [82].  
B. The BMP signaling system 
As discussed earlier, BMP4, but not BMP2, is a target of Shh in the stomach. Nitsche and 
coworkers showed that BMP4 regulates the expression of H+/K+ATPase-α subunit, through the 
activation of Smad-1, in an isolated canine parietal cell culture system  [98]. There are 
contrasting observations regarding the cellular identity of BMP4-producing cells. Van den Brink 
and colleagues found BMP4 solely in fibroblasts in-vivo  [95], whereas, Nitsche and coworkers 
recently showed that it is also expressed in parietal cells in-vitro  [98]. EGF acts by inhibiting 
H+/K+ATPase expression in parietal cells and this effect can be reversed by BMP4  [98]. 
Therefore, BMP4 may be a crucial regulator of differentiation and functional maturation in 
parietal cells. Indeed, inducible ablation of the Bmp4 gene in mice leads to hyperplastic polyp 
formation in the antral mucosa, indicative of a sustained role for BMP4 in suppressing antral 
proliferative response  [99, [100]. 
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Fig. A1.3. Interplay between developmental signaling pathways coordinating differentiation 
and maintenance of different cell lineages within the gastric unit. The gastric epithelium is 
constantly renewing which requires replenishment of the various differentiated cell types (each 
having a different life span), from multipotent stem cells. The schematic shows signaling 
intermediates involved in the maintenance of cell lineage homeostasis and phsysiology in the 
gastric unit. 
 
Conclusion 
In conclusion, multiple transcriptional regulators and spatially controlled signaling pathways 
contribute to the development of the stomach during fetal life, and to the continuing 
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differentiation of the gastric mucosa throughout adult life. The relatively recent evolutionary 
appearance of a separate stomach provides an interesting model system to study 
mesenchymal/epithelial signaling, which may provide information on similar processes 
elsewhere in the body. Given the high incidence and mortality of gastric cancer, discussed in 
detail elsewhere in this volume, an understanding of how these factors control epithelial biology 
is a prerequisite for improving diagnosis and treatment.  
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Abstract 
Chronic inflammation is a risk factor for cancer, including gastric and other gastrointestinal 
cancers.  For example, chronic inflammation caused by Autoimmune Gastritis is associated with 
an increased risk of gastric polyps, gastric carcinoid tumors, and possibly adenocarcinomas.  
This study details the progression of gastric cancer in a mouse model of Autoimmune Gastritis 
(AIG).  Disease is caused by CD4+ T cells which express a transgenic T cell receptor specific for 
a peptide from the H+/K+ ATPase proton pump, a protein expressed by parietal cells in the 
stomach.  Here, we show that autoimmune gastritis causes epithelial cell aberrations that mimic 
most of those seen during progression to gastric cancer in humans. These include: chronic 
gastritis followed by oxyntic atrophy, mucous neck cell hyperplasia, spasmolytic polypeptide-
expressing metaplasia (SPEM), dysplasia, and ultimately gastric intraepithelial neoplasias (GIN).  
These studies provide direct evidence that autoimmune gastritis supports the development of 
gastric neoplasias. This AIG model should be useful for studying inflammation induced gastric 
cancer. 
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Introduction  
Autoimmune gastritis (AIG) is one of the most common autoimmune conditions in humans, and 
is caused when the adaptive immune system (T and B cells) targets self-antigens expressed by 
parietal cells and chief cells in the gastric mucosa.  AIG may persist in an asymptomatic form for 
many years.  A subset of individuals will eventually develop Pernicious Anemia (PA).  PA is the 
major cause of vitamin B12 deficiency.  AIG and PA have respective prevalence of 2 and 0.15–
1% in the general population  [1, [2], which is increased 3- to 5-fold in individuals with other, 
concomitant autoimmune diseases, such as type 1 diabetes  [3, [4] and autoimmune thyroid 
disease  [5, [6]. Gastric carcinoid tumors, evolving from enterochromaffine-like (ECL) cell 
hyper/dysplasia induced by hypergastrinemia, develop in 4–9% of patients with AIG/PA  [7, [8, 
[9].  Gastric carcinoid tumors are relatively benign lesions, metastasizing in less than 10% of 
cases  [10].  Several studies have examined whether individuals with AIG/PA also have a higher 
risk of developing gastric adenocarcinomas, which is the second leading cause of cancer related 
deaths in the world.  Two recent studies, one with 4.5 million retired male veterans in the USA 
and the other with included 9 million individuals from Sweden, reported that individuals with PA 
had an increased risk of developing not only gastrointestinal carcinoids, but also stomach 
adenocarcinomas, small intestinal adenocarcinomas, squamous cell carcinomas (SCC), and 
esophageal SCCs  [11, [12].  
Gastric cancer is the fourth most common cancer and the second most deadly malignant 
neoplasia in the world.  A model, referred to as the Correa pathway, describes the development 
of gastric adenocarcinomas in humans from a histological perspective  [13].  This model details 
the progression of gastric cancer through a series of pathological steps the epithelium undergoes 
starting with chronic inflammation (gastritis), followed by atrophy (especially loss of parietal 
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cells), metaplasia, dysplasia, and eventually neoplasia.  A better understanding of how 
inflammation induces gastric epithelial cell changes could provide potential therapeutic strategies 
for diagnosing and preventing gastric cancer  [14].  To gain a better understanding of the 
progression of gastric cancer from a cellular and molecular perspective, numerous groups have 
developed animal models, mouse models in particular, to study gastric carcinogenesis.  Such 
strategies have included chronic infection with Helicobacter  [15], chemical depletion of parietal 
cells  [16, [17], and several different lines of genetically modified mice.  While these models 
have increased our understanding of the roles of infection, parietal cell loss, and genes involved 
in regulating epithelial cell biology, none have directly examined the role of chronic 
inflammation as the primary inducer of epithelial cell change, which would be useful for 
understanding the roles of cytokines and immune cells in promoting gastric cancer and for 
addressing the potential link between AIG and gastric cancer. 
We investigated the potential link between AIG and gastric cancer using a T cell receptor (TCR) 
transgenic mouse model of AIG  [18].  These transgenic CD4+ T cells recognizes a peptide from 
the parietal cell specific antigen H+/K+ ATPase, which is also the major autoantigen targeted by 
the immune system in humans with AIG/PA  [19].  All mice developed chronic gastritis that 
resulted from large numbers of CD4+ T cells that infiltrated the gastric mucosa and produced 
large amounts of IFN-γ and smaller amounts of IL-17.  Mice developed severe oxyntic atrophy 
and metaplasia by 2 to 4 months of age.  At this stage of disease, mice also developed several 
molecular features associated with the progression of gastric cancer in humans, including 
spasmolytic polypeptide expressing metaplasia (SPEM), increased levels of mRNA for gastric 
cancer biomarkers (HE4, OLFM4, TFF2), and increased levels of phosphorylated STAT3 
compared to non-transgenic control mice.  Finally, by 12 months of age, all mice with AIG 
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developed high grade dysplasia consistent with gastric intraepithelial neoplasia (GIN).  In 
summary, we report a new mouse model demonstrating that inflammation associated with AIG 
induces many of the pathologic and molecule features of gastric carcinogenesis, including the 
development of severe dysplasia/GIN.  These studies support a link between AIG and gastric 
cancer and highlight the importance of localized inflammation in the development of stomach 
cancer.  This new, immune-system-induced model of gastric cancer will be useful for studying 
important host factors that influence inflammation induced adenocarcinomas. 
 
Material and Methods 
Mice - TxA23 TCR transgenic mice have been previously described, and have been bred >15 
generations onto the BALB/c background  [18].  The BALB/c control mice described in these 
experiments are TCR transgene negative littermates that were co-housed with the TxA23 TCR 
transgenic mice.  All mice were maintained under specific pathogen-free conditions and cared 
for in our animal facility in accordance with institutional guidelines.  Our colony tested negative 
by PCR for the following: Helicobacter bilis, Helicobacter hepaticus, Helicobacter rodentium, 
Helicobacter sp., Helicobacter trogontum, and Helicobacter typhlonius.  
Histopathology - Stomachs were removed from mice, rinsed in saline, immersion fixed in 10% 
neutral-buffered formalin (Thermo Scientific), paraffin embedded, sectioned, and stained with 
hematoxylin and eosin.  Pathology scores were assigned using methods modified from Rogers et. 
al.  [20].  Slides were blinded and sections from individual mice were assigned scores between 0 
(absent) and 4 (severe) to indicate the severity of inflammation, oxyntic atrophy, mucinous 
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hyperplasia/metaplasia, and dysplasia. Scores were validated by an independent second 
pathologist blinded to experimental conditions. 
Immunofluorescence - Stomachs were fixed for 20 minutes with methacarn (60% methanol, 30% 
chloroform and 10% glacial acetic acid (all from Fisher)), washed with 70% ethanol, embedded 
in paraffin and sectioned into 0.5µm thick sections.  Slides were deparaffinized, rehydrated, 
stained, and imaged using methods modified from Ramsey et. al.  [21].  The primary antibodies 
used for immunostaining were rabbit anti-human gastric intrinsic factor (gifts of Dr. David 
Alpers, Washington University), rabbit anti-Ki67 (Abcam), and mouse anti-Ecadherin (BD 
Bioscience).  Secondary antibodies and GSII lectin (Molecular Probes) labeling were as 
described  [21]. 
A gastric unit is defined as an invagination of the gastric mucosa that is lined by a single layer of 
columnar epithelium.  Each gastric unit is lined by foveolar cells at the luminal end and 
zymogenic cells at the base.  Ki67 staining was quantified by counting each Ki67+ nucleus per 
gastric unit for >50 units per mouse and classified into <10, 10-20 and >20 positive nuclei per 
unit.  Percentages were calculated by dividing the number of gastric units in each category by 
total number of gastric units analyzed in that mouse stomach sample. 
Immunohistochemistry - Tissue was deparaffinized and rehydrated. Endogenous peroxidase was 
blocked using a 0.3% H2O2 in methanol for 15 minutes.  Antigen retrieval was done in a pressure 
cooker with Diva (Biocare: DV2004MX). Avidin/biotin kit (Biocare) was used to block 
endogenous biotin.  The antibody pStat3 (D3A7) from Cell Signaling was diluted in Davinci 
(Biocare) and incubated over night at 4°C.  The secondary antibody, biotinylated goat anti-rabbit 
and streptavidin-HRP from Jackson Labs were each applied for 1 hour at room temperature.  
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Visualization was done with Biocare's Betaziod DAB and slides were counterstained in 
hematoxylin. 
Immunoblot - A section from the stomach was homogenized with an electric pestle tissue 
homogenizer.  Cells were then lysed in .5 ml of lysis buffer (20 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-
glycerophosphate , 1 mM Na3VO4, 1 µg/ml leupeptin (Cell Signaling) and a protease inhibitor 
cocktail (Sigma)).  Lysates were vortexed for 1 minute and sonicated for 15 seconds followed by 
centrifugation for 10 min at 4°C.  Lysates were ran on a NuPAGE 4-12% BIS-TRIS gradient gel 
(Novex) and transferred to a nitrocellulose membrane.  Membrane was blocked for 1 hour with 
5% non-fat dairy milk.  Primary antibodies (all from Cell Signaling) were stained for 1 hour 
(rabbit mAB-β-Actin-and rabbit mAB-STAT3) or overnight (rabbit mAB-Phospho-STAT 3) in 
5% bovine serum albumin in 4˚C.  HRP-Linked secondary antibody (anti-rabbit IgG) was stained 
for 1 hours at room temperature in 5% non-fat dairy milk.  Protein was detected by 
chemiluminescence using LumiGLO (Cell Signaling) on CL-XPosure X-Ray film (Fisher). 
Flow cytometry - Cell surface staining was performed according to standard procedures using 
monoclonal antibodies against CD4, CD19, CD11b and Ly6G.  Intracellular cytokine staining 
was performed using monoclonal antibodies against IFNγ and IL-17A.  All antibodies were 
purchased from BD Pharmingen. All flow cytometry was performed on a BD LSRII or BD 
FACSCalibur and analyzed using FlowJo (TreeStar).  For intracellular cytokine staining, cells 
were stimulated with PMA (Calbiochem) and Ionomycin (Calbiochem) for 4 hours at 37°C. 
Golgi-stop (BD Bioscience) was added after 1 hour.  Cells were then washed, fixed in 4% formyl 
saline, washed, and permeabilized (0.5% BSA, 0.1% Triton, and 2mM EDTA in PBS) for 1 hr at 
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room temperature.  After washing, cells were incubated overnight with the anti-cytokine 
antibodies, washed and analyzed by flow cytometry. 
Isolation of cells from the gastric lymph nodes and gastric mucosa - The method for isolating 
cells from the stomach tissue has been described previously  [22, [23].  Briefly, the gastric lymph 
nodes (gLN) were removed from the stomachs, homogenized, and passed through a 40-μM pore 
nylon filter.  Stomachs were opened with an incision from the antrum to the fundus, and rinsed in 
PBS to remove food.  Cells were flushed from the gastric mucosa using a syringe with a 25 
gauge needle. PBS containing 5% FCS and penicillin/streptomycin (Sigma) was repeatedly 
injected within the mucosa causing the tissue to swell and rupture.  Single cell suspensions were 
collected, gently vortexed, and passed through a 40-μM nylon filter.  Cells were counted, stained 
with antibodies, and analyzed by flow cytometry.  To detect secreted cytokines, 1x106 cells were 
culture in vitro in 24 well plates containing 2 mL of supplemented RPMI.  Supernatants from 
cell cultures were collected after 48 hours and cytokines and chemokines were measured using 
Milliplex (Millipore). 
Quantitative Real Time PCR - Total RNA was prepared using the RNeasy Mini Kit system 
(Qiagen).  The quantity and quality of RNA was determined using a NanoDrop 2000 
spectrophotometer (Thermo Scientific) and 0.5 µg of the RNA was used to generate a first strand 
cDNA copy according to the manufacturer’s instruction (High Capacity cDNA Reverse 
Transcription Kit, Applied Biosystems).  Quantitative PCR was performed using TaqMan® 
Gene Expression Assays systems (Applied Biosystems).  GAPDH served as an internal reference 
standard. PCR was ran on the 7500 Real-Time PCR System (Applied Biosystems). 
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Statistical Analysis - Data are expressed as means of individual determinations +/- standard error.  
Statistical analysis was performed using the Mann-Whitney Test (*P<.05; **P<.01; ***P<.001) 
using GraphPad Prism 5. 
 
Results:   
Inflammation in TxA23 mice is characterized by CD4
+
 T cells secreting IFN-γ and IL-17. Our 
first goal was to characterize the cell types and cytokines of TxA23 mice.  Cells were isolated 
from the gastric mucosa and gastric lymph nodes of 2 month old mice and analyzed by flow 
cytometry.  The majority (>85%) of the hematopoietic derived cells isolated were either CD4+ T 
cells or CD19+ B cells (Figure 1A).  As expected, the majority of the CD4+ T cells that infiltrated 
the stomach expressed the transgenic TCR (TCRVα2/TCRVβ2) specific for the H+/K+ ATPase 
peptide (Figure 1B). Macrophages (CD11b+Ly6G-) and neutrophils (CD11b+Ly6G+) and a subset 
of dendritic cells (CD11b+CD11c+, data not shown) comprised the rest of the cells found in the 
gastric mucosa (Figure 1C).  Next, cells were re-stimulated and cytokine production by CD4+ T 
cells was determined by intracellular cytokine staining.  The majority of cytokine producing 
CD4+ T cells isolated from the stomachs and gastric lymph node produced IFN-γ, and fewer 
produced IL-2, and IL-17. IL-4 secretion by CD4+ T cells was not detected (Figure 1D).  Finally, 
total cells isolated from the gastric lymph node were cultured immediately after isolation.  The 
amounts of several cytokines secreted into the supernatants were determined after 48 hours.  The 
most abundant cytokines secreted by cells were IFN-γ and IL-17 (Figure 1E). Lower levels of 
IL-6, IL-2, IL-10, and IL-4 were also detected.  Thus the inflammatory cell infiltrate within the 
gastric mucosa consists primarily of a mixture of Th1 (IFN-γ+) and Th17 (IL-17+) CD4+ T cells, 
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and B cells.  This type of inflammation is consistent with the types of inflammation described in 
humans infected with H. Pylori and with autoimmune gastritis  [24, [25].  
 
Fig. A.2.1. Inflammation in TxA23 mice. Representative flow cytometric plots of cell types and 
cytokines from a TxA23 mice (n = 21). A, flow cytometry was used to identify T cells (CD4+) 
and B cells (CD19+). B, the majority of CD4+-gated T cells express the transgenic TCR 
(TCRVα2/TCRVβ2) that recognizes a peptide from H+/K+ ATPase. C, macrophages 
(CD11b+Ly6G−) and neutrophils (CD11b+Ly6G+) make up a large proportion of the 
remaining cells. D, intracellular cytokine staining showing IL-17, IFN-y, IL-2, and IL-4 
production by CD4
+
 T cells combined from the gastric mucosa and lymph node. E, cytokines 
secreted by cells isolated from the gastric lymph nodes of TxA23 mice were measured by bead-
based ELISA. Data are the mean ± SE of 7 mice from 3 independent experiments. 
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TxA23 progress through a series of pathological changes associated with the development of 
gastric cancer.  
 In humans, the progression of intestinal-type gastric cancer is thought to evolve through a series 
of discrete steps known as the Correa pathway  [13].  The first step in this pathway is 
inflammation (gastritis), then loss of parietal cells (oxyntic atrophy) and the development of 
mucinous metaplasia, followed by dysplasia and finally cancer.  We examined the pathological 
features of gastric disease in TxA23 mice. At 2 months of age, TxA23 mice had moderate 
degrees of inflammation, oxyntic atrophy and mucosal hyperplasia/metaplasia, but little or no 
evidence of dysplasia (Figure 2A).  By 4 months of age, inflammation, oxyntic atrophy, and 
mucosal hyperplasia/metaplasia were significantly more severe compared to 2 month old mice 
(Figure 2A).  Lesions in the stomachs of 4 month old TxA23 mice comprised large areas in 
which parietal cells were either reduced in number or absent from the gastric units, and the 
remaining mucosa was dominated by large, hyperplastic mucus-containing cells that expanded to 
the bases of gastric units (Figure 2B-C). Four of the 19 mice had developed mild focal dysplasia 
(Figure 2D). For comparison, Figure 2E is representative of the normal pathology observed in 11 
individual control mouse, which are transgene negative BALB/c mice that were co-housed with 
TxA23 littermates.  Disease severity was similar in male and female mice at all ages.  These data 
demonstrate that chronic inflammation resulting from autoimmune gastritis induced the 
development of preneoplastic lesions in the gastric mucosa of TxA23 mice with many 
pathological features in common with the Correa pathway. 
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Fig. A.2.2. Preneoplastic lesions in TxA23 mice. A, pathology scores of stomach sections from 
2-month-old (n = 9) and 4-month-old TxA23 mice (n = 19). B–D, representative images of 
pathology observed in TxA23 mice illustrating inflammation, oxyntic atrophy, and mucosal 
hyperplasia (B). C, extensive parietal cell loss accompanied by moderate levels of mucinous 
metaplasia (red bracket). D, focal regions of mild dysplasia (blue bracket). E, normal 
morphology in a BALB/c control mouse with healthy parietal cells and basal nonmetaplastic 
zymogenic chief cells at base of unit (red bracket, base region). Arrows point to healthy parietal 
cells. Statistics were conducted using the Mann–Whitney U test (**, P < 0.01; ***, P < 0.001). 
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Increased epithelial cell proliferation, phosphorylated STAT3, IL-6, and expression of gastric 
cancer-associated biomarkers in TxA23 mice. Next, we used immunofluorescence to compare 
the extent of gastric epithelial cell proliferation in 2 and 4 month old TxA23 mice compared to 
BALB/c control mice (Figure 3A-C).  In wild type BALB/c mice, the number of proliferating 
(marked by Ki67+ immunoreactivity) epithelial cells (marked by E-cadherin+) per individual 
gastric unit was always less than 10.  However, in TxA23 mice almost 70% of 2-month old 
gastric units had 10 or more proliferating cells, and by 4 months, more than 75% had more than 
10 with about a third of those having 20 or more (Figure 3D). 
176 
 
 
Fig. A.2.3. Increased epithelial cell proliferation in the gastric mucosa of TxA23 mice. A–C, 
images are representative of 2-month-old (A) and 4-month old (B) TxA23 mice and 4-month-old 
(C) BALB/c stomach sections. E-Cadherin (green) stains epithelial cells, Ki67 (red) stains 
proliferating cells, and Hoechst (blue) was used to stain nuclei. D, a quantitative analysis of the 
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percentage of gastric units containing proliferating epithelial cells (E-cadherin+Ki67+) in 
BALB/c and 2- and 4-month-old TxA23 mice. 
 
Increased levels of the active (phosphorylated) signal transducer and activator of transcription 3 
(pSTAT3) was involved in cellular transformation in numerous cancers of epithelial origin, 
including gastric cancer  [26].  A recent study suggested that pSTAT3 is a significant prognostic 
factor in gastric cancer in humans  [27].  To determine whether the level of pSTAT3 was 
increased in the stomachs of TxA23 mice, we performed western blots on gastric tissue lysates 
between age matched TxA23 and healthy BALB/c control mice.  Compared to BALB/c mice, 
TxA23 mice expressed slightly higher levels of total STAT3 and a much higher level of pSTAT3 
(Figure 4A).  Immunohistochemical analysis revealed a large number of pSTAT3 positive 
epithelial cells present in the gastric mucosa of TxA23 mice, and nearly undetectable levels in 
gastric tissue from BALB/c controls (Figure 4B), in agreement with the results observed by 
Western blot. 
 
Several members of the IL-6 cytokine family, including IL-6 and IL-11, activate STAT3  [28].  
IL-6 and IL-11 have important roles in maintaining gastric homeostasis by regulating mucosal 
proliferation, inflammation, angiogenesis, and apoptosis  [29, [30].  We performed quantitative 
real time PCR analysis using mRNA isolated from gastric tissue from 2 month old TxA23 and 
BALB/c mice to measure the relative levels of IL-6 and IL-11.  The levels of IL-11 mRNA were 
equivalent between the two genotypes; however, the levels of IL-6 mRNA were ~40 fold higher 
in TxA23 mice compared to BALB/c mice (Figure 4C). 
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Fig. A.2.4 Increased levels of cancer associated markers in TxA23 mice. A, representative 
Western blotting of STAT3, pSTAT3 and β-actin on whole stomach lysates of 2-month-old TxA23 
(n = 9) and BALB/c mice. B, immunohistochemistry staining for pSTAT3 in gastric pits of 
BALB/c and TxA23 stomachs (magnification, ×20). C, the relative expression of IL-6 and IL-11 
in mRNA extracted from the stomachs of TxA23 and BALB/c mice. D, the relative expression of 
genes (HE4, TFF2, and OLFM4) that serves as biomarkers for the SPEM and preneoplastic 
progress was compared between mRNA isolated from the stomachs of TxA23 mice and BALB/c 
controls. 
 
A number of genes have been described as biomarkers for precursor lesions like SPEM that are 
predisposing for gastric cancer.  Some of these genes include Human Epididymis 4 (HE4)  [16], 
Trefoil Factor 2 (TFF2) and Olfactomedin 4 (OLFM4)  [31].  HE4 is absent in normal stomach 
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and expressed in humans and mice with SPEM  [16].  Increased levels of OLFM4, also known as 
GW112, have been observed in gastric cancers, including 58% of stage III/IV gastric cancers  
[31].  TFF2 is also known as spasmolytic polypeptide, and, by definition, increases when SPEM 
is present.  We performed quantitative real time PCR analysis using mRNA isolated from 
sections taken from the body of the stomachs of TxA23 mice.  All of the TxA23 mice expressed 
higher levels of HE4 and OLFM4, and a majority, 5 out of 7 mice, expressed higher levels of 
TFF2 compared to age-matched BALB/c control mice (Figure 4D).  Together these data 
demonstrate that disease in TxA23 mice shares many of the molecular features of gastric cancer 
that have been reported in humans, including increased epithelial cell proliferation, increased 
levels of pSTAT3 protein, and higher levels of IL-6, HE4, OLFM4, and TFF2 mRNA. 
 
SPEM is present in the gastric mucosa of TxA23 mice.  Intestinal-type gastric cancer 
predominantly develops in the setting of oxyntic atrophy and mucous cell metaplasia  [13].  
Spasmolytic polypeptide-expressing metaplasia (SPEM), is a metaplasia in the gastric fundus 
resembling deep antral gland cells, and recent studies have indicated that SPEM may be directly 
linked to gastric neoplasia  [25, [32].  We used immunohistochemistry to determine whether 4 
month old TxA23 mice developed SPEM.  A representative section from a TxA23 mouse is 
shown in figure 5A.  In gastric units in which parietal cells have not yet been destroyed, chief 
cells are found at the base of the unit and are identified by staining with antibodies to gastric 
intrinsic factor (GIF).  Of note, the antrum/pyloris of TxA23 mice were indistinguishable from 
BALB/c control mice. In the corpus region, neck cells are found above and identified by lectin 
GSII staining (Figure 5B).  However, we also observed multiple gastric units in which the 
majority or all of the parietal cells had been lost (Figure 5B, C).  In these parietal cell depleted 
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units, there was an expansion of GSII-positive cells (mucous neck cell hyperplasia) and an 
emergence of cells expressing both neck cell specific and chief cell specific markers (GIF) in the 
base of the units, whereas in regions with parietal cell preservation, the normal basal marker 
expression pattern was maintained (Figure 5D).  Thus, GSII-positive GIF-positive cells in the 
base of gastric units that lack parietal cells also stained positive for TFF2 (data not shown), 
demonstrating13 that TxA23 mice developed regions of SPEM by 4 months of age.  
Fig. A.2.5. TxA23 mice have distinct 
regions of parietal cell loss coupled with 
the emergence SPEM. Representative 
immunostains of the corpus region of the 
stomach of TxA23 transgenic mice. A, the 
lamina propria is separated from the 
glandular mucosa by the white dotted lines 
wherein parietal cells are stained with 
VEGFB (teal) and nuclei with Hoechst 
(blue). Note the distinct regions of parietal 
cell loss as highlighted by solid white 
lines. B, the area highlighted by the yellow 
box in A was stained with GSII (green, 
neck cells), GIF (red, ZC), and Hoechst 
(blue, nuclei). The yellow box on the left 
indicates a region of SPEM where cells co-
express GSII and GIF (white arrowheads). 
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This region of the stomach has shown considerable parietal cell destruction. Higher 
magnification of this region is shown in C. White arrows indicate areas of relatively normal 
gastric epithelial cell differentiation that correlate with regions where parietal cell numbers are 
normal. Further magnification of this region is shown in D. 
 
TxA23 Mice Develop Gastric Intraepithelial Neoplasia (GIN). In the next set of experiments we 
allowed a cohort of TxA23 mice to age, and performed histopathological evaluations to 
determine whether disease in TxA23 mice progressed beyond SPEM to dysplasia.  Sections from 
stomachs of 4 and 12 month old mice were examined by a pathologist using a murine gastric 
histopathology scoring paradigm described previously  [20] (Figure 6A).  The analysis of mice at 
4 months of age revealed that 15 of 19 had dysplasia scores of 0, and 4 of 19 mice had dysplasia 
scores of 1, indicating focal irregularly shaped gastric glands, including elongated, slit, trident, 
and back to back forms (Figure 6B).  By 12 months of age, disease progressed to the point at 
which 7 of 8 mice developed severe dysplasia, indicated by scores of 3.5.  In this scoring system 
a score of 3 is used to indicate severe loss of gland organization and columnar orientation, 
marked cell atypia, visible mitoses, gastric intraepithelial neoplasia (GIN), and 0.5 is added for 
carcinoma in situ or invasion without frank malignancy.  We observed both focal and wide 
spread dysplasia, and most cases involved pseudoinvasion into the submucosa and/or serosa 
(Figure 6C-E).  We also observed the formation of irregular glandular forms on the adventitial 
surface of the stomach, some of which contained papillary projections of atypical epithelium 
(Figure 6F).  These data demonstrates that precancerous lesions observed in 4 month old TxA23 
mice ultimately progressed to neoplastic disease.  
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Fig. A.2.6. TxA23 mice develop masses with dysplastic foci as they age. A, dysplasia scores 
(where 1 = irregular glad forms, 3 = severe loss of glands and of columnar orientation of 
epithelium with regions of cellular atypia, increased mitotic figures, and 0.5 added when 
invasion of muscle or carcinoma in situ was identified) for sections at given ages. Each point 
represents an individual mouse. B, section of a mouse at 10 months of age (magnification, ×10). 
Note to formation of mass with abundant, dense chronic inflammatory infiltrates. C–F, images of 
stomach sections that represent pathology observed in 12-month-old mice with various degrees 
of pseudoinvasion of irregular glands into the submucosa. C, section showing submucosal focus 
of irregular gland formations (magnification, ×10). D, section showing focus of irregular glands 
in submucosal tissue with surrounding chronic inflammation (magnification, ×20). E, section 
showing deep submucosal pseudoinvasion by an irregular gland (magnification, ×10). F, 
irregular glandular form on the adventitial surface of the stomach (magnification, ×20). 
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Discussion 
Although chronic atrophic gastritis is believed to be important in initiating gastric 
carcinogenesis, the precise role(s) of inflammation in the complex changes in gastric epithelial 
cells during the progression of gastric cancer are not understood.  Furthermore, the relationship 
between AIG/PA and gastric cancer has been controversial and requires further investigation.  In 
this study we describe a new mouse model demonstrating that autoimmune gastritis induces 
precancerous lesions similar to those that precede gastric cancer in humans.  Mice with chronic 
inflammation caused by H+/K+ ATPase-specific CD4+ T cells developed severe oxyntic atrophy 
coupled with metaplasia, including SPEM by 4 months of age.  Similar to H. pylori infection and 
AIG in humans, inflammation in TxA23 mice contained CD4+ T cells of the Th1 (IFN-γ+) and 
Th17 (IL-17+) phenotype  [33, [34].  Consistent with the Correa pathway that describes the 
progression of gastric cancer in humans, TxA23 mice progressed through a series of stages that 
included inflammation, atrophic gastritis, mucous neck cell hyperplasia, SPEM, which over time 
progressed to dysplasia, and neoplasia.  These data indicate that the TxA23 model system is 
unique in that it allows for the study of the development and regulation of gastric carcinogenesis 
in a setting where chronic inflammation, in the absence of infection, toxins, and drugs, is the 
primary upstream instigator.  Our findings of carcinogenesis in our mouse model are consistent 
with reports that humans with AIG/PA are 3- to 6- times more likely to develop gastric 
adenocarcinoma and other cancers  [35, [36].  It has been reported that a subset of individuals 
contain T cells and antibodies specific for H+/K+ ATPase after they are infected with H. pylori  
[37, [38, [39, [40].  It is possible that individuals that develop autoimmune responses during H. 
pylori infection may remain at risk for gastric cancer even if they are treated for H. pylori 
infection.  Studies have shown that the eradication of H. pylori reduces risk for subsequent 
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gastric cancer by about 25%  [40, [41, [42].  Strategies to reduce inflammation in addition to 
eradicating H. pylori may further reduce the risk of gastric cancer. 
With the two recent studies reporting that individuals with Pernicious Anemia developed 
gastrointestinal cancers at a higher than expected rate, animal models that mimic AIG are likely 
to be useful for understanding the link between AIG and GI cancers.  There is no doubt that 
infection with H. pylori is an important, prerequisite risk factor for gastric cancer; however, the 
vast majority of infected patients do not develop cancer.  Therefore, it may be the types of 
chronic inflammation in the gastric mucosa that is triggered by H. pylori that are downstream 
adjuvants or causes of actual cancer.  The TxA23 mouse model described here mimics the 
human disease and demonstrates the progression of AIG to the development of SPEM and 
eventually severe to dysplasia.  Other genetically engineered mouse models have been useful for 
studying factors that influence the development of gastric cancer independently of Helicobacter 
infection.  For example, mice expressing gastrin under the insulin promoter  [43], mice deficient 
in: TFF1  [44], Smad4  [45], and Hip1r  [46], and mice expressing a mutated form of the IL-6 
family co-receptor gp130  [47] all develop forms of gastric metaplasia and some cases dysplasia.  
Our model specifically focuses on the immune response to H+/K+ ATPase and its role in 
promoting SPEM with progression to severe dysplasia.  By inducing severe dysplasia in the 
absence of infection, this model will allow for a direct examination of the mechanisms whereby 
inflammation influences gastric epithelial cell biology.  For example, when examining disease in 
cytokine knockout mice, using our model, we do not have to be concerned with the potential 
indirect effects of the importance of the cytokine in modulating Helicobacter infection itself.  
Our model will be also useful for evaluating the importance of immune cells, such as regulatory 
T cells and how they influence changes in gastric epithelial cells that are associated with the 
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progression of gastric cancer.  Finally, future studies using this model will address how various 
host factors, especially immune-related genes, influence the risk of developing gastric cancer. 
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